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Abstract 
Although many experts projected that the discovery of penicillin signaled an end to 
infectious diseases, the emergence of antibiotic resistant bacteria has unfortunately 
rendered many antimicrobial therapeutics ineffective. The arsenal of drugs that physicians 
once had to combat infections has been reduced to last resort antibiotics with high patient 
toxicity. In conjunction with the emergence of antibiotic resistant bacteria, we have 
witnessed a languid pursuit in the discovery of novel antimicrobials as the last clinically 
useful antibiotic was identified thirty years ago. As the number of efficacious antibiotics 
continues to rapidly dwindle without replenishment, the possibility of entering a post-
antibiotic era threatens to quickly become an ominous reality. To reverse this disconcerting 
trend, it is essential that novel antimicrobial therapeutics that target resistant bacteria be 
discovered.  
 The use of therapeutics which alter the host immune response have become 
attractive strategies for the treatment of cancer and virus affiliated diseases. As discussed 
in Chapter 1, these strategies act to stimulate or attenuate the host immune system in a 
manner that is advantageous to clearance of infection. Although these strategies have 
demonstrated great potential, especially in cancer treatment, the use of immunomodulation 
to target pathogenic bacteria has been lagging. We hypothesized that clearance of bacterial 
infections could be achieved by tethering hapten molecules recognized by the immune 
system to the bacterial cell surface. Hapten recognition was theorized to recruit endogenous 
antibodies to stimulate the innate immune system and ultimately achieve eradication of the 
pathogen. In developing this method, it was recognized that facile modulation of the 
bacterial surface would be necessary. Chapter 2 discusses different methods in which both 
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Gram-positive and Gram-negative bacteria surfaces can be modified. Through careful 
examination of these cell surface remodeling techniques, the use of exogenous D-amino 
acid cell wall analogues, which remodel the oligopeptide of peptidoglycan, were identified 
as an appropriate approach for incorporating hapten molecules onto the Gram-positive 
bacterial cell surfaces.  
The work discussed in Chapter 3 describes the initial efforts towards the 
development of D-amino acid Antibody Recruitment Therapy (DART). In this novel 
immunomodulation strategy, dinitrophenol (DNP) haptens, which are readily recognized 
by antibodies circulating in the human blood stream, were conjugated to the side chain of 
diverse D-amino acids. Incubation of bacteria in the presence of these DNP-D-amino acids 
led to extensive peptidoglycan remodeling and demonstrated enhancement of antibody 
recruitment to the bacterial surface. Furthermore, we demonstrated that incorporation of 
DNP-D-amino acids into bacterial peptidoglycan stimulates macrophage antibody-
dependent cellular phagocytosis of bacteria. These studies indicate the potential of DART 
as an immunomodulation strategy to combating pathogenic bacterial infections and 
demonstrate DNP-D-amino acids could serve as a new antimicrobial agent.  
From the initial development of DART, several questions were raised about D-
amino acid substrate side chain promiscuity exhibited by penicillin-binding protein (PBP) 
transpeptidase. In developing a highly efficacious DART agent, a D-amino acid substrate 
that is readily incorporated into the peptidoglycan would prove advantageous as more 
hapten molecules would be attached to the bacterial cell surface. To determine the extent 
of PBP transpeptidase side chain promiscuity, a series of fluorescent D-amino acids were 
synthesized and analyzed across several bacterial strains for peptidoglycan incorporation. 
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Additionally, an assay to rapidly assess if non-fluorescent D-amino acids are incorporated 
into the peptidoglycan was developed. From these studies, several trends were observed 
which could direct future generations of DART and are discussed in Chapter 4.  
Additionally, we hypothesized that the accessibility of DNP epitopes could 
drastically effect antibody recruitment to the bacteria surface and therefore reduce immune 
response. In Chapter 5, the development of a method to accentuate the protrusion of 
antibodies from the bacterial peptidoglycan for enhanced antibody recruitment is 
discussed. In this two-step method, a dipeptide cell wall analogue containing a reactive 
chemical handle was incorporated into the bacterial peptidoglycan. Following dipeptide 
incorporation, subsequent chemical reaction facilitated covalent attachment of peptide-
based DNP linkers varying in length. Through analysis of this two-step modulation system, 
it was determined that larger linkers, although less readily modulate bacterial 
peptidoglycan, are more adept to recruit antibodies to the bacterial surface.  
Lastly, in the pursuit of DART agents that could generate enhanced immune 
response, we decided to explore the ability of PBP transpeptidases to incorporate D-amino 
acids possessing diverse C-terminus modifications. Through this study, it was observed 
that exogenous D-amino carboxamide variants are more readily incorporated into the 
peptidoglycan than the natural carboxylic acid containing D-amino acid substrate. With this 
knowledge in hand, it was hypothesized that D-amino carboxamides displaying DNP 
haptens could engender a greater immune response. In Chapter 6, the enhanced antibody 
recruitment facilitated by D-amino carboxamides modified with DNP is discussed. 
Additionally, in this study, the recruitment of antibodies from pooled human serum is 
shown, thus validating the biological relevance of this immunomodulation strategy.  
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The work described in this thesis represents the initial developments of DART. 
Although future in vivo experiments must be completed to ascertain if this strategy will be 
viable in live organisms, the work described herein demonstrates the potential of targeting 
pathogenic bacteria through host immune system stimulation.  
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Chapter 1: 
Combating Pathogenic Bacteria through Immunomodulation 
 
1.1 Antibiotic Discovery 
Antibiotics were first discovered in 1928, when Alexander Flemming noticed 
contaminant mold spores of Penicillium notatum growing on his petri dishes inhibited the 
growth of Staphylococcus bacteria. This serendipitous event led to the discovery of the 
small antimicrobial molecule penicillin and spawned a new health care era in which 
bacterial infections were no longer life-threatening medical conditions.1 Following the 
initial discovery of penicillin, a plethora of other small molecules possessing antimicrobial 
activity were quickly discovered. Between 1950 and 1970, a time known as The “Golden 
Age” of antibiotic discovery, over half of the antibiotics utilized today were discovered.2 
These small antimicrobial molecules revolutionized the field of modern medicine. The 
advent of invasive surgeries and cancer therapies previously deemed too precarious due to 
risk of infection became routine procedures in the medical setting and led to a dramatic 
increase in the quality of life. It is no coincidence that since the introduction of antibiotics 
into the clinics, the average life expectancy has increased by nearly three decades.3  
Antibiotic treatment of bacterial infections traditionally impairs vital cellular 
processes such as cell wall biosynthesis, DNA replication, or protein synthesis.4 Each of 
these processes provide a unique method for targeting bacterial infections while leaving 
host cells intact. For example, targeting of peptidoglycan cell wall biosynthesis has been 
highly successful. This biopolymer, comprised of distinctive glycans and oligopeptides, is 
an essential component of bacterial cell which resides exteriorly of the cytoplasmic 
membrane. It is peptidoglycan which endows bacterial cell walls with the ability to resist 
6 
	  
osmotic shock and turgor pressure.5 Because of peptidoglycan’s critical role in bacterial 
survival, molecules that inactivate the enzymes responsible for the synthesis of this 
biopolymer, such as penicillin, are the basis of several potent classes of antibiotics, such as 
β-lactams.6 
 
1.2 Antibiotic Resistance Mechanisms 
For many decades, the number of new antibiotics introduced into the clinics easily 
outpaced the emergence of resistant strains. Previous life-threatening infections were 
quickly cleared with diverse antimicrobial agents. Although the discovery and use of 
antibiotics was thought to signal the end of infectious diseases, the emergence of antibiotic 
resistant bacteria has created a current outlook that appears much bleaker. Resistant 
bacteria are microbes which are not susceptible to the effects of an antibiotic.7 The use of 
antibiotics has created a selective pressure which enables the survival of bacteria not 
susceptible to the antibiotic mechanism of action. This generates an entire population of 
bacteria to which the previously efficacious antibiotic is rendered useless. 
Bacteria exhibit resistance to antibiotics by either possessing innate features or 
evolving mechanisms that provide immunity.8 Bacterial intrinsic resistance most 
commonly manifests itself through lack of the characteristic feature (protein or small 
molecule) targeted by an antibiotic. Another way bacteria intrinsically resist the deleterious 
effects of antibiotics is through prohibiting antibiotic access to its molecular target (Figure 
1.1B). For example, the glycopeptide antibiotic vancomycin is highly effective at binding 
peptidoglycan lipid II precursor molecules and inhibiting cell growth.9 Although both 
Gram-positive and Gram-negative bacteria possess peptidoglycan, Gram-negative 
bacterial peptidoglycan is surrounded by an outer membrane which inhibits the permeation 
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of vancomycin to its target. This impediment of vancomycin enables Gram-negative 
bacteria to resist the effects of this glycopeptide therapeutic and survive in its presence.10  
In addition to possessing inherent features that evade the effects of antibiotics, 
bacteria have generated several intricate mechanisms of eradicating efficacious antibiotics. 
One such method is the emergence of efflux pumps, which limit the accumulation of 
Figure 1.1 Bacterial Antibiotic Resistance Mechanisms. Bacterial have devised 
several methods of resistance to antibiotics. (A) Antibiotics inhibit target enzyme 
function and result in cell death. (B) Some bacterial are resistant to certain antibiotics 
due to poor antibiotic cell wall permeation. (C) Bacterial have evolved efflux pumps 
which actively transport antibiotics extracellularly to limit the concentration within 
cells. (D) Bacterial have developed mechanisms, such as enzyme mediated antibiotic 
hydrolysis, to alter the structure of the antibiotic and destroy the effects of the 
therapeutic. (E) Bacteria have evolved enzymes which can replicate the function of the 
antibiotic target but are not affected by the antimicrobial agent.   
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intracellular antibiotics. These membrane proteins facilitate the active transport of 
antibiotics to the cell exterior prior to it reaching its intended target (Figure 1.1C).11 
Because efflux pumps are indiscriminate of the antibiotics they transport, over expression 
of these transport proteins are thought to be responsible for the emergence of multidrug-
resistant (MDR) bacteria.12 Currently, small molecules which inhibit efflux pumps through 
competitive inhibition, are being investigated.13 The potential of this strategy was recently 
recognized as cefepime resistant Pseudomonas aeruginosa (P. aeruginosa) were 
resensitized to this cephalosporin antibiotic when coincubated in the presences of phenyl-
arginine-β-naphthylamide, a known efflux pump inhibitor.14 
Antibiotic modification rendering the therapeutic unrecognizable by the target is 
another mechanism by which bacteria avoid the effects of antibiotics (Figure 1.1D). For 
example, bacteria resistant to penicillin were found to express β-lactamase proteins which 
cleave the lactam bond in penicillin. The hydrolysis of this bond, dismantles the antibiotic’s 
ability to inhibit its PBP enzyme target and results in continued peptidoglycan synthesis.15 
Currently, β-lactam antibiotics represent more than half of the antibiotics that are used in 
the clinical setting. The frequent use of this class of antibiotics has produced bacteria 
demonstrating extended-spectrum β-lactamase (ESBL) activity.16 The use of β-­‐lactamase 
inhibitors in combination with a β-lactam antibiotic has previously proven effective at 
treating these antibiotic resistant bacteria. For example, use of the β-lactamase inhibitor 
tazobactam in conjunction with the broad-spectrum β-lactam antibiotic, piperacillin has 
effectively treated ESBL infections.17 Although this combination strategy has provided β-
lactam antibiotics with extended longevity, the emergence of new β-lactamase enzymes 
has given the upper-hand back to bacteria.18  
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Lastly, bacteria have developed methods of altering the target of an antibiotic to 
generate resistance (Figure 1.1E). As previously stated, one antibiotic mechanism of action 
is the enzymatic inhibition of the PBPs responsible for cell wall growth and division. To 
mitigate the effects of β-lactam antibiotics, the pathogen methicillin-resistant 
Staphylococcus aureus (MRSA) has evolved a PBP variant, PBP2a. This mutant PBP 
serves as a fully functional enzyme within the peptidoglycan biosynthetic pathway, but 
remains insusceptible to the effects of β-lactam antibiotics. Additional evidence of protein 
modification to elude antibiotics can be observed in the case of ribosomal targeting 
antibiotic, linezolid. This antibiotic binds the 50S subunit of bacterial ribosomes and is 
responsible for the inhibition of protein synthesis. Antibiotic resistance observed in S. 
aureus, has been attributed to mutations within the ribosomal complex which alter the 
binding site of linezolid. This ribosomal adaptation inhibits the binding of linezolid and 
concurrently enables protein synthesis.19 
In addition to proteins, antibiotics also target small molecules that are critical for 
bacterial survival. For example, vancomycin as previously stated, binds the D-Ala-D-Ala 
moiety of the critical lipid II peptidoglycan precursor molecules. The binding of this small 
molecule inhibits the ability of downstream enzymes to process lipid II, resulting in 
inhibition or bacterial cell wall growth and division. Although vancomycin has sustained 
longer success in the clinical setting than any other antibiotic, the emergence of resistance 
has occurred in pathogens such as S. aureus and Enterococcus faecium (E. faecium).20, 21 
In this resistance mechanism, the terminal D-alanine of the peptidoglycan stem is 
exchanged for a D-lactic acid. This exchange results in the loss of a hydrogen bond and 
creates electronic repulsion that reduces the ability of vancomycin to bind its target by 
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1000-fold.22 Vancomycin resistance is facilitated by the expression of five genes encoding 
for enzymes that work in concert to destroy the original lipid II molecule. 23 This gene 
cassette has been observed in several other microbial organisms, primarily commensal 
lactobacilli, which may have served as the origins by which pathogens evolved this 
mechanism.24 Although synthesis of molecules capable of binding both the original and 
the variant D-lactic acid target is currently being conducted, the emergence of vancomycin 
resistant bacteria is highly troublesome.25  
These mechanisms of antibiotic resistance have generated several populations of 
pathogenic bacteria which result in thousands of deaths and billions of additional health 
care costs each year.26 Complicating this dire situation, the alarming increase of antibiotic 
resistant bacteria has been accompanied by a drastic decrease in the number of United 
States Food and Drug Administration (FDA) approved antibiotics being introduced into 
the clinic. The severe paucity of novel antibiotics discovered in the past 50 years has given 
the upper hand back to pathogenic bacteria.27-29 Furthermore, the rampant, and sometimes 
unregulated, use of FDA-approved antibiotics has directly contributed to a rapid rise in the 
number of antibiotic resistant bacteria.30 With the culmination of the Golden Age of 
antibiotic discovery, the question as to what novel antibacterial therapies may be used in 
the future remains to be answered.31, 32 To reverse this disconcerting trend, the development 
of new therapeutics targeting bacterial infections through novel mechanisms of action is 
necessary. 
1.3 Immunomodulation 
One method to combat bacterial infections that has garnered recent interest is the 
use of immunomodulation. Immunomodulatory therapeutics differ from traditional 
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antibiotics by their mechanism of interaction with the bacteria. Rather than directly 
attacking pathogenic bacteria, immunomodulatory molecules act to stimulate or suppress 
the host immune system in a beneficial manner that allows for clearance of the bacterial 
infection solely by the host immune system.33 Treatment of microbial infections using this 
novel methodology possesses two main benefits. First, the immune system has evolved to 
combat pathogenic bacteria. In fact, the innate human immune system is constantly 
detecting, engaging, and destroying pathogenic bacteria. It is only when the homeostatic 
balance between the host immune system and the pathogenic bacteria is compromised that 
a bacterial infection ensues. Secondly, by targeting the immune system of the host rather 
than the bacteria, the propensity for bacteria to evolve resistance via selective pressure is 
potentially reduced.33 It is due to these two clear advantages that immunomodulatory drugs 
provide great potential as future antimicrobial therapeutics 
 
1.3.1 Innate Immune System Toll-Like Receptor Modulation 
One immunomodulation strategy for combating pathogenic bacteria through is the 
alteration of the innate immune response via targeting mammalian cell surface Toll-like 
receptors (TLRs).33 TLRs belong to the class of pattern recognition receptors (PRRs) which 
recognize pathogen-associated molecular patterns (PAMPs) characteristic of bacteria 
pathogens. Common PAMPs recognized by TLRs are bacterial flagella, lipopolysaccharide 
(LPS), lipoteichoic acid, peptidoglycan, and methylated nucleic acids.34 Upon recognition 
of these PAMPs, TLRs signal an immune response that culminates in the production of 
inflammatory cytokines that cause the destruction of the pathogen (Figure 1.2).35  
It has been hypothesized that the use of small molecule TLR agonists and 
antagonists could modulate the immune response in a manner beneficial for infection 
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clearance. The use of TLR 
agonists and antagonists has 
been widely explored for 
the treatment of cancer, 
however the use of these 
molecules as a therapeutic 
against bacterial pathogens 
remains a relatively new 
concept.36 Although in its 
infancy, TLR agonists have 
witnessed great success in 
modulating the immune 
system in response to 
bacterial infections. For 
example, the use of the 
bacterial protein flagellin 
has been observed to increase survival rates of mice challenged with Streptococcus 
pneumoniae (S. pneumoniae) and P. aeruginosa.37, 38 These pathogens are causative agents 
of lung infections and have been known to inhibit immune response to the site of 
infection.39 Flagellin, is recognized by TLR5 and stimulates the production of tumor 
necrosis factor-α	  (TNF-α)	  cytokines.40 Flagellin treatment of mice challenged with either 
S. pneumoniae or P. aeruginosa increased proinflammatory cytokine production and led to 
increased survival rates. The use of this TLR5 molecule has also proven efficacious against 
Figure 1.2 TLR Activated Proinflammatory Cytokine 
Production. TLRs 1/6, 2, and 4 recognize bacterial 
structural features such as LPS or flagellin. These 
agonists cause a signaling cascade that promotes binding 
of the TIR. Further cell signaling can activate signaling 
pathways which the gene expression of proinflammatory 
cytokines such as TNF-α. 
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vancomycin-resistant Enterococcus infections, which are highly resistant to traditional 
antibiotics.41 Other studies involving TLR4 agonists have generated similar results against 
Bordetella pertussis (B. pertussis).42  
Although production of proinflammatory cytokines can be beneficial to the 
clearance of infections, overproduction of these molecules can produce adverse effects. 
Sepsis, a condition in which overstimulation of the immune system results in 
uncontrollable inflammation and damage of bodily organs, is a highly fatal disease. It has 
been hypothesized that treatment of septic infections using TLR antagonists could inhibit 
the production of proinflammatory cytokines and result in increased patient outcomes. 
Recently, TLR4 antagonist therapeutics were developed for the treatment of sepsis and 
demonstrated potential in mouse models.43 However, this success did not translate to 
human subjects and ultimately failed in phase II clinical trials.44 Although not currently 
successful at treating sepsis, TLR4 antagonists have demonstrated potential in treating 
inflammatory bowel disease (IBD).45 IBD is characterized by the over expression of TLR4 
on intestinal mucosa membranes. This increased protein expression results in 
overstimulation of the immune system in response to both pathogenic and commensal 
bacteria.46 Recently, colitis induced mice treated with an antibody raised to inhibit 
activation of TLR4, reduced intestinal inflammation.45 This study highlights that infection 
induced autoimmune diseases, such as IBD, may be treatable by suppressing TLR 
response.  
 
1.3.2 Innate Defense Regulator (IDR) Peptides 
An alternative method for priming the host immune system to combat bacterial 
infections involves using the template that nature itself has provided. All organisms have 
14 
	  
evolved to possess their own antibiotics as a first-line defense against bacterial infections.47 
These antibiotics most commonly exist in the form of peptides derived from proteolytic 
cleavage of endogenous proteins and are appropriately termed host defense peptides 
(HDPs).48 HDPs are typically short peptides (12-50 amino acids) and are often cationic and 
amphiphilic at physiological pH. The cationic charge, typically ranging from +2 to +9, aids 
in the interaction of the peptide with the anionic membrane of both Gram-positive and 
Gram-negative bacteria.49 Some members of the HDP family of peptides have been shown 
exhibit bactericidal activities. By self-assembling at the cell membrane into higher order 
structures, such as pores within the cell membrane, HDPs can lead to bacterial cell lysis.  
Most HDPs are known to display direct cytotoxicity to bacterial cells at high 
concentrations. However, at biologically relevant conditions, HDPs have not been shown 
to directly affect bacterial cell viability, but rather modulate the innate immune system of 
the host.49 With this knowledge in hand, the use of synthetic mimics to improve on the 
immunomodulatory properties of HDPs has recently been investigated. This work has been 
spearheaded by the Hancock laboratory, which synthesized and discovered the first 
synthetic innate defense regulator (IDR) peptide almost a decade ago.50 The first IDR was 
discovered via the screening of peptides that were established to have no antimicrobial 
effect in a well-known infection model. Emerging from this screen, a 13 amino acid peptide 
(KSRIVPAIPVSLL-NH2) called IDR-1, demonstrated the ability to provide robust 
protection against bacterial infections. Further in vivo evaluation of this peptide was 
conducted by challenging mice with S. aureus and administering IDR-1 treatment. Mice 
treated with IDR-1 peptide exhibited decreased bacterial loads and improved overall 
survival rates. Inhibition of macrophage production reduced the ability of IDR-1 to clear 
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bacterial infections, thus providing key insight into its immunomodulatory mechanism of 
action. Subsequent mechanistic studies demonstrated that increased survival and decreased 
pathogenic bacterial load was a direct consequence of IDR-1 suppressing the up-regulation 
of anti-inflammatory cytokine TNF-α that occurs upon bacterial infection. Furthermore, 
IDR-1 was shown to up-regulate Interleukin-10 (IL-10), an anti-inflammatory cytokine. 
These mechanistic studies demonstrated that treatment with IDR-1 led to an improved 
balance in the inflammatory response which enabled more effective bacterial infection 
clearance (Figure 1.3).50	   
Since the discovery of IDR-1, quantitative structure-activity relationship (QSAR) 
methods have facilitated the discovery of more efficient HDPs by primarily isolating the 
immunomodulatory activities from peptide libraries.51, 52 One such peptide derived from 
this screen of antimicrobial peptide derivatives was the 12 amino acid IDR-1002.53 This 
second generation IDR demonstrated greater efficacy over IDR-1 in protecting S. aureus 
infected mice. Mechanistic studies of IDR-1002 showed that the improved efficacy was 
Figure 1.3 IDR Peptide Mechanism of Bacterial Clearance. Bacterial infections 
which are not treated with IDR peptides result in high proinflammatory cytokine 
production, low anti-inflammatory cytokine production, and chemokine production. 
Conversely, bacterial infections which are treated with IDR-1 result in reduced 
proinflammatory cytokine production, increased anti-inflammatory production, and 
modulated chemokine production. The combination of these three factors allow for 
greater control over macrophage recruitment to the site of infection, reduction in 
inflammation, and more efficient clearance of bacterial infections. 
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due to up-regulation of chemokines CCL2, CXCL1, and CCL5, which enhanced 
chemotaxis of leukocytes to the site of infection. Later, it was shown that the induced 
recruitment of immune cells promoted by IDR-1002 was mediated by stimulation of 
monocyte adhesion to the extracellular matrix protein fibronectin, which allows for 
increased monocyte retention.54 Since its discovery, IDR-1002 has been shown to also be 
effective as a vaccination agent against B. pertussis when incorporated into 
microparticles.55 Furthermore, this particular IDR displayed extended immunomodulatory 
applications beyond antimicrobial activity. The use of IDR-1002 has been evaluated to 
modulate inflammatory responses to synovial fibroblasts and could have applications in 
the treatment of rheumatoid arthritis.56  
Many other IDRs have been unveiled since the initial discovery of IDR-1 and IDR-
1002, such as IDR-1018.57 This particular peptide variant displayed 10-fold greater 
chemokine induction than IDR-1. Additionally, a greater reduction in TNF-α expression in 
LPS challenged mice was observed to promote more efficient clearance of bacterial 
infections. In addition to its immunomodulation properties, IDR-1018 additionally displays 
direct bactericidal activity against Gram-negative bacteria (although it was not shown to 
directly bind to LPS). At the same time, it demonstrated minimal cytotoxicity toward 
mammalian cells as shown through hemolysis analysis of erythrocytes.57 Furthermore, in 
wound mice models, IDR-1018 displayed strong antimicrobial activity and disrupted 
bacterial biofilm formation, which have been shown to be 100 to 1000 times more resilient 
to typical antibiotics than planktonic pathogenic bacteria of the same species.58, 59 Together, 
these features make IDR-1018 a lead candidate for treatment of bacterial infections using 
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immunomodulatory peptides and provides the basis for using IDRs as a novel antibiotic to 
combat pathogenic bacteria. 
 
1.3.3 Innate Immune System Stimulation 
Lastly, engaging the immune system by facilitating the recruitment of antibodies to 
bacterial cell surfaces displaying another immunomodulation technique.60 In this strategy, 
synthetic antibody-recruiting small molecules (ARMs), which consist of a target binding 
domain and an antibody binding domain, are used to modify the surface of target cells. The 
target-binding domain facilitates the attachment of an antigen molecule onto the target cell 
surface. The attachment of the antigen molecules serves a “homing beacon” to recruit 
antibodies to the target cell and elicit an immune response.60 This method of 
immunomodulation facilitates immune-mediated cytotoxicity through two different 
mechanisms. In the first method, the recruitment of antibodies to the target cell surface 
induces a complement-dependent cytotoxic (CDC) response. In this immune response, the 
binding of antibodies to the bacterial cell surface induces the complement system of the 
immune system to form protein aggregates in bacterial membranes and initiates the 
membrane attack complex (MAC).61 The formation of the MAC produces pores in the 
membrane, which ultimately results in target cell lysis. This CDC mechanism of immunity 
does not require the use of any other immune cells and is thought to be commonly utilized 
in the targeting of Gram-negative pathogenic bacteria. 
Alternatively, antibody recruitment to target cells can procure an immune response 
which facilitates the recruitment of other effector immune cells. In these types of immune 
responses, antibodies opsonizing the surface of target cells are recognized by effector 
immune cells. In the case of antibody-dependent cellular phagocytosis (ADCP), 
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macrophages and neutrophils recognize opsonized bacterial surfaces and phagocytose 
target cells.62 Conversely, recognition of the antibody Fc region by natural killer cells 
results in immune cell release of proteins such as perforin, which subsequently destroy the 
target through lysis. This mechanism of immunity is termed antibody-dependent cellular 
cytotoxicity (ADCC).63, 64 Stimulation of these afore mentioned immune system 
mechanisms represents an immunomodulation strategy that could hold great promise.  
To date, the display of antibody-recruiting small molecules (ARMs) on targets such 
as cancer cells, viruses, and bacteria has demonstrated high potential as an in stimulating 
the host immune system.60 In using this immunomodulation strategy, the choice between 
two types of antigen molecules exists. The first type of molecule requires vaccination of 
the host. Conjugation of the ARM to another protein followed by subsequent vaccination 
of the host generates antibodies against the synthetic antigen.65 Upon antigen labeling of 
target cell surfaces, these adaptive antibodies facilitate an immune response. The second 
option is to utilize an antigen to which the host already has pre-existing endogenous 
antibodies. By utilizing antigens that bind preexisting antibodies circulating within the 
bloodstream, the need for vaccination is eliminated and presents an attractive alternative to 
the afore mentioned immunization strategy.60 
Currently, few antigens are known to be recognized by endogenous antibodies. The 
first and most prominently utilized endogenous ARM is the carbohydrate galactosyl-(1-3) 
galactose (α-Gal) (Figure 1.4). It has been estimated that up to 8% of antibodies found 
within humans recognize and bind the α-Gal epitope.66, 67 The origins of these antibodies 
are thought to be the result of the human immune system recognizing the glycosylated cell 
surfaces of prokaryotic bacteria.68 Because of the high percentage of α-Gal antibodies 
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circulating in the human blood stream, decorating target surfaces with this trisaccharide 
epitope has produced robust immune responses used in developing cancer and HIV 
treatments.69-72  
In addition to α-Gal, several other carbohydrate-based antigens which are 
recognized by endogenous antibodies have recently been discovered.73-75 Of particular 
interest is the sugar L-rhamnose (Figure 1.4). Through extensive analysis of human sera 
samples derived from subjects of diverse ethnicities, ages, and gender, antibodies which 
bind L-rhamnose were found in greater concentrations in a higher proportion of people than 
the previously mentioned α-Gal.76 This simple sugar has been reportedly found in the outer 
cell membrane of Mycobacterium bacteria, which exhibit high levels of glycosylation 
within their cell membranes, and could possibly be the origins of these antibodies.77 
Recently L-rhamnose was used to label tumor cells and demonstrated its ability to inhibit 
tumor growth in vivo.78 
Another antigen molecule that is known to recruit endogenous antibodies is DNP 
(Figure 1.4).79 The reasons as to why humans possess antibodies against this nitro aromatic 
compound has been widely debated. Although the direct source of these antibodies remains 
Figure 1.4 Chemical Structures of Antigens that Recruit Endogenous Antibodies. 
Galactosyl-(1-3) galactose, rhamnose, and dinitrophenyl are known epitopes of 
antibodies found circulating in the human blood stream. 
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controversially, it is known that 1% of all antibodies circulating within the human blood 
stream will bind to DNP haptens.80-82 Because of its chemical structure and properties, 
creating synthetic ARMs using the DNP antigen is facile in comparison to the previously 
mention carbohydrate antigens. The use of DNP-modified ARMs has previously been used 
to elicit immunomodulation responses that have targeted human immunodeficiency virus 
(HIV), lung cancer, prostate cancer, and colon adenocarcinoma.83-85  
Although the use of ARMs in the cancer and HIV research fields has generated 
numerous cases of success in modulating host immune responses, the bacterial research 
community has generally lagged in utilizing this immune stimulant technology. When 
starting the work presented in this dissertation, only three examples of immunomodulation 
using ARMs for combating live bacterial pathogens existed. The Bednarski laboratory first 
established the concept of modifying bacterial cell surfaces to induce the recruitment of 
antibodies. This initial study targeted a mannose sugar receptor expressed on the pili of the 
Gram-negative bacterium Escherichia coli (E. coli).86 By utilizing a biotinylated α-C-
glycoside of mannose (BCM), avidin conjugated monoclonal anti-avidin IgG antibodies, 
and a protein A-gold colloidal conjugate, labeling of the bacterial cell pili was established. 
To validate the opsonization effect following BCM labeling of bacterial surfaces, induction 
of cell killing was demonstrated. Indeed, incubation of bacteria with the BCM conjugate 
led to bacterial cell death through activation of the complement system and macrophage-
mediated phagocytosis.87 Eventual studies were conducted to evaluate the ability of α-Gal-
mannose conjugates to recruit endogenous antibodies to the cell surface. Although in vitro 
ELISA binding of α-Gal antibodies was demonstrated with these molecules, no report on 
killing of bacterial pathogens is known.88 
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The first example of antigen-mediated antibody recruitment to Gram-positive 
bacterial cell surfaces originated from the Whitesides laboratory. Using vancomycin-
fluorescein isothiocyanate (FITC) conjugated polymers, the successful modification of S. 
aureus bacterial cell surfaces was observed. In this strategy, vancomycin was used to target 
the binding of the conjugate to the site of new peptidoglycan biosynthesis.89 Upon binding 
of the polymer, the FITC moiety promoted opsonization of bacterial surfaces with anti-
FITC IgG antibodies.89 The benefit of utilizing this multi-valent polymer technique was 
further revealed when S. aureus labeled with these bifunctional polymers resulted in a two-
fold increase in macrophage-mediated phagocytosis.90 
Although these two previously discussed reports demonstrate the potential of ARM 
mediated immunomodulation, the antigens utilized, biotin and FITC, would not be suitable 
for inducing an immune response without prior immunization. To mitigate this 
shortcoming, the hapten utilized should ideally recruit endogenous host antibodies to the 
bacterial surface. Recently, a unique strategy was developed in which surface-bound 
saccharides of Gram-negative pathogen Helicobacter pylori (H. pylori) were altered with 
the synthetic N-azidoacetylglucosamine (Ac4GlcNAz). The incubation of cells in the 
presence of this unnatural sugar molecule led to the mischarging of the azido containing 
sugar in place the highly abundant N-acetylglucosoamine (GlcNAc) found on surface 
glycan proteins. This strategy was successful in modifying the cell surface with DNP 
immune stimulant molecules by performing a Staudinger ligation reaction. Bacterial cell 
surfaces remodeled with this chemistry were subsequently shown to have decreased cell 
viability when incubated in the presence of peripheral blood mononuclear cells (PMBCs).91  
22 
	  
Each of these previous studies demonstrate the feasibility of stimulating the host 
immune system as an effective strategy to thwart off pathogenic bacterial infections. 
However, these methods suffer drawbacks such as vaccination, low bioavailability, or 
indirect antigen cell surface labeling. In this thesis, the development of an 
immunomodulation strategy to target pathogenic bacteria which mitigates these 
shortcomings is discussed. Using a direct targeting agent, bacterial cell surfaces were 
selectively modified with antigens that recruit endogenous antibodies to eliminate the need 
for vaccination. The antibody recruitment molecule was designed to afford high levels of 
bioavailability and selectively modulate bacterial surfaces in a direct manner to reduce off 
target immune responses effecting host cells. In vitro testing of this bacterial 
immunomodulation strategy demonstrated high levels of antibody recruitment to the 
surface of labeled cells and ultimately led to ADCP of modified bacteria. The results of 
this thesis demonstrate that our immunomodulation strategy may prove valuable as a new 
therapeutic against pathogenic bacteria.  
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Chapter 2: 
Small Molecule Bacterial Cell Surface Remodeling Strategies 
2.1 Bacterial Cell Surface Modulation 
In developing an immune stimulant method for targeting pathogenic bacteria, 
prominent antigen display was hypothesized to be critical for ensuring an immune 
response. Several different techniques to modulate the bacterial cell surface have been 
developed over the past few decades. These modulation methods were carefully assessed 
for the ability to rapidly display accessible antigens on the bacterial surface. This chapter 
discusses the different strategies that exist for modulating the surface of bacterial cells and 
describes how we eventually selected our method for displaying immune stimulant 
molecule.  
Bacterial cell surfaces are heterogeneous mixtures comprised of lipids, proteins, 
and glycans. These complex molecular structures are responsible for providing bacteria 
with structural support and mediating interactions with its environment.92 The composition 
and architecture of bacterial walls provides the basis by which bacteria are classified. 
Gram-negative bacteria characteristically possess a cytoplasmic lipid bilayer membrane 
surrounded by an outer lipid membrane. The periplasmic space between the two 
membranes harbors a thin layer of peptidoglycan (Figure 2.1A).93 Conversely, the 
possession of only a cytoplasmic membrane surrounded by a thick layer of peptidoglycan 
is a hallmark feature of Gram-positive bacteria (Figure 2.1B).94 Modulation of both Gram-
positive and Gram-negative bacterial surfaces has been pursued for several decades. The 
use of recombinant genes encoding initially afforded modifications to be displayed within 
bacterial cell surface proteins.95, 96 Future variations of these original studies has generated 
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novel biologically catalyzed reactions, therapeutics, and insights into bacterial cell wall 
structures.97-99 The use of this technology enabled cell surface modulations of several 
surface proteins but was limited to the display of biologically synthesized permutations. 
To expand the understanding of bacterial growth dynamics and cell surface applications, 
alteration of bacterial surfaces without the limitations of biologically encoded surface 
display platforms is necessary. Herein, this chapter focuses on the use of metabolically 
incorporated cell wall analogues possessing non-biologically encoded probes to modulate 
bacterial cell surfaces. The use of these chemical probes have provided insight into cell 
wall growth and dynamics, improved bacterial diagnostics, and have been developed as 
new antibiotic therapeutics.  
Figure 2.1	   Classification of Bacteria. (A) Gram-negative bacteria cell walls 
characteristically possess an inner and outer lipid membrane. A thin layer of 
peptidoglycan resides between the lipid membranes in the periplasmic space. (B) Gram-
positive bacteria possess only one lipid membrane that is surrounded by a thick layer of 
peptidoglycan. 	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2.2 Direct and Two-Step Labeling of Bacterial Cell Envelopes 
 When modulating bacterial cell surfaces using metabolic probes, two approaches 
can be taken to facilitate the incorporation of non-biologically synthesized molecules. The 
“direct” approach relies on metabolic incorporation of natural cell wall analogues 
conjugated to the desired unnatural cell surface modification (Figure 2.2 (bottom)). As no 
further chemical reaction is needed, this direct method for labeling provides facile 
modulation of bacterial surfaces and has been utilized to modify several different 
components of the bacterial cell wall (Table 2.1). However, when utilizing this labeling 
method, precaution must be exerted. Metabolic incorporation of cell wall analogues relies 
Figure 2.2	  Direct versus Two-Step Cell Wall Modulation. Metabolic cell wall 
analogues can be integrated into bacterial cell surfaces through either direct or two-
step processes. In the direct method, the desired probe moiety is attached to the cell 
wall analogue. Upon metabolism of the probe, the bacterial cell surface is 
conclusively modified. With two-step labeling, cell wall analogues containing a 
bioorthogonal chemical reactive handle are metabolized and incorporated onto the 
bacterial cell surface. Upon cell surface attachment, the reactive handle is 
selectively reacted with an appropriate bioorthogonal reactive handle that is 
conjugated to the desired cell surface modulating probe. Following the completion 
of the bioorthogonal reaction, the cell surfaces are modified with the desired probe. 	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upon the broad substrate preferences exhibited by enzymes within the synthetic pathway. 
Direct labeling entails conjugation of molecular probes, which vary in size and polarity, to 
the natural enzymatic substrate. Depending upon physical and chemical features of the 
probe, conjugation can result in the disruption enzymatic metabolism of the cell wall 
analogue, thus eliminating cell surface labeling. Additionally, metabolic pathways often 
require several enzymes working in concert. Depending upon where incorporation of the 
cell wall analogue occurs within the metabolic pathway, several enzymes may need to 
tolerate the probe. Finally, labeling of some cell surface molecules requires cellular 
internalization for metabolic incorporation. The probe molecule attached to the substrate 
can influence cell wall permeability and must be considered when attempting to directly 
modify bacterial cell surfaces. 
Table 2.1 Direct Bacterial Cell Wall Labeling Techniques 
Direct Cell Wall Analogue Labeling Techniques 
Protein Labeling 
Cell Wall Analogue Target Probe References 
Amino acid SecY pBpa photocrosslinking Mori et al.108 
Amino acid Wza pBpa photocrosslinking Nickerson et al.112 
Lipid Labeling 
Cell Wall Analogue Target Probe Authors 
Trehalose mycolates FITC Backus et al.129 
Peptidoglycan Labeling 
Cell Wall Analogue Target Probe Authors 
D-amino acid Oligopeptide FITC, NBD, Coumarin, 
TAMRA 
Kuru et al.141 
D-amino acid  Oligopeptide DNP Fura et al.207 
D-amino acid Oligopeptide Biotin  Qiao et al.146  
D-amino carboxamide  Oligopeptide NBD Pidgeon et al.151 
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D-amino carboxamide  Oligopeptide FITC Lebar et al.150  
D-amino carboxamide  Oligopeptide DNP Fura et al.220 
Tripeptide  Oligopeptide NBD Olrichs et al.155 
Pentapeptide  Oligopeptide FITC, Alexa Fluor 568 Gautam et al.165, 166 
SrtA Peptide  Oligopeptide FITC, Biotin Nelson et al.159 
Vancomycin-SrtA 
Peptide 
Oligopeptide FITC Manaskova et al.164 
 
Although direct labeling methods have successfully modified bacterial cell surfaces, the 
use of indirect, two-step labeling may be necessary depending upon the cell surface target. 
In this method, cell wall analogues containing reactive bioorthogonal handles are 
modulated to the cell wall through cellular metabolism. Subsequent reaction with a small 
molecule probe containing the appropriate reactive handle counterpart allows for detection 
of cell wall analogue metabolism (Figure 2.2 (top)). The bioorthogonal reactions readily 
utilized to modulate bacterial surfaces are copper-catalyzed alkyne-azide cycloadditions 
(CuAAC), strain-promoted alkyne-azide cycloadditions (SPAAC), Staudinger ligations, 
ketone and hydroxylamine condensations, and tetrazine and trans-cyclooctene strained 
cycloadditions.100 The use of two step modulation methods have provided valuable insights 
into bacterial cell wall dynamics which could not be previously characterized using a direct 
labeling method and are discussed throughout this review. 
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Table 2.2 Two-Step Bacterial Cell Wall Labeling Techniques 
Two-Step Cell Wall Analogue Labeling Techniques 
Protein Labeling 
Cell Wall 
Analogue Target Reactive Handle Probe References 
Amino acid OmpC azidohomoalanine biotin (CuACC) Link et al.102 
Amino acid OmpC azidonorleucine, 
azidonorvaline 
biotin (CuACC) Link et al.103 
fatty acid Lipoproteins alkyne biotin (CuACC) Rangan et al.113 
pseudominic 
acid 
Flagella azide Biotin                
(Staudinger 
Ligation) 
Liu et al.116 
GlcNAc Glycoproteins azide Flag, DNP       
(Staudinger 
Ligation) 
Koenigs et al.117  
Kaewsapsak et 
al.91  
GlcNAc Glycoproteins ketone Biotin (Ketone-
Hydrazine 
Coupling) 
Sadamoto et 
al.118 
Lipid Labeling 
Cell Wall 
Analogue Target Reactive Handle Probe References 
Trehalose mycolates Azide FITC (CuACC) Swarts et al.130 
KDO O 86 
Lipopolysaccharide 
Azide FITC (CuACC) Dumont et al.133 
Legionaminic 
acid 
O 86 
Lipopolysaccharide 
Azide Biotin 
(CuACC) 
Mas Pons et 
al.134 
Fucose O86 
Lipopolysaccharide 
Azide FITC (CuACC) Yi et al.135 
Fucose Glycoproteins Azide Biotin 
(CuACC) 
Besanceney-
Webler et al.136 
Peptidoglycan Labeling 
Cell Wall 
Analogue Target Reactive Handle Probe References 
D-amino acid  Oligopeptide Alkyne/azide FITC, DBF 
(CuACC) 
Siegrist et al.143 
Ngo et al.145 
D-amino acid  Oligopeptide Tetrazine TCO (SPAAC) Pidgeon et al.147 
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D-amino acid  Oligopeptide Nitrone DIBO 
(SPANC) 
MacKenzie et 
al.148 
Dipeptide  Oligopeptide ethynyl-D-Ala-        
D-Ala 
Alexa Fluor 
488 (CuACC) 
Liechti et al.153 
Dipeptide  Oligopeptide D-Cys-D-Ala NBD, DNP 
(maleimide)  
Fura et al.215 
Dipeptide  Oligopeptide 4-Azido-D-Phe- 
D-Pra  
Photo-
crosslinking + 
Biotin 
(CuACC) 
Sarkar et al.153 
UDP-MurNAc 
Pentapeptide 
 Oligopeptide Ketone Mannopentose 
(ketone-
hydrazine 
coupling) 
Sadamoto et 
al.156 
SrtA Peptide  Oligopeptide Azide Alexa Fluor 
488 (SPAAC) 
Nelson et al.159 
 
2.3 Protein Remodeling 
 Bacterial cell surfaces are decorated with a plethora of proteins which can serve as 
effective targets for modulation of the bacterial envelope. The use of recombinant 
technology to incorporate cell surface modulations has provided a valuable platform for 
studying proteins within the cell wall. However, this method suffers from the inescapable 
fact that only biologically encoded molecules can be utilized. To circumvent this limitation, 
the use of two-step protein labeling to facilitate the chemical integration of non-genetically 
encodable probe molecules onto proteins has been investigated.101, 102 Initial studies 
originated from Tirrell and coworkers, who demonstrated the specific incorporation of non-
natural amino acids containing azide reactive handles into E. coli outer membrane protein 
C (OmpC). Originally, azidohomoalanine was shown to serve as a surrogate for methionine 
and labeled both wildtype and mutant strains of OmpC. Successive reaction with an alkyne-
biotin probe facilitated the binding of avidin proteins to labeled cell surfaces and served as  
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a means for detection of protein modulation via western blot analysis and flow 
cytometry.101 Future investigations demonstrated several other amino acids, such as 
norvaline and norleucine, also serve as surrogates for methionine. However, these probes 
were readily utilized as the original azidohomoalanine amino acid due to poor OmpC 
incorporation (Figure 2.3).102 Since this study, the identification of a methionine-tRNA 
synthetase which efficiently utilizes azidonorleucine for Met codons, has enabled live cell 
labeling of cell surface proteins.103, 104 The chemical handles of these non-natural amino 
acid probes has also been expanded to incorporate a variety on non-natural amino acids 
into cell surface proteins.105 
 In addition to the use of natural mischarging of unnatural amino acids into surface 
proteins, the development of amber stop codons has provided structural and mechanistic 
insights of bacterial cell walls. Originally designed by Schultz and coworkers, this 
Figure 2.3	  Protein Modification Metabolic Cell Wall Analogues. Cell surface 
protein modulation can be achieved through metabolic incorporation of probe 
molecules via protein mischarging, amber stop codons, protein lipidation, or 
proteoglycan labeling. 	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technology readily allows for the incorporation of unnatural amino acids into prokaryotic 
systems.106 The use of the amber stop codon to encode for the incorporation of the unnatural 
photoaffinity probe p-benzoyl-L-phenylalanine (pBpa) has been used to label cell surface 
bacterial proteins (Figure 2.3). UV irradiation of these cell wall analogues generates a 
highly reactive radical species that reacts with nearby C-H bonds.107 The first use of 
photoaffinity probes in the bacterial cell wall membrane elucidated the interaction sites of 
the SecY and SecA proteins involved in the Sec-mediate protein translocation process in 
live E. coli.108 The incorporation of this unnatural amino acid afforded temporal control 
over protein interactions and demonstrated that certain SecY loops interact with the C-
terminus of SecA or cytoplasmic loop C6 in an adenosine triphosphate dependent manner. 
Use of these probes has also elucidated the interaction interface of the SecA dimer.109 
Development of genetic mutants in which certain residues of the SecA protein were 
deleted, photocrosslinking experiments determined amino acid residues 2-11 to be critical 
in the formation of SecA oligomers. Furthermore, use of this affinity probe has been 
applied to the Wza lipoprotein of E. coli which is pore protein found in the outer membrane 
that is responsible for polysaccharide export.110-112 Through generation of genetic mutants 
encoded to incorporate pBpa in place of hydrophilic residues present within the membrane 
pore, photocapture of polysaccharide translocation intermediates was obtained. Altogether, 
these studies highlight the mechanistic insights of protein oligomerization and membrane 
translocation that are afforded through use of non-natural photoaffinity amino acid 
analogues.  
The metabolic incorporation of chemically modified fatty acids has also provided 
a method to analyze lipoproteins within bacteria (Figure 2.3). In one study, E. coli 
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incubated in the presence of alkynyl-fatty acids demonstrated metabolic lipidation of 
proteins.113 Through use of CuAAC, metabolically altered lipoproteins were biotinylated, 
which provided a handle for selective pull down of metabolically labeled targets. Ensuing 
selective pulldown, proteomic analysis identified the lipoprotein targets and led to the 
discovery of lipoprotein modifications. Additional studies using a lipid metabolic probes 
have facilitated labeling of bacterial proteins. However, these probes label secreted effector 
proteins of bacterial pathogens, which are not bound to the bacterial cell surface and thus 
are beyond the scope of this chapter. Readers are referred to the work of Ivanov et al. and 
Hicks et al. for more information on how pathogenic bacterial effector proteins are 
metabolically labeled to target host organelles.114, 115 
 The labeling of glycoproteins in both Gram-negative and Gram-positive bacteria 
has also been demonstrated (Figure 2.3). The use of azdio-pseudoaminic acid effectively 
glycosylated the flagellin of the Gram-negative pathogen Campylobacter jejuni (C. 
jejuni).116 Reaction of the azido with a biotinylated-phosphine probe allowed for western 
blot detection of labeled flagella. Similar to labeling flagella of C. jejuni, the use of 
peracetylated N-azidoacetylglucosamine (Ac4GlcNAz) indiscriminately labeled the 
surface of Helicobacter pylori surface glycoproteins.117 These labels were subjected were 
also subjected to Staudinger ligations to covalently attach FLAG peptide epitopes to 
modified proteins for detection. As discussed in chapter 1, the use of Ac4GlcNAz attached 
DNP haptens to the pathogen surface through Staudinger ligations. Successful antibody 
recruitment to the surface of H. pylori led to pathogen killing through antibody dependent 
cell-mediated cytotoxicity (ADCC) and highlights the immunomodulation potential of this 
metabolic oligosaccharide engineering.91 Additional uses of GlcNAc containing an 
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unnatural ketone modification have been used for modification of lactobacilli bacteria 
through use of a ketone-hydrazine reaction.118 
 
2.4 Glycolipid Remodeling  
	   Additional surface molecules, such as the glycans contained within bacterial cell 
walls, have provided a fruitful target for metabolically incorporated bacterial cell surface 
probes. The Mycobacterium species, in particular, has been highly studied using glycan 
probes. The classification of this group of mycobacteria has been highly controversial. 
Similar to other Gram-positive bacteria, Mycobacterium possess a single outer lipid bilayer 
membrane that is surrounded by peptidoglycan. However, covalent attachment of long-
chain mycolic acids to the peptidoglycan forms an additional lipid membrane.119 The 
presence of this outer lipid membrane provides these bacteria with increased membrane 
rigidity and is thought to be the basis for the poor antibiotic susceptibility witnessed with 
these pathogens.120 In fact, Mycobacterium tuberculosis (M. tuberculosis), which causes 
the disease tuberculosis, possess this type of membrane structure and cause 2 million 
annual deaths worldwide.121 These pathogens are known to accumulate within macrophage 
cells within the infected host.122 Although macrophages typically eradicate phagocytosed 
bacteria, M. tuberculosis evades the human immune system and lies dormant within 
macrophages, which results in the formation a tuberculosis granuloma.123 Eventually, 
disruption of the granuloma leads to release of the bacteria and active infection of the host. 
In order to develop more efficacious therapeutic treatments of M. tuberculosis, the 
understanding of the mycobacteria cell envelope in both extracellular and intracellular 
bacteria is necessary.  
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 To answer the questions of mycobacteria outer membrane structures and dynamics, 
several cell wall glycan analogues have been utilized. This outer membrane is abundant in 
trehalose glycolipids, making analogues that mimic this sugar excellent candidates for high 
levels of membrane modulation.124 In short, trehalose disaccharides are fused to the 
mycolic acid within the cytoplasm and subsequently transported and anchored to the 
mycomembrane by Ag85 proteins creating a thick waxy membrane.125-128 The first report 
of metabolic labeling of the mycomembrane using cell wall analogues was reported by 
Backus et al.129 In this study, trehalose disaccharides were modified with fluorescein FITC 
to afford a fluorescent cell wall analogue. Several bacteria (M. tuberculosis, S. aureus, 
Haemophilus 
influenza, and P. 
aeruginosa) were 
incubated in the 
presence of FITC-
trehalose (Figure 
2.4A). Fluorescence 
microscopy analysis of 
these bacteria revealed 
only M. tuberculosis 
membranes to be 
fluorescent, 
indicating FITC-
trehalose membrane 
Figure 2.4	   Trehalose Cell Wall Analogues. The use of 
trehalose cell wall analogues has afforded researchers with the 
ability to modify the cell surface of mycobacteria.  (A) 
Conjugation of FITC to trehalose allows for the direct 
incorporation of fluorophores to the surface of mycobacteria. 
(B) The use of azido modified trehalose cell wall analogues 
facilitates the modulation of mycobacteria surfaces through a 
two-step approach.  	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incorporation. Further investigations with this probe demonstrated that macrophage 
phagocytosed M. tuberculosis were also able to be fluorescently labeled. Additional studies 
using azide-modified trehalose demonstrated that this metabolic incorporation was 
conserved throughout several different mycobacteria and that a wide range of unnatural 
substrates could be tolerated (Figure 2.4B).130, 131 Although synthesis of trehalose 
analogues can be challenging, recent work has shown the use of trehalose synthase derived 
from Thermoproteus tenax to readily synthesize trehalose cell wall analogues containing 
diverse chemical modifications.132  
In addition to glycan labeling of Mycobacterium, sugar cell wall analogues have 
been utilized to modulate the surface of several other bacteria. Gram-negative bacteria 
possess an outer membrane comprised of lipopolysaccharides that is lacking in Gram-
Positive bacteria. Analysis of this lipopolysaccharide membrane revealed high presence of 
3-deoxy-D-manno-octulosonic acid (KDO). Rapid labeling of E. coli, Salmonella 
typhimurium, and Legionella pneumophila, demonstrated that use of 8-azido-8-deoxy-
KDO followed by consequent reaction with alkyne-fluorophores, revealed highly specific 
Gram-negative bacterial labeling (Figure 2.5A).133 Further studies using 6-azido-2,4-
diacetamido-2,4,6-trideoxy-D-manose demonstrated the ability to specifically label the 
surface of Legionella pneumophila (Figure 2.5B).134 
Additional methods utilizing fucose modified sugars containing azido reactive 
groups facilitated fluorescent labeling of E. coli lipopolysaccharides through CuACC 
(Figure 2.5C).135 The use of azido-fucose has also been used to label the surface of 
commensal Bacteroidales, which highlights that these metabolic techniques can be applied 
to both pathogenic and symbiotic bacteria.136 
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2.5 Peptidoglycan Remodeling 
Peptidoglycan consists of repeating N-acetylglucosamine (GlcNAc) and N-
acetylmuramic acid (MurNAc) sugar residues that are connected through β-1,4- glycosidic 
linkages. Attached to the MurNAc sugar is an oligopeptide strand comprised of amino 
acids alternating in stereochemistry. The biosynthesis of polymeric network requires an 
ensemble of over 20 enzymes to generate a functioning polymeric network of sugars and 
peptides (Figure 2.6).137 Initially, in the bacterial cytosol, several enzymes work in concert 
to create a uridine diphosphate-GlcNAc-MurNAc-oligopeptide monomer. This nucleotide-
sugar-peptide molecule is subsequently attached to undecaprenyl phosphate in the lipid 
Figure 2.5	  Lipopolysaccharide Cell Wall Analogues. The use of carbohydrate cell 
wall analogues has generated successful modification of lipopolysaccharides in E. 
coli and Bacteriodales. (A) The use of 8-azido-8-deoxoy KDO permits 
lipopolysaccharide modulation of several Gram-negative bacteria. (B) 6-azido-2,4-
diacetamido-2,4,6-triedeoxy-D-mannose allows for selective modulation of 
Legionella pneumophila. (C) Azido-fucose enables the modulation of 
lipopolysaccharides in E. coli and commensal Bacteriodales.	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membrane to create the lipid II precursor. Enzymatic activity facilitates the transport of 
this molecule to the exterior of the cell, where it is then attached to the growing 
peptidoglycan network by glycosyltransferase enzymes. Lastly, adjacent oligopeptides 
within the peptidoglycan are crosslinked by PBP enzymes to endow bacterial cell walls 
with the ability to resist osmotic shock and turgor pressure.5 Due to the critical role of these 
proteins and their uniqueness to bacteria, molecules that inactivate PBPs, such as penicillin, 
are the basis of several potent classes of antibiotics, such as β-lactams.6 
Figure 2.6 Peptidoglycan Biosynthesis. Peptidoglycan synthesis begins in the 
cytosol of the cell where enzymes facilitate the formation of the lipid II 
peptidoglycan precursor. Subsequent enzymatic activity flips the precursor 
molecule to the lipid membrane exterior where it is further enzymatically processed 
to produce mature peptidoglycan.137	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The promiscuity of the enzymes involved in peptidoglycan biosynthesis has been 
well documented and makes cell wall analogues that mimic nature peptidoglycan monomer 
substrates prime candidates for modulation of this biopolymer. It has been known for 
nearly two decades that bacteria can incorporate exogenously added natural D-amino acids 
into the peptidoglycan. Although recognized, the physiological reasons for this 
incorporation are still unknown.138, 139 Recently, it was shown that bacteria can incorporate 
non-natural D-amino acids into the peptidoglycan stem peptide (Figure 2.7). In vitro studies 
demonstrated that “swapping” of unnatural D-amino acids for the terminal D-ala residue 
was facilitated by the transpeptidase domains of penicillin-binding proteins (PBPs).140 By 
conjugating small fluorophores to the side chain of D-amino acids and incubating bacteria 
in the presence of this probes, it was demonstrated that both Gram-negative and Gram-
positive cell surfaces could be directly modulated. The use of these fluorescent probes was 
used to visualize for the first time, real-time synthesis of bacterial peptidoglycan.141  
Additionally, peptidoglycan incorporation of exogenous D-amino acids containing 
bioorthogonal chemically reactive handles has been demonstrated. The benefit of utilizing 
these orthogonal reaction groups is their relatively small size, which permits high levels of 
enzymatic mediated incorporation.142 Using alkyne-modified D-ala side chains, the 
peptidoglycan of the intracellular pathogen, Listeria monocytogenes (L. monocytogenes) 
was observed inside macrophage cells using azido-fluorophores.143 This provided new 
insight into the dynamics of intracellular pathogen peptidoglycan and could provide 
perspective as to how these microbes evade the immune system. Future studies using this 
D-amino acid probe elucidated intracellular bacterial interactions with mammalian cell 
actin demonstrated this interaction alters bacterial cell division.144 Recent studies using  
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Figure 2.7	  Peptidoglycan Cell Wall Analogues. Several metabolic probes have been 
utilized to modulate the peptidoglycan of bacteria. (A) Transpeptidase enzymatic 
promiscuity has shown to incorporate D-amino acids and D-amino carboxamides into 
the terminal position of the oligopeptide within peptidoglycan. (B) Exploitation of 
MurF allows for dipeptide cell wall analogues to modulate both the fourth and fifth 
position of the peptidoglycan oligopeptide. (C) Recycling pathways contained within 
E. coli have been utilized to modulate the L-Lys within the peptidoglycan with 
fluorophore probes. (D) The use of pentapeptides has been demonstrated to integrate 
fluorophores into S. aureus peptidoglycan. (E) The ability of sortase A enzyme to 
recognize the LPXTG peptide sequence has enabled a method by which diverse cargo 
can be attached to the N-terminus of this peptide motif and covalently attached to the 
surface of S. aureus. (F) The use of UDP-MurNAc-pentapeptides has allowed 
modulation of the epsilon amine of Lys within the pentapeptide to be modified and 
integrated within the peptidoglycan. 	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alkyne-D-Ala to label L. monocytogenes surfaces enabled electron microscopy analysis of 
peptidoglycan incorporation patterns. This study discovered cytoplasmic biosynthesis 
metabolism of this probe, thus representing an additional mechanism by which D-amino 
acids are attached to the cell wall.145  
 Other D-amino acids containing unique chemical sidechains have also been found 
to be incorporated into the peptidoglycan. D-amino acids modified with biotin have been 
used to detect peptidoglycan precursor molecules.146 Recently, two studies demonstrated 
the incorporation of D-amino acids containing copper-free bioorthogonal click chemistry 
handles. In the first study published, D-amino acids conjugated to norbornene and tetrazine 
were used to modulate the surface of S. aureus. Subsequent reaction with either alkene or 
trans-cyclooctene fluorophores, respectively, yielded fluorescently labeled bacteria.147 In 
a separate study, an unnatural D-amino acid containing a side chain modified nitrone, D-
Ala-nitrone, was used to modify and fluorescently label Listeria innocua through a strain-
promoted alkyne-nitrone cycloaddition reaction.148 Because these probes use strain-
promoted ligations, the addition of copper, which is bactericidal is not required.149 These 
studies have expanded the scope of chemical functionalities that can be utilized to label 
and visualize live bacteria.  
 In addition to the enzymatic side chain promiscuity demonstrated by 
transpeptidase, the swapping of D-amino acids containing diverse C-terminus functionality 
has also been observed.150, 151 Through amidation of the carboxylic acid of D-
phenylalanine, Kahne and coworkers demonstrated B. subtilis (B. subtilis) PBP1 readily 
accepts the unnatural carboxamide.150 Conversely, PBP1A of E. coli discriminated against 
the carboxamide thus highlighting differences of PBPs across bacterial species. Further in 
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vivo analysis of B. subtilis using FITC conjugated D-lysine demonstrated increased cell 
surface labeling when utilizing D-amino carboxamides compared to the D-amino acid 
probe. Additional studies performed by our group elucidated the scope of transpeptidase 
D-amino acid C-terminus promiscuity. This study demonstrated different bacterial species 
possess transpeptidases which can accommodate unique modifications to the D-amino acid 
carboxylic acid.151 
 Other enzymes involved in the peptidoglycan biosynthetic pathway also 
demonstrate substrate promiscuity. Recently, MurF, the enzyme responsible for the 
ligation of the D-Ala-D-Ala dipeptide onto the growing lipid II precursor molecule has been 
demonstrated (Figure 2.7).152 In vitro studies demonstrated MurF readily tolerates D-Cys 
at the N-terminal position of a D-Cys-D-Ala dipeptide and incorporates these thiol probes 
into the oligopeptide precursor molecule. The promiscuity was first exploited in live cells 
to illustrate the presence of peptidoglycan in the pathogen, Chlamydia trachomatis (C. 
trachomatis).153 Through use of an indirect labeling procedure, an ethynyl-D-Ala-D-Ala 
dipeptide cell wall analogues were installed into peptidoglycan oligopeptides. Subsequent 
reaction with an azido containing fluorophore yielded labeled peptidoglycan, thus 
answering the five-decade Chlamydial anomaly debate. Additionally, the use of chemically 
reactive dipeptides containing both photoaffinity and alkyne handles were used by our 
group to elucidate proteins involved in the transportation of cytoplasmic lipid II molecules 
to the extracellular cell wall.154 In this work, a 4-azdio-D-phenylalanine-D-
propargylglycine photoaffinity dipeptide probe was metabolized into the peptidoglycan 
synthetic pathway. Through UV irradiation, proteins associated with the dipeptide probe 
were covalently conjugated to modified peptidoglycan oligopeptides and precursor 
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molecules. Subsequent bioorthogonal labeling of the alkyne handle with biotin afforded 
selective pulldown of dipeptide associated proteins which were identified through 
proteomics.  
 Additionally, tripeptides, which mimic the L-Ala-D-Glu-L-Lys (AeK) portion of the 
peptidoglycan oligopeptide, have been utilized to directly label E. coli. In this method, a 
small NBD fluorophore was attached to the AeK tripeptide lysine sidechain (Figure 2.7).155 
By exploiting peptidoglycan recycling pathways that Gram-negative bacteria use, small 
fluorescent probes were introduced into the peptidoglycan stem peptide. This labeling 
provided insight into the E. coli peptidoglycan recycling mechanism. Pulse labeling 
experiments using this cell wall analogue demonstrated minimal labeling at the septal 
region, which differs from several other peptidoglycan cell wall mimics. The utilization of 
a triple knockout genetic mutant identified that the protein FtsZ is responsible for the 
hydrolysis of oligopeptide side chains.  
Larger peptide probes have also been shown to demonstrate cell surface labeling 
through the cytoplasmic peptidoglycan biosynthetic pathway. Use of UDP-MurNAc 
precursor molecules in which the epsilon amine of the L-Lysine side chain was labeled 
with FITC or a ketone, was shown to be readily accepted as a metabolite for E. coli and 
Gram-positive lactobacilli (Figure 2.7).156, 157 However, other lipid I and lipid II precursors 
in which UDP is removed, demonstrated no labeling.156 The use of a ketone modified 
precursor was eventually used to control the surface adhesion of bacterial cells.158 
 Several other methods of modifying peptidoglycan exist. Spiegel and coworkers 
developed a methodology to decorate the cell surface of the Gram-positive pathogen S. 
aureus using the enzymatic activity of the membrane anchored protein sortase A (SrtA).159 
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This enzyme is tasked with anchoring secreted proteins, such as protein A, to the 
peptidoglycan surface of the pathogen.160, 161 In anchoring proteins, SrtA recognizes the 
short , LPXTG peptide motif (where X is any amino acid) and catalyzes amide bond 
cleavage between the threonine and glycine residues to generate an acyl enzyme 
intermediate. Further reaction of this intermediate with the nucleophilic amine of a penta-
glycine crosslinking oligopeptide anchors the secreted proteins to the membrane.162 
Although the natural SrtA substrate is LPETG in S. aureus, the use of methionine in the 
central position of the pentapeptide demonstrated enhanced cell surface labeling.163 By 
modifying the N-terminus of the LPXTG peptide sequence, the incorporation of small 
fluorophores and affinity probes were tethered to the surface of S. aureus (Figure 2.7).159 
Recently, the conjugation of the C-terminus of the LPXTG to the antibiotic vancomycin 
was pursued in hopes of utilizing vancomycin’s lipid II binding ability to increase the 
effective concentration of the SrtA substrate at the cell surface by.164 This SrtA-
glycopeptide substrate demonstrated a 500 fold improvement in labeling efficiency at low 
micromolar concentrations. Additionally, the use of SrtA to modify the surface of S. aureus 
has since been used as a possible immunomodulatory strategy. While the work of this thesis 
was being conducted, the conjugation of FITC to the N-terminus of LPXTG enabled the 
surface of S. aureus to be decorated with this small fluorophore molecule and demonstrated 
the ability to recruit anti-FITC antibodies to the bacterial cell surface.165 Although this 
highlights this cell surface modulation strategy as an immunotherapy, it still suffers from 
drawbacks such as bioavailability and the need for vaccination.  
Additional peptides have recently been shown to modify the bacterial cell surface 
and provide great insight into physiological phenomenon occurring during cellular growth. 
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The conjugation of small fluorophores to the N-terminus of the oligopeptide sequence 
found in peptidoglycan enabled fluorescent labeling of live bacteria (Figure 2.7).166 These 
fluorescent mimics were found to be selectively recognized by PBP4 in S. aureus. Through 
pulse labeling experiments the localization of PBP4 was obtained. These experiments 
revealed PBP4 activity throughout the entirety of the cell, which was previously 
hypothesized to occur only at the septal region of bacterial growth.167 
2.6 Conclusion 
Numerous methods to modulate bacterial cell surfaces currently exist. The 
incorporation of non-genetically encoded molecules using cell wall analogues has greatly 
advanced the field of microbiology within the past decade. Dynamics of bacterial cell 
growth through imaging, proteomic techniques for identification of proteins involved in 
metabolic pathways, and rapid diagnostics of bacteria have all been developed through cell 
wall analogue probe assimilation into bacterial surfaces. To expand upon the applications 
of bacterial cell wall modulation, we strived to develop a novel immunomodulation 
strategy as a potential treatment of bacterial infections. We hypothesized that the use of a 
cell surface modulation technique to facilitate the adornment of hapten molecules on the 
bacterial surface could serve as an immune stimulant therapy to combat pathogenic 
bacteria. In developing this immunomodulation strategy, we envisioned rapid and 
extensive hapten modification of the bacterial cell surface would be critical. Additionally, 
haptens must be readily accessible to facilitate a proper immune response. For these 
reasons, we initially chose to utilize the peptidoglycan D-amino acid “swapping” technique 
to modulate the peptidoglycan of Gram-positive bacteria. From herein, the development of 
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D-amino acid antibody recruitment therapy (DART) using D-amino acid-DNP hapten 
molecules will be discussed.  
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Chapter 3: 
Development of D-amino acid Immunomodulation Therapy (DART) 
 
3.1 Abstract 
 As the number of antibiotic resistant bacteria continues to rapidly increase, the 
development of new methodologies to treat bacterial infections is of paramount 
importance. Recently it was discovered that the bacterial transpeptidase enzymes 
incorporate exogenous D-amino acids into the oligopeptide chain of the peptidoglycan 
monomer. In this chapter, the development of a novel immunomodulatory therapy to 
combat pathogenic bacteria is explored. Initially, fluorescent probes were conjugated to the 
side chain of D-amino acid cell wall analogs and utilized to modulate the peptidoglycan of 
Gram-positive bacteria. Through these studies, the stereoselective nature of this enzymatic 
promiscuity was observed and optimal conditions for bacterial peptidoglycan modification 
utilizing D-amino acids were determined. Using these empirically determined conditions, 
the conjugated fluorophore on the D-amino acid side chain was exchanged with a DNP 
hapten moiety to facilitate the recruitment of anti-DNP antibodies which are readily found 
in human blood serum. The studies presented in this chapter demonstrate that the 
incorporation of DNP haptens within the bacterial peptidoglycan scaffold enhances the 
recruitment of endogenous anti-DNP antibodies to the bacterial cell surface by nearly four-
fold compared to unlabeled cells. Additionally, bacterial cells that were labeled with DNP-
D-amino acids were observed to be phagocytosed by macrophages twice as readily 
compared to unlabeled cells. In conjunction, these results demonstrate the initial 
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framework towards developing a D-amino acid Antibody Recruitment Therapy (DART) 
that could be used as a novel means to possibly combat bacterial pathogens. 
3.2 Introduction 
The cell wall of Gram-positive bacteria has served as a fruitful target for the 
development of antibacterial therapies for decades.168 As discussed previously, Gram 
positive bacteria are surrounded by a mesh-like scaffold of peptidoglycan, which is 
composed of multiple layers of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid 
(MurNAc) glycan strands that are cross-linked by oligopeptides.169 Peptidoglycan provides 
bacteria with immense structural support. Due to the critical role of the cell wall during 
cellular growth and division, molecules that interfere with the necessary enzymatic 
processes related to peptidoglycan synthesis have become some of the most successful 
antibiotic agents.170 In addition, the chemical remodeling of the surface of bacteria has 
drawn considerable attention as of late due to its potential to reveal fundamental insights 
into many biological processes such as cell division and bacteria−host interactions.171 
Several approaches have been explored to decorate the surface of both Gram-
positive and Gram-negative bacteria, including the use of unnatural sugars, cell wall 
components, and enzymatic modification to the oligopeptides. Recently, it was revealed 
that diverse species of bacteria can readily incorporate unusual D-amino acids (e.g., D-
methionine, D-valine, D-tyrosine) into their peptidoglycan from the surrounding medium 
by replacing the terminal D-alanine of the oligopeptide chain.172 All species of bacteria 
analyzed to date have been found to possess this feature, an indication that the process of 
D-amino acid incorporation may be inherent to all peptidoglycan-containing bacteria. 
Incorporation of exogenous D-amino acids has been attributed to a promiscuous enzymatic 
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activity of bacterial D,D-transpeptidases.140 When starting this thesis, these enzymes were 
known to exhibit little discrimination in terms of side chain selectivity of the D-amino acid, 
an unusual property for most enzymes.141, 143, 173  
We set out to develop a potentially novel antimicrobial strategy by exploiting the 
propensity of bacteria to incorporate exogenous D-amino acids into their peptidoglycan that 
are conjugated with antibody-recruiting antigens (Figure 3.1). We hypothesized that a 
synthetic immunology approach could provide a highly efficient method for developing 
alternative antibiotic agents. The human immune system is adept at combating the vast 
majority of pathogenic bacteria it encounters. During instances of bacterial infection, 
bacteria manage to elude the actions of the immune response of the host. Instead of using 
cytotoxic small molecules to directly destroy bacteria, a strategy that has recently yielded 
few successful agents, we hypothesized that a selective immunomodulator could 
potentially function to reactivate the host immune system to seek out and clear pathogenic 
bacteria.  
Figure 3.1 Schematic Representation of DART. The bacterial cell surface 
peptidoglycan is labeled with D-amino acids conjugated to an immune stimulant 
molecule. For this study, the immune stimulant selected was the DNP epitope. 
Following bacterial cell surface modification, the binding of anti-DNP IgG antibodies 
leads to the eventual clearance by the immune system.	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 The field of synthetic immunology via small molecules may be in its infant stages, 
but it already shows great potential for the development of next-generation immune-
modulating therapies. As discussed in chapter 1, recent efforts in this field have led to the 
development of synthetic antigen-displaying molecules to recruit endogenous antibodies 
to promote the macrophage mediated elimination of HIV particles and have also shown 
promising results as novel anticancer agents. 69, 70, 84, 88, 90, 174 Herein, we describe the 
successful development of the framework for bacterial D-amino acid antibody recruitment 
therapy (DART). DART relies on the bacterial cell surface remodeling via the 
incorporation of D-amino acids modified with the DNP epitope into the peptidoglycan 
(Figure 3.1). We show that when DNP is conjugated to the appropriate D-amino acid 
backbone, there is both efficient incorporation and subsequent recruitment of anti-DNP 
antibodies. 
 
3.3 RESULTS AND DISCUSSION 
3.3.1: Fluorescent D-Amino Acid Labeling of B. Subtilis.  
Initially, we sought to determine the level at which transpeptidases can 
stereoselectively incorporate D-amino acids into the peptidoglycan of the Gram-positive 
bacterium, B. subtilis. This was accomplished by conjugating the small fluorophore 4-
chloro-7-nitro-2,1,3-benzoxadiazole (NBD) to the side chain of D- and L-lysine (Figure 
3.2). The species B. subtilis is widely utilized as a model Gram-positive bacterium due to 
its ease of handling and its similarity to other pathogenic bacteria.175 The mutant strain B. 
subtilis ΔdacA, which lacks the D-alanyl-D-alanine carboxypeptidase, has previously been 
used to yield higher D-amino acid incorporation levels and, as such, was the strain of choice  
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Figure 3.2 Transpeptidase Mediated Swapping of Exogenous D-Lys(NBD). 
Exogenous D-Lys(NBD) can be exchanged with the terminal D-Ala of the stem 
peptide through transpeptidase enzymatic promiscuity to fluorescently label bacterial 
cell surfaces.  
Scheme 3.1 Synthesis of NBD Conjugated Amino Acids. Boc-protected amino acids 
were conjugated to NBD fluorophores through standard solution phase chemistry 
procedures. Following conjugation, TFA deprotection of protecting groups afforded 
side chain conjugated NBD fluorophore to both D- and L-Lys.	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for our experiments.141, 143, 176, 177 Both D-Lys-(NBD) and L-Lys(NBD) were synthesized 
by reacting N-Boc protected amino acids with the amino reactive NBD-Fluoride, followed 
by trifluoroacetic acid (TFA) Boc deprotection (Scheme 3.1).  
At first, B. subtilis cells were incubated in medium supplemented with D-Lys(NBD) 
and visualized via fluorescence microscopy (Figure 3.3). We observed a uniform 
fluorescence signal through the entire cell, a finding that is consistent with the remodeling 
of the cell surface using D-amino acids.141 Next, we set out to determine relative 
incorporation levels of the amino acid and the stereospecificity of this remodeling strategy 
using flow cytometry. B. subtilis cells were incubated with various concentrations of either 
D-Lys(NBD) or L-Lys(NBD) during the exponential growth phase and analyzed for the 
acquisition of fluorescence. Flow cytometry analysis of labeled cells revealed that bacteria 
exposed to 250 µM of D-Lys(NBD) displayed a 30-fold increase in fluorescence signal 
compared to its enantiomeric L-Lys(NBD) counterpart and a 100-fold increase over 
unlabeled B. subtilis (Figure 3.4).  
Figure 3.3 DIC and Fluorescent Microscopy Image of D-Lys(NBD) Labeled B. 
subtilis ΔdacA. B. subtilis ΔdacA were incubated in LB media containing 1 mM D-
Lys(NBD) for 4 hours at 37⁰C. Cells were washed three times and imaged. Scale bar 
represents 3μM.  
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The significant 
difference between the 
fluorescence levels in bacteria 
treated with the enantiomeric 
molecules suggests that a 
specific process (in this case, 
we presume it to be the 
transpeptidase activity) is 
responsible for selecting one 
compound over another. The 
low levels of fluorescence 
associated with L-Lys(NBD) 
treated bacteria may have 
resulted from nonspecific 
binding of the amino acid to 
the bacterial surface or from 
low levels of intracellular 
accumulation. Notably, at 
concentrations as low as 10 
µM, we observed significant 
differences in fluorescence 
levels between the two 
enantiomers (Figure 3.5). We 
Figure 3.4 Stereoselectivity of Transpeptidase 
Mediated Amino Acid Swapping. Flow cytometry 
analysis of B. subtilis incubated for 4 hours in LB alone 
and LB supplemented with either 250 µM of D-
Lys(NBD) or 250 µM of L-Lys(NBD). 
Figure 3.5 Concentration Scan of Transpeptidase 
Mediated Amino Acid Incorporation. Flow 
cytometry analysis of B. subtilis cells incubated 
overnight in LB supplemented with either D-Lys(NBD) 
or L-Lys(NBD) at various concentrations. Data are 
represented as mean ± SD, (n = 3). 
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also observed that the transpeptidases appear to be saturated at a concentration around 1 
mM of D-Lys(NBD) as the fluorescence levels start to plateau at this concentration. 
The initial discovery that transpeptidases possess the unique ability to accept 
unusual D-amino acids was confirmed by competition experiments with the natural 
substrate D-alanine.143 Likewise, we performed competition labeling experiments using D-
alanine with bacterial cells incubated with D-Lys(NBD) (Figure 3.6). When cross-linking 
the peptide chains of peptidoglycan, transpeptidases form an acyl-enzyme intermediate 
with the donor strand that can either be cross-linked to the acceptor strand or react with an 
exogenous D-amino acid to reform the pentapeptide chain. We observed that the labeling 
Figure 3.6 D-Ala Inhibition of Transpeptidase Mediated D-amino acid 
Swapping. Flow cytometry analysis of B. subtilis cells incubated for 4 hours in LB 
supplemented with 150 µM D-Lys(NBD) and co-incubated with various 
concentrations of D-Ala. Data are represented as mean + SD. 
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of cells with D-Lys(NBD) was effectively inhibited by increasing the concentration of D-
alanine, which is consistent with the incorporation of the D-amino acid via transpeptidases.  
Finally, a time-course analysis of the process was conducted to determine the 
incubation time required for adequate incorporation of the unnatural D-amino acid. We 
observed that significant levels of peptidoglycan modification can be detected within 20 
min of bacterial incubation with the D-amino acid fluorophore and increases through the 
exponential growth phase (Figure 3.7).  
Figure 3.7 Time Course Analysis of Transpeptidase Mediated D-Amino Acid 
Incorporation. Flow cytometry analysis of B. subtilis cells incubated in LB 
supplemented with either D-Lys(NBD) for various times. Data are represented as mean 
± SD, (n = 3). 
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3.3.2: DNP-D-amino acid Mediated Opsonization of B. subtilis 
Having determined working concentrations and incubation times for D-amino acid 
peptidoglycan integration, we set out to explore the possibility of using D-amino acids 
modified with immune stimulant epitopes to recruit antibodies to the surface of labeled 
bacteria. DNP was chosen as the epitope due to the naturally high concentration of anti-
DNP antibodies in human serum and its small size.75 In designing a D-amino acid that could 
recruit endogenous antibodies, we envisioned two distinct factors that would have to be 
carefully balanced: epitope accessibility and incorporation efficiency. First, to be available 
for antibody binding, the DNP epitope must be accessible to the extracellular space. In 
Gram-positive bacteria, mature peptidoglycan can range in thickness from 20nm to 80 
nm.94 The pores within the peptidoglycan have been estimated to be between 5nm and 25 
nm, roughly the same dimensions of an antibody.178 Due to the possibility that antibodies 
permeate poorly into the peptidoglycan, we anticipated that only surface exposed DNP 
epitopes would be highly available for antibody recruitment (Figure 3.8A). One possible 
way to facilitate the presentation of the DNP epitope to antibodies in the extracellular 
medium is to anchor the DNP onto a long flexible linker connected to a D-amino acid unit. 
However, it is important to also consider the second and possibly opposing factor, 
peptidoglycan incorporation efficiency. Although it is evident from past studies that 
bacteria have some inherent flexibility to the incorporation of various D-amino acids, we 
presumed there to be structural limitations in regards to the size and physical characteristics 
of the amino acid side chain. The efficiency of incorporation will dictate the total number 
of D-amino acids found within the peptidoglycan scaffold and subsequently affect the 
ability to recruit anti-DNP antibodies to the bacterial surface (Figure 3.8B).  
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Due to our limited understanding of the side chain tolerability exhibited by 
transpeptidase when integrating D-amino acids into the peptidoglycan, we chose to 
construct a small panel of DNP-displaying D-amino acids. Our D-amino acid panel was 
designed to encompass molecules of varying linker lengths between the amino acid α-
carbon and the DNP epitope (Figure 3.9). All compounds were synthesized using standard 
solution phase chemistry or solid phase peptide synthesis (SPPS) and purified via reverse-
phase high performance liquid chromatography (RP-HPLC) (Scheme 3.2). Masses were 
confirmed using either electrospray ionization mass spectrometry (ESI-MS) or matrix-
assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) 
(Appendix 3.1). 
Figure 3.8 Epitope Accessibility versus D-amino acid Incorporation. When 
designing our D-amino acid panel, we hypothesized two competing factors would 
need to be balanced to generate an immune response. A) Only surface exposed 
epitopes will be accessible for antibody binding. B) Larger side chains were 
hypothesized to sterically inhibit the transpeptidase mediated incorporation of D-
amino acids. Although these side chains could protrude further from the surface, 
reduction of epitopes incorporated into the peptidoglycan could hinder the 
recruitment of antibodies to the bacterial cell surface.  
 
57 
	  
For this set of experiments, B. subtilis cells were incubated in medium containing 
the DNP-displaying D-amino acid and labeled through the exponential growth phase. 
Figure 3.9 Structures of D-amino acid-DNP Series Tested for Antibody 
Recruitment 
Scheme 3.2 Synthesis of DNP Conjugated D-amino acids. D-amino acids were 
synthesized using standard solid phase peptide chemistry. Side chain length was varied 
and DNP epitopes were conjugated the terminus of the side chain to possibly afford 
better epitope accessibility.  
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Following the initial 4-hour peptidoglycan remodeling period, bacteria were washed and 
incubated with Alexa Fluor 488-conjugated anti-DNP IgG antibodies. The ability of each 
compound to recruit anti-DNP antibodies to the surface of the bacteria was quantified by 
monitoring the fluorescence levels using flow cytometry (Figure 3.10).  
We observed a distinct pattern of antibody recruitment, whereby amino acids with 
shorter or longer linker lengths recruit less readily than the intermediary D-Lys(DNP). 
While the shorter linkers, D-2,4 diaminobutyric acid(DNP) (D-Dab(DNP)) and D-
Ornithine(DNP) (D-Orn(DNP)), still effectively mediated low levels of antibody binding, 
we observed a loss of antibody recruitment for amino acids with longer linkers. These 
findings are consistent with our hypothesis that long and flexible side chains reduce 
incorporation efficiency, while shorter linker lengths reduce the accessibility of the DNP 
epitope within the peptidoglycan scaffold. D-Lys(DNP) displayed the highest antibody 
recruitment capacity, presumably because it represents a balance of the two competing 
Figure 3.10 Anti-DNP Antibody Recruitment to the Surface of B. subtilis. Cells 
were incubated for 4 hours in LB supplemented with 250 µM of specified D-amino 
acids followed by incubation with anti-DNP antibodies. Data are represented as 
mean + SD (n = 3). Inset, DIC and fluorescence microscopy imaging of cells labeled 
with 1 mM D-Lys(DNP) followed by anti-DNP. Scale bar represents 3 µm. 
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factors of accessibility and 
incorporation. Next, we evaluated the 
antibody-recruitment ability of D-
Lys(DNP) at concentrations 
approaching near the maximum 
incorporation levels (1 mM). We 
observed a marked increase in 
fluorescence levels with the labeling 
of bacteria at this concentration, 
consistent with higher levels of D-
Lys(DNP) displayed on the bacterial 
surface (Figure 3.11). The 
fluorescence level observed under 
these conditions is indicative of robust 
antibody binding of surface-anchored DNP, especially considering the size of individual 
B. subtilis cells. It is worth noting that even at 1 mM of amino acid, we observed minimum 
bacterial growth inhibition (Figure3.12).  
Finally, we set out to visualize anti-DNP antibody binding to the surface of DNP-
decorated bacteria using fluorescence microscopy (Figure 3.8, inset). We observed 
antibody binding throughout the surface of the cell, but with increased binding at the central 
portion of the cell compared to either pole. The relatively low levels of surface-bound 
antibodies at the site of daughter cell separation during cell division is consistent with the 
location of new peptidoglycan synthesis (Figure 3.13).94 The 1-hour incubation period of 
Figure 3.11 Concentration Dependence of 
D-Lys(DNP) for Antibody Recruitment. 
Cells were incubated for 4 hours in LB alone 
or LB supplemented with the specified 
concentration of D-Lys(DNP). Following the 
labeling period, bacteria were incubated with 
Alexa Fluor 488-conjugated anti-DNP 
antibodies and analyzed via flow cytometry. 
Data are represented as mean + SD, n =3. 
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bacteria with the antibodies at 
physiological temperatures is 
long enough to allow partial or 
complete cell division. This 
division or cell elongation would 
take place in medium lacking D-
Lys(DNP). Therefore, the newly 
synthesized cell wall would not 
retain the ability to recruit 
antibodies in our assay 
conditions.  
Clearly, the availability 
of DNP epitopes to the 
extracellular medium is a critical factor in determining antibody recruitment. We presume 
that the longer linker length of D-Lys(DNP) led to higher antibody recruitment than in 
bacteria decorated with the shorter linker D-Dab(DNP). To probe the DNP accessibility 
further, we first incubated the bacteria in the presence of the DNP-modified D-amino acids 
at 37 °C and then performed the binding step at two different temperatures, 4 °C and 37 °C 
(Figure 3.14). Basic thermodynamic principles would predict weaker binding between anti-
DNP antibodies and surface-bound DNP epitopes at physiological temperatures relative to 
4°C. Yet, we observed that the recruitment of anti-DNP antibodies to bacteria labeled with 
D-Lys(DNP) was more prominent at the higher temperature. We hypothesize that, at the 
higher temperature, the polymeric chains within the peptidoglycan can display greater 
	  
Figure 3.12 Evaluation of D-Lys(DNP) Toxicity 
towards B. subtilis. B. subtilis cells were 
incubated in LB alone or LB supplemented with 
the specified concentration of D-Lys(DNP) and the 
optical density was monitored at 600 nm at various 
time intervals. Data are represented as mean ± SD 
(n = 3). 
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molecular mobility. In turn, either the DNP epitopes on the muropeptide become more 
accessible to the surrounding medium or the anti-DNP antibodies gain greater permeability 
into the peptidoglycan scaffold. Alternatively, it may be possible that the anti-DNP 
antibody used in this study was 
evolved and functions optimally 
at 37 °C. Consequently, antibody 
binding to the DNP epitopes on 
the cell surface maybe more 
favorable at 37 °C. Another 
feature that makes DART an 
appealing therapeutic is its 
ability to recruit antibodies to 
the surface of bacteria during 
stationary phase. A feature that 
renders bacterial infections 
Figure 3.14 Antibody Cell Surface Binding 
Temperature Dependence. Cells were incubated 
for 4 hours in LB alone or LB supplemented with 1 
mM of D-Lys(DNP). Following the labeling period, 
bacteria were incubated with Alexa Fluor 488-
conjugated anti-DNP antibodies at 4 oC and 37 oC 
and analyzed via flow cytometry. Data are 
represented as mean + SD. 
Figure 3.13 Septal Region of B. subtilis. Bacterial peptidoglycan is synthesized at the 
septal region, which is also where bacteria divide. 
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difficult to treat is the 
presence of persister 
cells−cells that are in 
a quiescent-like 
state.179-181 Persister 
cells include slow- 
and non-dividing 
cells that have altered 
metabolic states. 
Persister bacterial 
cells are less 
susceptible to many 
traditional antibiotics 
as these agents target 
the processes 
involved in actively growing bacteria. We infer from the elevated levels of antibody 
recruitment by cells labeled in the stationary phase that slow and non-dividing bacteria 
may, in fact, be more prone to the incorporation of D-Lys(DNP) than rapidly dividing 
bacteria (Figure 3.15). Moreover, we observed detectable antibody recruitment at medium 
concentrations of D-Lys(DNP) down to 50 µM upon overnight incubation as opposed to 
the typical 4-hour incubation used for all other labeling experiments (Figure 3.16). The 
slower turnover in peptidoglycan from slow-dividing or persister cells combined with 
extended exposure to antibody recruiting D-amino acids may result in an enhanced 
Figure 3.15 Bacterial Cell Opsonization Phase Dependence. 
B. subtilis cells were incubated for 4 hours in LB alone or LB 
supplemented with 1 mM of D-Lys(DNP) either during the 
exponential phase or during the stationary phase. Following the 
labeling period, bacteria were incubated with Alexa Fluor 488-
conjugated anti-DNP antibodies and analyzed via flow 
cytometry. Data are represented as mean + SD (n = 3).  
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clearance potential. Moreover, a slow peptidoglycan turnover may allow for the use of 
reduced extracellular dosages of the D-amino acid required to attain a critical level of DNP 
displayed on the cell surface. 
In addition to antibody recruitment ability, we set out to assess the toxicity of D-
Lys(DNP) against host mammalian cells. One of the major possible advantages of using 
D-Lys(DNP) to target bacteria derives from the fact that it relies upon the enzymatic 
incorporation at the surface of the cell. No mammalian enzymes are known to exist and 
accept D-amino acid substrates, potentially giving this strategy high selectivity. 
Furthermore, the zwitterionic character of the free amino acid should greatly reduce its 
ability to passively diffuse into cells. Therefore, it is anticipated that in a living organism, 
administered D-amino acids would be preferentially utilized by bacteria. To evaluate the 
Figure 3.16 Overnight Modulation Effect on Bacterial Opsonization. 
B. subtilis cells were incubated for 16 hours in LB alone or LB 
supplemented with the specified concentration of D-Lys(DNP). Following 
the labeling period, bacteria were incubated with Alexa Fluor 488-
conjugated anti-DNP antibodies and analyzed via flow cytometry. Data are 
represented as mean + SD (n =3).  
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toxicity of D-Lys(DNP), HeLa cells were incubated in the presence of varying 
concentrations of D-Lys(DNP) for 72 h and analyzed by standard viability assays (Figure 
3.17). At all concentrations examined, we observed no significant loss of viability, thus 
highlighting an important feasibility consideration of our strategy.  
 
3.3.3: Characterization of DNP-D-amino acid Modified Peptidoglycan  
The ability of D-Lys(DNP)-treated bacteria to bind anti-DNP antibodies and the D-
alanine competition experiments are strong indicators that D-Lysine derivatives are likely 
to be anchored onto the surface by the enzymatic action of transpeptidases. However, these 
experiments do not definitively determine D-amino acids are incorporated into the 
peptidoglycan. To confirm covalent modification of the cell wall, we isolated the 
peptidoglycan from bacteria and digested the glycosidic linkages using muramidase.182 The 
Figure 3.17 D-Lys(DNP) Induced Mammalian Cell Toxicity. HeLa cells were 
incubated for 72 hours in the absence or the presence of increasing concentrations 
of D-Lys(DNP). Cellular viability was evaluated with MTT by measuring 
absorbance at 580 nm. Data are represented as mean + SD (n = 3). 
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crude muropeptides were separated on a RP-HPLC column and fractions displaying an 
absorbance consistent with the presence of DNP were collected. MALDI-TOF MS analysis 
of the collected sample confirmed the incorporation of the unnatural D-Lys(DNP) and D-
Dab(DNP) (Figures 3.18 and 3.19).  
Figure 3.18 MALDI-TOF MS of D-Lys(DNP) Modified Peptidoglycan. 
MALDI-TOF analysis of peptidoglycan isolated from B. subtilis cells labeled 
with D-Lys(DNP) following RP-HPLC separation. Inset, structure of expected 
peptidoglycan repeating unit with the inclusion of D-Lys(DNP) and the expected 
molecular weight. 
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Next, we utilized the peptidoglycan isolation procedure to quantify relative 
incorporation levels of the D-amino acid derivatives. Because we observed different 
antibody-recruitment among D-Dab(DNP), D-Lys(DNP), and D-Lys-PEG1(DNP), we 
were particularly interested in analyzing the relative incorporation of these three amino 
acids. We hypothesized that the increased accessibility afforded by the longer linker of D-
Lys(DNP) relative to D-Dab(DNP) led to higher recruitment levels. Conversely, we 
Figure 3.19 MALDI-TOF MS of D-Dab(DNP) Modified Peptidoglycan. 
MALDI-TOF Analysis of Peptidoglycan isolated from B. subtilis cells labeled with 
D-Dab(DNP) following RP-HPLC separation. Inset, structure of expected 
peptidoglycan repeating unit with the inclusion of D-Dab(DNP) and the expected 
molecular weight	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believed the poorer 
incorporation of D-
Lys-PEG1(DNP) was 
responsible for 
decreased antibody 
recruitment. Using 
DNP absorbance as a 
method of detection, 
we found that D-
Dab(DNP) and D-
Lys(DNP) displayed 
comparable 
incorporation levels, 
while incorporation 
levels were much lower for D-Lys-PEG1(DNP) (Figure 3.20). Together, these data agree 
with our hypothesis that there is a size-dependency for the incorporation of D-amino acids 
and that an elongated linker connecting DNP can have positive effects on antibody 
recruitment.  
 
3.3.4: S. aureus Opsonization using DART 
Next, we set out to determine if DART was compatible with a pathogenic Gram-
positive bacterium S. aureus. Initially, we sought to determine if NBD modified D-amino 
acids were readily incorporated into the pathogen’s peptidoglycan. As with B. subtilis and 
consistent with previous reports, we observed cell labeling of D-Lys(NBD) by the 
Figure 3.20 UV-Vis Spectrum of Soluble Peptidoglycan 
Modified with DNP-D-amino acids. B. subtilis cells were 
incubated for 4 hours in LB containing either 500 µM of D-
Dab(DNP), D-Lys(DNP), and D-Lys-Peg1(DNP). Cells were 
harvested, peptidoglycan was isolated and subjected to 
lysozyme digestion. Soluble peptidoglycan was isolated and 
then analyzed with UV-Vis spectroscopy.  
68 
	  
pathogenic S. aureus at both 250 µM and 1 mM (Figure 3.21). In conjunction with the 
previously discussed B. subtilis peptidoglycan modulation, these data demonstrate there is 
rapid and extensive incorporation of D-Lys(NBD) under a wide-set of conditions. 
Following the determination that S. aureus peptidoglycan was modified through 
fluorescent D-amino acids, the ability of D-Lys(DNP)-remodeled S. aureus to recruit anti-
DNP antibody was evaluated (Figure 3.22). For this set of experiments, it was expected 
that endogenous S. aureus protein A would facilitate IgG binding of the cell surface, thus 
contributing to background fluorescence. The addition of soluble protein A to anti-DNP 
IgG antibodies prior to incubation with the bacteria cells was successful in greatly reducing 
the non-DNP mediated IgG antibody binding. When S. aureus was labeled with 1 mM D-
Figure 3.21 D-Lys(NBD) Modulation of S. aureus Peptidoglycan. Flow 
cytometry analysis of S. aureus cells incubated for 4 hours in LB alone or 
LB supplemented with D-Lys(NBD) at the stated concentrations. Data are 
represented as mean + SD (n = 3).  
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Lys(DNP), we observed a marked increase in anti-DNP antibody recruitment compared to 
unlabeled cells.  
Additionally, we hypothesized that teichoic acid−based polyanionic polymers (wall 
teichoic acid and lipoteichoic acid) contained within the cell wall of S. aureus may serve 
to hinder the permeation and binding of anti-DNP antibodies to the modified 
peptidoglycan.183-185 By growing the bacteria in the presence of D-Lys(DNP) and 
tunicamycin, a known wall teichoic acid inhibitor, cell surface antibody binding was 
greatly increased compared to anti-DNP binding observed in previous experiments. This 
increased pathogen opsonization is attributed to the increased peptidoglycan porosity and 
demonstrates the effects of epitope accessibility. This increased antibody recruitment 
Figure 3.22 S. aureus Anti-DNP Antibody Opsonization. S. aureus were incubated 
for 4 hours in LB alone or LB supplemented with 1 mM D-Lys(DNP). Following cell 
surface labeling, modified bacteria were incubated with Alexa Fluor 488 conjugated 
anti-DNP antibodies in the presence of protein A and analyzed using flow cytometry. 
Data are represented as mean + SD (n = 3).  
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demonstrates that our strategy has the potential to target pathogenic bacteria and could be 
enhanced by other small molecules (Figure 3.23).  
 
3.3.5: DART Mediated B. subtilis Opsonophagocytosis 
Finally, we investigated the ability of anti-DNP opsonized bacterial cells to induce 
a specific response from immune system components. In the general, the binding of 
antibodies to the surface of bacteria can lead to the clearance of the pathogen by opsonic 
phagocytosis, complement activation mediated by complement-dependent cytotoxicity 
(CDC), and antibody dependent cellular toxicity (ADCC).186 It is well established that 
Gram-positive bacteria are inherently resistant to the actions of the complement system. 
Figure 3.23 S. aureus Anti-DNP Antibody Opsonization with Tunicamycin 
Coincubation. S. aureus were incubated for 4 hours in LB containing 0.4µg/mL of 
tunicamycin with 1 mM D-Lys(DNP). Following cell surface modulation, bacteria 
were incubated with Alexa Fluor 488 conjugated anti-DNP antibodies and analyzed 
using flow cytometry. Data are represented as mean + SD (n = 3).  
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The presence of a thick layer of peptidoglycan on the cell wall surface is believed to inhibit 
the actions of the membrane attack complex (MAC).187, 188 Additionally, the degree of 
natural killer cell mediated cytotoxicity of opsonized Gram-positive bacteria is poorly 
understood. Although activated lymphocytes and natural killer cells can utilize cytotoxic 
molecules to induce an antimicrobial response in the presence of these pathogens, it is 
unclear to what extent this activity is coupled to the opsonization of Gram-positive 
bacteria.189 On the contrary, the recognition and phagocytosis of opsonized bacteria by 
macrophages has been widely recognized as the predominant mode of bacterial clearance 
upon primary antibody binding. 90, 190, 191  
In vitro testing of the immune response to DNP labeled bacterial cell surfaces was 
conducted. The surface of B. subtilis was remodeled overnight with D-Lys(DNP) followed 
by opsonization with anti-DNP antibodies. Additionally, B. subtilis were labeled with 
calcein-AM to facilitate the tracking of the bacteria into macrophages. Incubation of 
opsonized B. subtilis in the presence of macrophages led to a 2-fold increase in 
phagocytosis compared to unlabeled B. subtilis (Figure 3.24). Macrophage uptake of 
unlabeled cells is likely due to the natural bacterial engagement of endogenous toll-like 
receptors.192 No increase in uptake was observed with the introduction of anti-DNP 
antibodies to unlabeled B. subtilis, an indication that there is little nonspecific binding of 
anti-DNP to the bacterial surface. 
72 
	  
3.4 Conclusion 
The utilization of immunomodulatory strategies for combating pathogenic bacterial 
infections represents an attractive alternative to traditional antibiotic therapeutics. Here we 
have demonstrated the initial steps toward the development of DART, a novel synthetic 
immunology approach which remodels the surface of Gram-positive bacteria for clearance 
by the host immune system. This strategy utilizes the inherent promiscuity of bacteria to 
incorporate extracellular D-amino acids into their peptidoglycan. We show D-amino acids 
Figure 3.24 Phagocytosis of D-Lys(DNP) Modified B. subtilis Cells. Phagocytosis 
of bacterial cells were evaluated following an overnight incubation period with 1 mM 
D-Lys(DNP) or in the absence of the D-amino acid. Untreated or opsonized cells (with 
anti-DNP antibody) were incubated with J774A.1 macrophages for 20 min in the 
presence of calcein-AM labeled B. subtilis cells. Fluorescence was analyzed using flow 
cytometry. Data are represented as mean + SD (n = 3). 
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containing DNP-epitope modified side chains are readily incorporated into the stem peptide 
of peptidoglycan and subsequently, an immune response is generated towards these 
modified organisms. To ensure the generation of this immune response, sufficient display 
of DNP epitopes is necessary. Our studies indicate that a carefully balancing the side chain 
length for antibody accessibility while retaining the ability to be enzymatically 
incorporated into the stem oligopeptide is critical for ensuring immune response. Through 
systematically scanning side chain length and incorporation of these amino acids, we 
successfully identified D-Lys(DNP) as the optimal molecule for modulation of Gram-
positive bacterial surfaces to recruit antibodies to the bacterial cell surface.  
Through these studies, we demonstrated DART to be successful in specifically 
recruiting antibodies to the surface of B. subtilis and S. aureus and believe this provides 
unique platform for the development of next generation antimicrobial therapies. We 
anticipate that the unique features of DART may reduce the potential for the emergence of 
resistance. The coupling of the antigen to a nonessential surface-bound protein could have 
resulted in the possibility of the bacteria rapidly evolving resistance. Instead, we utilized a 
surface modification method whereby the antigen is covalently conjugated to an essential 
scaffold. Furthermore, peptidoglycan remodeling should generate a surface with a high-
valency of DNP epitopes, and, therefore, a robust recruitment of antibodies. Finally, the 
propensity of bacteria from across various phylogenetic groups to incorporate unnatural D-
amino acids hints at a well conserved process. It is reasonable to expect that this unusual 
property of transpeptidases is critical for the survival and proliferation of bacteria, and, 
therefore, may be less prone to resistance-conferring mutations. 
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One outstanding question related to the D-amino acid mediated labeling of bacteria 
as it pertains to its therapeutic potential will be its specificity for pathogenic bacteria versus 
beneficial bacteria. To date, only pathogenic bacteria have been evaluated for their 
susceptibility for unnatural D-amino acid labeling. We anticipate that some beneficial 
bacteria may also be labeled with DNP-displaying D-amino acids in the strategy described 
here. However, as with other molecules that indiscriminately target transpeptidase 
mediated enzymatic activities, such as penicillin and its many derivatives, it may be the 
case that lack of specificity may not prevent therapeutic activity. We plan to explore the 
peptidoglycan remodeling specificity in the future by using live organism models infected 
with pathogenic bacteria. 
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Chapter 4: 
D-amino acid Probes for Penicillin Binding Protein Mediated  
Bacterial Surface Modulation 
 
4.1 Abstract  
Metabolic bacterial peptidoglycan remodeling via unnatural D-amino acids has 
provided unique insight into peptidoglycan biosynthesis of live bacteria, improved 
diagnostics, and has served as the basis of a DART, a synthetic immunology strategy with 
potential therapeutic implications discussed in Chapter 3. A striking feature of this 
metabolic incorporation of cell wall analogs is the vast promiscuity displayed by PBPs in 
tolerating entirely unnatural side chains. Although these diverse probes have successfully 
modulated bacterial cell surfaces, the chemical space and physical features governing this 
side chain promiscuity has not been systematically determined. In this chapter, we discuss 
our design and synthesis of a D-amino acid variant library displaying diverse side chains to 
comprehensively establish the tolerability of these PBP substrates in both Gram-positive 
and Gram-negative organisms. In addition, nine Bacillus subtilis PBP-null mutants were 
evaluated with the goal of identifying a potential primary PBP responsible for unnatural D-
amino acid incorporation and gaining insight into temporal control of PBP activity. Finally, 
the development of a D-amino acid competition assay, which enables the detection of the 
non-fluorescent D-amino acid peptidoglycan incorporation is discussed. Through this 
competition assay, 106 D-amino acids were scanned for peptidoglycan incorporation and 
the defining chemical features governing transpeptidase mediated D-amino acid 
peptidoglycan incorporation were elucidated. Together, this data allowed us to empirically 
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established the scope of physical and chemical parameters that facilitate metabolic 
incorporation of unnatural D-amino acids into bacterial peptidoglycan and could be used to 
further develop DART.  
 
4.2 Introduction  
Peptidoglycan is an essential and highly conserved mesh structure that surrounds 
bacterial cells. It plays a critical role in retaining a defined cell shape and, in the case of 
pathogenic Gram-positive bacteria, lies at the interface between bacterial cells and the host 
organisms. As such, its composition and structure are linked to cell wall stiffness and 
susceptibility to binding-partners; features that have important implications in drug 
resistance to cell-wall antibiotics and host immunity. Recently, it was demonstrated that 
changes in levels stem peptide chain crosslinking by PBP transpeptidases correlate with 
methicillin-resistance in S. aureus.193 In another example, the replacement of the fifth 
position D-alanine with D-lactic acid in the stem peptide of E. faecium and Enterococcus 
faecalis (E. faecalis) directly renders these pathogens resistant to the antibiotic 
vancomycin.194 This conversion of the amide backbone to an ester backbone on the stem 
peptide is sufficient to reduce the affinity of vancomycin for the stem peptide by three 
orders of magnitude.195 Additionally, peptidoglycan stem peptides play a central role in the 
recognition of pathogenic bacteria by the human immune system. Nucleotide-binding 
oligomerization (NOD)-like receptors sense motifs within the peptidoglycan, thus 
activating response mechanisms.196 Clearly, structural changes to the stem peptide can 
potentially have profound physiological consequences. The recent demonstration that 
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peptidoglycan stem peptides are prone to chemical remodeling by unnatural D-amino acids 
from the growth medium reveals an additional mode of stem peptide modification. 
Given the importance of PBPs as drug targets, it is surprising that the roles of 
various PBPs in cell wall assembly remain subject of active research. To date, it has not 
been possible to conclusively determine which PBPs are most critical for transpeptidation 
activity in live cells. Redundancy within PBPs further compounds the difficulties in 
establishing the role of PBP in peptidoglycan biosynthesis. Recent work has demonstrated 
that S. aureus can survive despite genomic deletion of seven of the nine total PBPs.197 
Likewise, strains of B. subtilis lacking PBP1, PPB2c, PBP2d, and PBP4 (either alone or in 
various combinations) display little to no change in peptidoglycan cross-linking ratios.198 
Genetic deletion of PBP2b in B. subtilis is lethal, suggesting that it may play a primary role 
in transpeptidase activity.199 Together, these examples highlight the limitations of using 
genetic manipulations alone to track PBP enzymatic activity. Chemical probes that report 
on the activity of PBPs in live bacterial cells can complement genetic-based models by 
providing critical information on enzymatic activity with spatial and temporal 
resolution.144, 167, 200, 201 A more comprehensive examination of PBP transpeptidase activity 
may have a profound impact in our understanding of cell wall biosynthesis and lead future 
antibiotic development.  
Metabolic stem peptide remodeling via synthetic peptidoglycan cell wall mimics 
has paved the way for a novel class of PBP chemical probes. As previously discussed, 
unnatural D-amino acids facilitate the tracking of new peptidoglycan production and have 
revealed the presence of peptidoglycan in Chlamydia trachomatis for the first time, a 
subject of intense debate for the past 50 years. 143, 144, 153, 167, 202 Supplementation of 
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unnatural D-amino acids to the culture media leads to their incorporation onto bacterial cell 
surfaces by mischarging at the transpeptidation step, thus generating a swapped terminal 
amino acid.140 Swapping of the terminal D-alanine with unnatural D-amino acids from the 
medium has provided robust method to decorate bacterial surfaces with diverse chemical 
handles and is facilitated by PBPs.141, 143, 148, 202-206  
Prior studies involving unnatural D-amino acids to remodel bacterial surfaces 
suggest that PBP transpeptidase domains possess extraordinary promiscuity in tolerating 
diverse amino acid side chains. Yet, to date no systematic correlation between 
incorporation efficiency and side chain structural features such as charge, size, and polarity 
of unnatural D-amino acids had been established. Using fluorescent D-amino acid probes 
we quantitatively determined the D-amino acid side chain tolerability exhibited by bacterial 
PBP transpeptidases in live cells. Additionally, nine B. subtilis mutant strains lacking PBPs 
reported to possess transpeptidase activity were probed with fluorescent D-amino acids to 
assess if specific PBPs are active during certain bacterial growth phases. Lastly, we 
conceived and performed a D-amino acid competition to detect the incorporation of non-
fluorescent D-amino acids into the peptidoglycan. Through these experimental results, the 
chemical and physical properties of D-amino acid side chains that govern D-amino acid 
bacterial cell surface peptidoglycan modulation were elucidated. We anticipate this 
comprehensive map of the structural elements tolerated by PBP transpeptidases to guide 
future designs of unnatural side chains of D-amino acid for mechanistic investigations and 
therapeutic interventions such as DART.  
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4.3 Results and Discussion 
4.3.1: B. subtilis D-amino acid Peptidoglycan Swapping 
At first, we evaluated a set of two amino acid derivatives, D-Lys(NBD) and L-
Lys(NBD), for the ability to label the peptidoglycan of B. subtilis. We had previously 
shown D-Lys(NBD) to be incorporated within the peptidoglycan stem peptide by a 
combination of peptidoglycan isolation and mass spectrometry.207 To further show that 
fluorescence signals measured by flow cytometry are reflective of D-amino acid 
incorporation within the cell wall, we performed a fluorescence quenching assay. 
Following the labeling of B. subtilis cells with either D-Lys(NBD) or L-Lys(NBD), cells 
were exposed to a short treatment of the reducing agent sodium dithionite. Sodium 
dithionite is known to reduce the NBD nitro group to produce a non-fluorescent aryl amine 
derivative.208 The poor lipid bilayer permeation of the highly polar dithionite species limits 
the fluorescence quenching of the NBD to the extracellular space of the cell.209 We 
reasoned that complete quenching of the fluorescence signal following treatment with 
sodium dithionite would be consistent with extracellular incorporation of the NBD moiety 
(Figure 4.1A). Intracellular accumulation of the unnatural D-amino acid or a combination 
of intracellular/extracellular accumulation would be expected to yield a fluorescence signal 
above basal levels. B. subtilis cells were labeled with D-Lys(NBD) and analyzed by flow 
cytometry with and without sodium dithionite treatment (Figure 4.1B). As we had observed 
previously, the fluorescent D-Lys(NBD) efficiently labeled B. subtilis cells. The exposure 
of labeled bacterial cells to sodium dithionite reduced fluorescence signals to basal levels 
similar to unlabeled cells, a result consistent with the site selective incorporation of the 
NBD label on the exterior of the cell. Next, the same procedure was performed with the 
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enantiomer L-Lys(NBD). As expected, minimal B. subtilis labeling was observed in the 
absence of sodium dithionite. The stereospecificity of the labeling is indicative of  
Figure 4.1 Sodium Dithionite Quenching of NBD Modified B. 
Subtilis. (A) Schematic diagram demonstrating the three possible 
labeling locations within the bacterial cell. Only extracellular 
labeling would lead to complete reduction of the signal in the 
presence of the reducing agent sodium dithionite. Inset: reduction of 
the nitro group on NBD by sodium dithionite quenches the green 
fluorescence. (B) B. subtilis cells were labeled with either 100µM D-
Lys(NBD) or L-Lys(NBD) overnight, quenched with a 5mM sodium 
dithionite solution, and analyzed by flow cytometry. Data are 
represented as mean + SD (n=3). 
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incorporation of D-Lys(NBD) by PBP transpeptidase.140 Together, these results establish 
that NBD-conjugated D-amino acids can report on the incorporation of unnatural D-amino 
acids into bacterial peptidoglycan.  
 
4.3.2 Synthesis of NBD-D-amino acid Series 
Next, we set out to comprehensively assess the PBP transpeptidase tolerability of 
D-amino acid side chain modifications. We synthesized a library of sixteen unnatural D-
amino acid derivatives with diverse side chains (Figure 4.2). Because it has been previously 
demonstrated as a suitable fluorescent probe for tracking peptidoglycan biosynthesis NBD 
was covalently conjugated onto a side chain amino group of all variants to track 
incorporation.141, 210 The side chains were chosen to encompass a broad range of chemical 
and physical parameters including structural elements that vary in length, bulkiness, 
flexibility, polarity, and charge. Synthesis of the NBD-D-amino acid variants was 
performed via SPPS. Molecules were further purified by RP-HPLC and characterized by 
either ESI-MS or MALDI-TOF MS (Table 4.1).  
 
4.3.3 B. subtilis Peptidoglycan Incorporation of NBD-D-amino acid Series 
With the NBD-modified D-amino acids assembled, we performed a series of 
labeling experiments that quantitatively established the relative incorporation of these 
variants. Initially, we determined incorporation levels of the unnatural D-amino acids in the 
model organism B. subtilis. Clear preferences for side chain composition emerge from this 
first set of data. Expectedly, the overall size of the side chain has a strong influence on 
incorporation efficiency. The variant with the smallest side chain, 1, displayed the highest 
incorporation levels. The endogenous substrate (most commonly D-alanine) for PBP 
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transpeptidase has a small side chain: a feature that is likely matched by the cavity in the 
transpeptidase active site. The elongation of the side chain by methylene units from 1 to 4 
highlights the correlation between side chain length and labeling levels. There is 
approximately a 3.5-fold decrease in surface labeling from D-diaminopropionic acid (1) to 
D-lysine (4). Further elongation of the side chain by conjugation to flexible/polar 
polyethylene glycol (PEG) spacers (5-7) reduced incorporation to near basal levels. From 
these results, it can be concluded that there is considerable intolerance of long linear tethers 
connecting the backbone to the NBD moiety (Figure 4.3). The combination of linker length 
and location of an internal amide bond was assessed among derivatives 8-12. Amidation 
of D-diaminopropionic acid with glycine to yield 8 was a well-tolerated modification. This 
Figure 4.2 Chemical Structures of NBD-D-amino acids. 
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variant is important due to the combination of small side chain size and an easy point of 
acylation to various conjugates of interest (e.g., fluorophores). Minimal discrimination was 
observed based on the location of the tether amide bond for similarly sized tethers (variants 
10, 11, and 12). Three additional side chain attributes were assessed among derivatives 13-
16: side chain charge, tolerance of aromatic group, and secondary amino group. The 
positively charged 13 and the negatively charged 15 have the same tether as the uncharged 
11. The introduction of a negative charge drastically reduced labeling levels, while a 
positive charge was permissible. Perhaps surprisingly, the aromatic side chain in 14 proved 
to be compatible with surface labeling. Finally, it was observed that the pyrrolidine ring of 
D-proline in 16 abolished incorporation altogether. Steric constraints imposed by a 
secondary amine, the nucleophilic species in the transpeptidation reaction, may kinetically 
disfavor acylation onto the peptidoglycan-anchored tetrapeptide. (Figure 4.3). 
The incorporation profile of a mutant B. subtilis strain lacking the dacA gene was 
also obtained. PBP5, the protein product of dacA, exhibits D,D-carboxypeptidase activity, 
which hydrolyzes the 5th position D-amino acid in the peptidoglycan oligopeptide. Overall, 
incorporation levels were elevated in B. subtilis DdacA approximately 10-fold for most of 
the D-amino acid variants compared to wild type B. subtilis. There are two possible 
explanations for the increase in D-amino acid incorporation. One possibility is that 
increased abundance of terminal D-alanine result in higher levels of PBP transpeptidase 
activity, and, consequently allow for greater mischarging with unnatural D-amino acids. 
Hydrolysis of the stem peptide by PBP5 serves to trim it to a tetrapeptide, a product that is 
no longer a substrate for D,D-transpeptidase, thus rendering the oligopeptide unable to be 
modified. Secondly, PBP5 may act to remove unnatural D-amino acids incorporated into 
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the 5th position of the stem peptide. Along these lines, we hypothesize that differences in 
relative incorporation between wild type and B. subtilis DdacA strains may correlate with 
Figure 4.3 B. subtilis Labeling with NBD-D-amino acid Series. Labeling of B. subtilis 
wildtype cells (A) and B. subtilis ΔdacA (B) was performed with all the members of the 
D-amino acid NBD conjugates. Cells were incubated overnight at 100 µM and analyzed 
by flow cytometry. Data are represented as mean + SD (n=3). 
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inherent PBP5 carboxypeptidase preferences for side chains on the terminal position of the 
stem peptide. For example, surface labeling of 1 is greater than 2-fold compared to 3 in 
wild type B. subtilis, while no significant difference is observed in B. subtilis DdacA. The 
decreased labeling of 3 in wild type B. subtilis may reflect on decreased retention within 
the stem peptide due to PBP5 carboxypeptidase activity (Figure 4.3B).  
 
4.3.4 Sulfhydryl-D-amino acid Peptidoglycan Incorporation 
The conjugation of NBD fluorophore to D-amino acids variants 1-16 was critical in 
facilitating quantitative measurement of surface labeling. While its small size is expected 
to minimally contribute to the trends in incorporation profiles, it still prevented our ability 
to assess the incorporation of small side chains. It has previously been demonstrated that 
D-cysteine can be incorporated into the stem peptide of bacterial peptidoglycan through a 
variety of methods.138, 211 We devised an alternative strategy to measure labeling efficiency 
to corroborate our findings with NBD-conjugated D-amino acids based on sulfhydryl-
maleimide coupling (Figure 4.4A). B. subtilis cells were treated with the sulfhydryl-
displaying variants (SH1-SH6), exposed to a short treatment of dithiothreitol (DTT) to 
reverse oxidation, and detected with an NBD-maleimide conjugate (Figure 4.4B). The 
incubation of D-cysteine (SH-1) served to establish the conditions for cell surface labeling. 
As noted in previous experiments, incubation of cells with SH-1 led to a marked increase 
in cellular fluorescence.138 Remarkably, D-lysine derivative SH-2 labeled nearly as well as 
the much smaller SH-1. These results highlight the unusual tolerance of accommodating  
large side chains equally well to small side chains. The addition of a PEG chain (SH-3) 
resulted in significantly lower levels of cell surface labeling. Clearly, the tolerance of side 
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chain bulk has some limitations – consistent with our NBD-conjugated D-amino acids. 
Interestingly, D-cystine (SH-4) was incorporated to high levels despite its larger size.  
  
Figure 4.4 Sulfhydryl D-amino acid Labeling of B. subtilis. (A) Schematic 
representation of two-step modification of B. subtilis bacteria with sulfhydryl 
containing D-amino acids and maleimide-NBD fluorophores. (B) Chemical structures 
of sulfhydryl D-amino acids. (C) B. subtilis cells were incubated with 500µM 
sulfhydryl-D-amino acids, incubated with NBD-L-Lys(Maleimide), and analyzed by 
flow cytometry. Data are represented as mean + SD (n=3). 
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Perhaps, it represents a homologated analog of the endogenous transpeptidase substrate m-
DAP. Display of the sulfhydryl onto a D-proline resulted in no surface labeling, consistent 
with 16. Lastly, the FDA- approved agent D-penicillamine (SH-6) was chosen to evaluate 
the tolerance of steric bulk near the N-terminus. A complete lack of incorporation was 
observed for cells treated with SH-6, a strong indication that side chain bulk near the 
backbone can interfere with incorporation (Figure 4.4C).  
We further confirmed that all the observed fluorescent signals originate from the 
incorporation of exogenous D-amino acid sulfhydryl compounds, by incubating sulfhydryl 
labeled cells with N-ethyl maleimide, prior to exposing the cells to NBD-maleimide 
conjugate. The exposure of the cells to the non-fluorescent N-ethyl maleimide reduced 
fluorescent signals to basal levels, thus confirming that the observed fluorescent signals are 
Figure 4.5 Quenching of B. subtilis Sulfhydryl D-amino acid Peptidoglycan 
Labeling. B. subtilis cells were labeled with 500 µM sulfhydryl D-amino acids or L-
Cys overnight. Following labeling, cells were either reacted with 50 µM NBD-L-
Lys(Maleimide), 50 µM NEM followed by 50 µM NBD-L-Lys(Maleimide), or NBD-
L-Lys(Maleimide) followed by 5mM sodium dithionite. Cells were analyzed for 
fluorescence using flow cytometry. Data are represented as mean + SD (n =3).  
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a result of cellular incorporation of the D-amino acid sulfhydryl compounds (Figure 4.5). 
Additionally, to confirm that these compounds were located in the peptidoglycan, we again 
took advantage of the cell impermeable compound sodium dithionite. Sulfhydryl labeled 
cells were first incubated with a NBD-maleimide conjugate, followed by a second 
incubation with sodium dithionite, which resulted in the quenching of fluorescent signals 
to background levels (Figure 4.5). These two results in conjunction indicate that 
fluorescence is due to the incorporation of the sulfhydryl displaying D-amino acids into the 
bacterial peptidoglycan.  
 
4.3.5 Bacterial Peptidoglycan Incorporation of NBD-D-amino acid Series 
Having determined the features that govern D-amino acid incorporation into B. 
subtilis, we set out to determine if these features were universal across diverse species of 
bacteria. First, the incorporation profile was obtained for wild type S. aureus (Figure 4.6). 
As with other B. subtilis, there is a size-dependence in incorporation efficiency and 
additional structural preferences appear to be mostly conserved. However, differing from 
B. subtilis, no increased incorporation was observed for compound 9 when compared to 
compound 8, indicating a possible difference in active sites between the PBPs of the two 
species. The incorporation profile of methicillin resistant S. aureus (MRSA) cells was also 
obtained. Despite the established difference in PBPs between methicillin resistant and 
methicillin sensitive S. aureus, minimal difference in labeling profile was observed (Figure 
4.6).212 There appears to be a slight decrease in labeling across some of the D-amino acid 
derivatives, an intriguing finding that will be the subject of future investigations. Having 
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established the incorporation profile of one human pathogen, we sought to gain a similar 
insight into the side chain preference for additional organisms.  
The incorporation profile of Staphylococcus epidermidis (S. epidermidis) displayed 
similar labeling preferences to S. aureus, a finding that is consistent with a shared genus 
(Figure 4.7). Next, we set out to evaluate the incorporation profile of a distinct Gram-
positive pathogen. E. faecalis has emerged as a problematic pathogen due to increasing 
instances of drug resistance. While many of the trends are similar, there are some 
prominent deviations (Figure 4.8). The aromatic variant 14 labeled E. faecalis cell surfaces 
most efficiently. The incorporation profile of Gram-negative E. coli bacteria was also 
obtained. Despite differences in the architecture of the peptidoglycan, the trend remained 
in line with the Gram-positive organisms evaluated. Interestingly, in vitro experiments 
previously demonstrated D-proline be incorporated into peptidoglycan monomers by E. coli 
Figure 4.6 S. aureus Labeling with NBD-D-amino acid Series. Labeling of S. 
aureus cells (methicillin sensitive and resistant) was performed with all the members 
of the D-amino acid NBD conjugates. Cells were incubated overnight at 100 µM and 
analyzed by flow cytometry. Data are represented as mean + SD (n=3). 
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PBP1A.140 The lack of labeling with the similar D-proline- based 16 may reflect altered 
substrate specificity in live E. coli cells (Figure 4.9).  
 
 
  
Figure 4.7 S. epidermidis Labeling with NBD-Modified D-amino acid Series. 
Labeling of S. epidermidis cells was performed with all the members of the D-
amino acid NBD conjugates. Cells were incubated overnight at 100 µM and 
analyzed by flow cytometry. Data are represented as mean + SD (n=3). 
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Figure 4.9 E. coli Labeling with NBD-D-amino acid Series. 
Labeling of E. coli cells was performed with all the members of 
the D-amino acid NBD conjugates. Cells were incubated overnight 
at 500 µM and analyzed by flow cytometry. Data are represented 
as mean + SD (n=3). 
Figure 4.8 E. faecalis Labeling with NBD-D-amino acid Series. 
Labeling of E. faecalis cells was performed with all the members 
of the D-amino acid NBD conjugates. Cells were incubated 
overnight at 100 µM and analyzed by flow cytometry. Data are 
represented as mean + SD (n=3). 
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4.3.6 B. subtilis PBP Analysis of NBD-D-amino acid Incorporation 
Having established comprehensive incorporation profiles for several organisms, we 
next sought to apply our D-amino acid library towards activity profiling of individual PBP 
with transpeptidase activity in B. subtilis. We anticipated that the fluorescently labeled D-
amino acids could form the basis of a class of chemical probes that reveal insight into PBP 
activity. Surprisingly, to date the specific PBP responsible for transpeptidase activity has 
not been conclusively established. It was recently shown in vitro that B. subtilis PBP1a/b 
can catalyze the installment of unnatural D-amino acids onto stem peptides.150 Although 
instrumental in deciphering the mechanism of unnatural D-amino acid incorporation, it is 
unclear whether the same PBP would be the primary protein responsible for this process in 
live bacteria. In all, eight single PBP transpeptidase deletion mutant B. subtilis strains were 
subjected to evaluation. Overall, it appears that most of the PBP-null strains result in 
minimal change in labeling across all sixteen D-amino acid variants (Appendix 4.2 and 
Figure 4.10). However, closer inspection reveals subtle but significant differences in 
several strains that may reflect distinctions in transpeptidase active sites. In the case of 
PBP2c-null incorporation profile, there is increased incorporation of 2 and 3 but lower 
incorporation of 9 relative to the wild type strain. PBP3-null cells labeled considerably 
better with 12 and 14 but displayed lower incorporation of 9. Interestingly, significant 
increases in incorporation were observed upon the deletion of PBP4b or PbpH. Perhaps, 
the deletion of a PBP leads to compensatory activity of complementary PBPs whose 
transpeptidase activity can more efficiently mischarge with unnatural D-amino acids. Most 
importantly, a prominent decrease in incorporation across the board was observed for 
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PBP4-null cells. From these results, we propose that PBP4 is the primary protein 
responsible for the incorporation of unnatural D-amino acids on B. subtilis peptidoglycan 
stem peptides.  
Cell wall biosynthesis and cell division require the orchestration of PBPs within the 
cell surface. Localization of PBPs and defined regulation of their activity is crucial for the 
proper assembly of newly synthesized peptidoglycan and septation.150 We hypothesized 
that we could gain insight into the temporal control of PBP transpeptidase activity by 
leveraging the combination of fluorescently labeled D-amino acids with the panel of PBP-
null B. subtilis strains. During various stages of cell growth and division, there may be 
distinct cellular requirements of cell wall modifying PBPs. Regulation of PBPs may not be 
Figure 4.10 B. subtilis PBP Mutant Labeling Heat Map. Figure Heat map of 
labeling a series of B. subtilis mutants with the NBD-conjugated D-amino acids. (Data 
derived from Appendix A.4). The heat map of incorporation shows relative 
fluorescence levels to unlabeled cells – red cells indicate elevated incorporation and 
blue cells indicate lower incorporation. 
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found at the DNA/RNA level, and, therefore, not trackable by traditional techniques, such 
as real-time polymerase chain reaction. Instead, we propose that D-amino acid activity- 
based probes could be used to monitor potentially subtle changes in PBP transpeptidase 
activities. We hypothesized the quantification of probe incorporation at different growth 
stages of B. subtilis would allow for sensitive measurements of PBP transpeptidase activity. 
We sampled B. subtilis at three distinct stages: early log, mid-log, and stationary phase by 
a pulse incubation with D-Lys(FITC), another suitable fluorescent probe for monitoring 
peptidoglycan biosynthesis.141, 210 The change in the fluorophore from NBD to FITC did 
not appreciably alter relative incorporation within the panel of PBP-mutants, while at the 
same time allowed for better quantification of signals in comparison to NBD (Figure 4.11). 
For wild type B. subtilis, there is substantially greater incorporation at the early log phase. 
By the mid-log stage, all labeling levels are approximately halved. Finally, there is another 
four-fold reduction at stationary phase (Figure 4.12). The relative labeling to wild type 
Figure 4.11 B. subtilis Analysis of D-Lys(FITC) Incorporation. (A) Chemical 
structures of D-Lys(FITC). (B) B. subtilis PBP-null mutant cells were incubated with 
100 µM of D-Lys(FITC) and analyzed by flow cytometry. Data are represented as 
mean + SD (n =3).  
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cells within each stage reveals PBP-
dependent patterns (Figure 4.13). For 
most mutants, there is a relative 
decrease in labeling at stationary phase 
compared to the two other phases. For 
example, PBP1a/b and PBP2c mutant 
cells label half as efficient in the 
stationary phase, while there is almost 
no distinguishable difference between 
early- and mid-log phases. Other 
mutants, such as PBP2d and PBP4b, 
curbed the difference across growth 
phases, an indication that they may not 
play a significant role in PBP 
transpeptidation. Primarily septal 
labeling was observed for all B. subtilis 
strains including wild type (Figure 
4.14). A slight deviation from this 
pattern was observed in PBP2d-null 
cells at early log phase in which 
labeling was observed throughout the 
entire cell surface at approximately 
equal intensity with no punctate 
Figure 4.12 Phase Analysis of B. subtilis 
Labeling with D-Lys(FITC). B. subtilis PBP-
null mutant cells were labeled with 1mM for 
15 minutes at either (A) early log phase, (B) 
Mid log phase or (C) stationary phase and 
analyzed for total cellular fluorescence using 
flow cytometry. Data are represented as mean 
+ SD (n =3).  
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fluorescence at the septal interface. Analysis of the labeling at mid-log phase revealed an 
intriguing switch in labeling for PBP4-null cells (Figure 4.15). PBP transpeptidase activity 
in PBP4-null cells is observed through the entire cell at early log phase. However, by mid 
log phase the labeling is heavily concentrated at the septal regions. These results suggest 
temporal control in PBP transpeptidase activity that is linked with the growth phase of the 
cells. The previously discussed work demonstrates how fluorescent D-amino acid probes 
can be utilized to illuminate the side-chain promiscuity of the transpeptidase domains 
within PBPs. This work provided insight to the type of side chains which govern bacterial 
cell surface modulation when using D-amino acids.  
Figure 4.13 Phase Analysis of Relative PBP Mediated D-Lys(FITC) Labeling of B. 
subtilis. B. subtilis PBP-null mutant cells were labeled with 1mM D-Lys(FITC) for 15 
minutes at specified phases and analyzed using flow cytometry. Data are represented as 
mean relative to B. subtilis wild type + SD (n =3).  
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Figure 4.14 Fluorescent Microscopy of Early Log B. subtilis Labeling with D-
Lys(FITC). B. subtilis PBP-null mutant cells were labeled with 1mM D-Lys(FITC) 
for 15 minutes at early-log phase and analyzed by fluorescence microscopy.  
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Figure 4.15 Fluorescent Microscopy of Mid Log B. subtilis Labeling with D-
Lys(FITC). B. subtilis PBP-null mutant cells were labeled with 1mM D-Lys(FITC) 
for 15 minutes during mid-log phase and analyzed by fluorescence microscopy.  
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4.3.7 B. subtilis D-amino Acid Competition Assay 
To further develop DART, extensive knowledge of the D-amino acid side chain 
tolerance exhibited by transpeptidase would be beneficial. By understanding which D-
amino acid side chains are highly tolerated, it may be possible to develop a D-amino acid 
immune stimulant molecule that is incorporated into the peptidoglycan with much greater 
efficiency. This could allow for improved antibody recruitment levels and lead to an 
enhanced immune response. Towards elucidating the side chains that are highly tolerated 
by transpeptidase, a facile method which allows for the determination of D-amino acid 
peptidoglycan incorporation would prove valuable. In expanding our studies of 
transpeptidase side chain tolerance, we developed an initial framework for a D-amino acid 
competition assay which allows for rapid assessment of non-fluorescent D-amino acid 
peptidoglycan incorporation.  
 The premise of this D-amino acid incorporation assay is based upon two 
exogenously added D-amino acid substrates competing for the transpeptidase active site. 
The first D-amino acid exogenously added to the media is the fluorescent D-Lys(NBD). As 
described previously, D-Lys(NBD) is readily incorporated into both Gram-positive and 
Gram-negative bacterial peptidoglycan through transpeptidase promiscuity. This 
fluorescent D-amino acid probe allows for rapid detection of total cellular fluorescence. 
The second D-amino acid exogenously added to the media is a non-fluorescent D-amino 
acid for which peptidoglycan incorporation is being investigated.  
In developing this assay, we envisioned three possibilities that would provide 
insight into the extent to which exogenously added non-fluorescent D-amino acids are 
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incorporated into the peptidoglycan (Figure 4.16). First, we envisioned the possibility that 
the non-fluorescent D-amino acid is readily accepted by transpeptidase and incorporated 
into the peptidoglycan. The result of this scenario would produce bacterial cells that exhibit 
low cellular fluorescence due to the non-fluorescent D-amino acid out competing the 
fluorescent D-Lys(NBD) probe. Conversely, a scenario in which the non-fluorescent D-
amino acid is not readily accepted by transpeptidase would lead to highly fluorescent 
bacteria due to D-Lys(NBD) being incorporated into the peptidoglycan. Lastly, the 
possibility of moderately fluorescent bacteria exists if the non-fluorescent D-amino acid is 
incorporated with average efficiency. Through comparing the cellular fluorescence of 
Figure 4.16 Schematic Representation of D-amino acid Competition Assay. 
Bacterial cells are incubated in the presence of unmodified D-amino acid and D-
Lys(NBD). If the unlabeled D-amino acid is incorporated, D-Lys(NBD) fluorescence 
will decrease relative to cells labeled only with D-Lys(NBD). If the unlabeled D-
amino acid is not tolerated by PBPs, the cellular fluorescence will remain similar to 
cells labeled only with D-Lys(NBD). 	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bacteria subjected to competition assay to bacteria labeled with D-Lys(NBD) only, a 
relative percent change in cellular fluorescence can be calculated. This facile method 
allows for the detection and the extent to which non-fluorescent D-amino acids are 
incorporated into the bacterial peptidoglycan.  
To expand upon our 16 NBD-D-amino acid variant series, we utilized 106 non-
fluorescent D-amino acids in this competition assay. The D-amino acids selected for this 
experiment encompassed a broad scope of side-chains (Table 4.2). To date, we have 
conducted testing only in B. subtilis bacterium as proof of concept for this methodology. 
Interestingly, the relative percent change in fluorescence fluctuated greatly depending on 
the nature of the D-amino acid side chain and provided several insights into the chemical 
parameters which govern D-amino acid incorporation into the peptidoglycan of B. subtilis 
(Figure 4.17). 
 Within the 106 amino acids analyzed, subsets of D-amino acids possessing similar 
features were analyzed. The first subset of amino acids analyzed for peptidoglycan 
incorporation were the naturally occurring D-amino acids (Figure 4.18). Although these 
amino acid side chains are diverse in chemical nature, from a physiological standpoint it is 
of high interest to determine which naturally occurring D-amino acids are accepted as 
transpeptidase substrates. From this data, it is observed that several of the canonical amino 
acids readily serve as surrogate substrates for transpeptidase. D-methionine and D-cysteine 
exhibited 62% and 60% percent changes in total cellular fluorescence, respectively. This 
data indicates that D-amino acid side chains containing thiols may aid in peptidoglycan 
incorporation. Consistent with our findings that positively charge D-amino acids are well 
accepted by transpeptidase, the competition of D-lysine with D-Lys(NBD) also resulted in  
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Figure 4.17 Competition Assay: Percent Change of B. subtilis Cellular 
Fluorescence. B. subtilis cells were incubated overnight in the presence of 
100 µM D-Lys(NBD) and 2mM non-fluorescent D-amino acid. Cells were 
analyzed for fluorescence using flow cytometry. Percent change in cellular 
fluorescence was calculated by comparing fluorescence of coincubated cells 
with cells incubated in the presence of D-Lys(NBD) only. Data are 
represented as mean + SD (n = 3). 	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a large percent change. Conversely, D-aspartic acid and D-glutamic acid exhibited low 
relative percent changes in fluorescence further indicating that negatively charged D-amino 
acids are not readily accepted as transpeptidase substrates. Additionally, the low relative 
percent change in fluorescence for D-proline is consistent with our findings for the 
fluorescently labeled NBD-D-proline substrate, thus further highlighting the accuracy of 
this assay.  
 To further determine side chain features governing transpeptidase mediated 
incorporation, other non-fluorescent D-amino acids containing similar characteristics were 
examined. To determine the effect of side-chain charge, seven additional D-amino acids 
Figure 4.18 Competition Assay: Detection of Natural D-amino acid Incorporation. 
B. subtilis cells were incubated overnight in the presence of 100 µM D-Lys(NBD) and 
2mM non-fluorescent natural D-amino acid. Cells were analyzed for fluorescence using 
flow cytometry. Percent change in cellular fluorescence was calculated by comparing 
fluorescence of coincubated cells with cells incubated in the presence of D-Lys(NBD) 
only. Data are represented as mean + SD (n = 3). 	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containing positively charged side chains and two additional negatively charged side chain 
containing D-amino acid side chains were examined for peptidoglycan incorporation 
(Figure 4.19). Analysis of all positively charged D-amino acid side chains revealed a greater 
than 50% percent change in relative fluorescence, with the exception of compound 26, 4-
amino-D-phenylalanine (43%). Opposing this high rate of peptidoglycan modulation 
through positively charged D-amino acids, both negatively charged D-amino acids 
demonstrated under 20% change in relative fluorescence (Figure 4.20). This is consistent 
with our earlier hypothesis that negatively charged D-amino acids are not readily 
incorporated into the peptidoglycan. This could be a result of electrostatic repulsion at the 
negatively charged bacterial cell membrane, which would affect the availability of the D-
Figure 4.19 Competition Assay: Detection of Positively Charged D-amino acid 
Incorporation. B. subtilis cells were incubated overnight in the presence of 100 µM 
D-Lys(NBD) and 2mM non-fluorescent natural D-amino acid. Cells were analyzed for 
fluorescence using flow cytometry. Percent change in cellular fluorescence was 
calculated by comparing fluorescence of coincubated cells with cells incubated in the 
presence of D-Lys(NBD) only. Data are represented as mean + SD (n = 3). 	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amino acid substrate for transpeptidase. It is also plausible that negatively charged D-amino 
acid side chains are not tolerated in the active site of the transpeptidase enzyme.  
 Additionally, the effect of amine classification was further examined to determine 
if secondary amines are not tolerated as transpeptidase substrates. In addition to proline, 
five D-amino acids containing secondary amines were examined for peptidoglycan 
incorporation. In analyzing the percent changes in fluorescence, no bacteria exhibited 
greater than a 25% change in fluorescence. This trend indicates that secondary amines are 
not well tolerated as transpeptidase substrates (Figure 4.21).  
 Lastly, to further develop DART, it would be beneficial to know the extent to which 
D-amino acids containing nitro functionalities are incorporated into the peptidoglycan. Six 
D-amino acids containing nitro functionalities were subjected to the competition assay     
Figure 4.20 Competition Assay: Detection of Negatively Charged D-amino acid 
Incorporation. B. subtilis cells were incubated overnight in the presence of 100 µM D-
Lys(NBD) and 2mM non-fluorescent natural D-amino acid. Cells were analyzed for 
fluorescence using flow cytometry. Percent change in cellular fluorescence was 
calculated by comparing fluorescence of coincubated cells with cells incubated in the 
presence of D-Lys(NBD) only. Data are represented as mean + SD (n = 3). 	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(Figure 4.22). Interestingly, 2,4-dinitro-D-phenylalanine, 13, demonstrated the lowest 
levels of peptidoglycan modulation with a 27% percent change in cellular fluorescence. 
Removal of one aromatic nitro group restored peptidoglycan incorporation as was seen 
with compounds 2, 34, and 46. The low percent change in cellular fluorescence of 2,4-
dintro-D-phenylalanine indicates low levels of peptidoglycan incorporation. This may 
indicate that switching the immune stimulant molecule attached to the D-amino acid may 
result in an enhanced immune response.  
  
Figure 4.21 Competition Assay: Detection of Secondary Amine Containing 
D-amino acid Incorporation. B. subtilis cells were incubated overnight in the 
presence of 100 µM D-Lys(NBD) and 2mM non-fluorescent natural D-amino 
acid. Cells were analyzed for fluorescence using flow cytometry. Percent change 
in cellular fluorescence was calculated by comparing fluorescence of coincubated 
cells with cells incubated in the presence of D-Lys(NBD) only. Data are 
represented as mean + SD (n = 3). 	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4.4 Conclusion  
Although there are a few examples of D-amino acids being generated and utilized 
in eukaryotic organisms, it was believed that its existence in bacteria was limited to being 
a building block for non-ribosomal peptide synthesis and the core component of the 
peptidoglycan. The discovery that many bacterial species are capable of generating diverse 
D-amino acids, which are expelled into the surrounding media, suggests that this process 
may have specific physiological consequences.172, 213 Yet, there has not been any 
conclusive physiological role assigned to peptidoglycan remodeling via unnatural D-amino 
acids. In the short time since the initial discovery that unnatural D-amino acids are 
Figure 4.22 Competition Assay: Detection of Nitro-D-amino acid Incorporation. B. 
subtilis cells were incubated overnight in the presence of 100 µM D-Lys(NBD) and 
2mM non-fluorescent natural D-amino acid. Cells were analyzed for fluorescence using 
flow cytometry. Percent change in cellular fluorescence was calculated by comparing 
fluorescence of coincubated cells with cells incubated in the presence of D-Lys(NBD) 
only. Data are represented as mean + SD (n = 3).  
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incorporated into bacterial peptidoglycan, this mode of surface remodeling has spurred 
peptidoglycan probes and potentially unique antimicrobial strategies. Our scan represents 
the most comprehensive analysis of D-amino acid incorporation to date and it may give 
unique insight into the physiological function of this remodeling process. We anticipate 
this thorough evaluation of the incorporation of unlabeled D-amino acids will further 
elucidate aspects that control peptidoglycan remodeling.  
A striking feature of the replacement of bacterial surface bound D-alanine with 
unnatural D-amino acids is the vast promiscuity displayed by PBPs in tolerating entirely 
unnatural side chains. In this study, we assembled a series of sixteen D-amino acid variants 
with diverse side chains. For all the variants, the small fluorophore NBD was covalently 
conjugated onto an amino group. The side chains were chosen to encompass a diverse set 
of chemical space by including structural elements that vary in length, bulkiness, 
flexibility, polarity, and charge. With the NBD-modified D-amino acids in hand, we 
measured incorporation levels using flow cytometry in several bacteria including B. 
subtilis, S. epidermidis, E. faecalis, S. aureus, and E. coli. In addition to serving as guides 
for the design of unnatural side chain of D-amino acids, our scan represents the most 
comprehensive analysis of D-amino acid incorporation to date and it may give unique 
insight into the physiological function of this remodeling process. In addition, we evaluated 
labeling with unnatural D-amino acids for a series of PBP-null B. subtilis mutants and found 
specific mutations that modulate the incorporation. 
 
4.5 Future Work 
 Using the D-amino acid competition assay, we have further elucidated the trends 
that were observed using fluorescently labeled D-amino acids for the modulation of B. 
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subtilis peptidoglycan. This competition assay allows for the detection of D-amino acid 
peptidoglycan incorporation without the use of fluorescently modified side chains. Because 
the need for a fluorescent side chain modification is eliminated several D-amino acids can 
be rapidly analyzed for peptidoglycan modulation and may provide insights into the 
uniqueness of bacterial peptidoglycan. Future experiments are currently being conducted 
to investigate if all bacteria exhibit these trends in D-amino acid side chain incorporation. 
These competition assays may provide information that would enable the design of DART 
agents that specifically modify the surface of a certain bacterial species. This could provide 
enhanced immune response when using DART as other bacteria would not utilize the 
immune stimulant substrate. Additionally, this peptidoglycan modulation specificity would 
enable the targeting and removal of only the pathogenic bacteria, while leaving the 
remaining microbiome of the patient intact. Traditional antibiotics are currently unable to 
differentiate between pathogenic and commensal bacteria which can lead to harmful side 
effects. Through understanding bacterial species D-amino acid side specificity, the decisive 
targeting of pathogenic bacteria may lead to enhanced infection clearance with improved 
patient outcomes.  
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Chapter 5: 
Development of a Two-Step Dipeptide Antibody Recruitment Therapy 
for Enhanced Immunomodulation 
5.1 Abstract 
 
In chapter 3, the development of a DART, which represents the first direct method 
for covalent modulation of bacterial cell surfaces to elicit an innate immune response, was 
introduced as means to combat pathogenic bacterial infections. In developing DART, the 
immune response was demonstrated to be proportional to the number of surface exposed 
DNP epitopes. Further analysis of the structure and biosynthesis of peptidoglycan, led us 
to develop a methodology that allows for the increased number of surface exposed epitope 
molecules and thus greater immune response. In this chapter, the development of a 
dipeptide based peptidoglycan modulation strategy utilizing MurF enzymatic promiscuity 
for increased DNP epitope modulation of bacterial peptidoglycan is discussed. The basis 
for utilizing a dipeptide remodeling strategy was to introduce haptens at an alternative site 
within the peptidoglycan stem peptide. Based on our findings in Chapter 4, this alternate 
site of modulation was hypothesized to improve peptidoglycan retention of DNP through 
diminishing epitope removal mediated by cell wall processing enzymes. Our initial 
investigations of this dipeptide strategy elucidated the extent of MurF enzymatic 
promiscuity and stimulated a redesign in our strategy to use a two-step modulation tactic. 
Through this new approach, the ability to rescue DNP epitopes previously buried within 
the peptidoglycan was investigated in hopes of enhancing immune response. By exploiting 
MurF enzymatic promiscuity, we determined size restraints of peptidoglycan remodeling 
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molecules and utilized the knowledge of these limitations to develop a Two-Step Dipeptide 
Antibody Recruitment Therapy capable of producing high levels of antibody recruitment 
to bacterial cell surfaces.  
 
5.2 Introduction 
Recently, it has been established that several of the enzymes in the peptidoglycan 
biosynthetic pathway display broad substrate promiscuity.203, 213, 214 This idiosyncrasy 
facilitates the metabolic labeling of peptidoglycan using unnatural cell wall analogs as 
discussed in Chapter 2. We proposed that immune-modulatory therapeutics may provide 
an alternative to traditional bactericidal agents. In chapter 3, we demonstrated the 
successful remodeling of bacterial cell surfaces with the ultimate goal of inducing a 
selective immune response.207 Treatment of bacteria with D-amino acids conjugated to 
DNP led to the covalent attachment of immune epitopes to the bacterial surfaced and 
promoted the recruitment of the endogenous anti-DNP antibodies. In attempting to 
generate a second generation DART molecule, we hypothesized that utilizing a metabolic 
probe that hijacks another enzyme within the peptidoglycan biosynthetic pathway may 
afford greater DNP epitope display.  
A prominent feature of bacterial cell walls is the continuous remodeling that occurs 
during cell growth and division.137 Chemical modifications to the polymeric peptidoglycan 
chains by endogenous enzymes are essential for maintaining cellular viability. Two of the 
processes mediated by cell wall-linked enzymes (carboxypeptidase and transpeptidase 
activity) can potentially lead to the removal of the C-terminal position on the peptidoglycan 
stem peptide (Figure 5.1A). D,D-transpeptidase peptidoglycan crosslinking involves the 
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hydrolysis of the terminal residue to activate the acyl-donor chain while, D,D-
carboxypeptidases catalyze the hydrolysis of the terminal residue to generate truncated 
tetrapeptides.176 In regards to DART, we hypothesized that both of these two reactions may 
hydrolyze hapten-conjugated amino acids installed at the terminal position of the 
peptidoglycan oligopeptide, thus reducing the hapten valency at the cell surface. To 
Figure 5.1 Peptidoglycan Maturation Removes Terminal D-amino acid of 
Oligopeptide. (A)Transpeptidase D-amino acid “swapping” results in the 
incorporation of DNP-D-amino acids into the C-terminal position of the stem peptide. 
During peptidoglycan maturation, transpeptidase and carboxypeptidase enzymatic 
activity may result in removal of DNP-D-amino acids. (B) Intracellular dipeptide 
ligation via MurF enzymatic promiscuity installs the DNP hapten on the fourth 
position of the stem peptide, thus eliminating removal through peptidoglycan 
transpeptidase and carboxypeptidase activity. The retention of the DNP hapten 
enhances antibody recruitment to bacterial cell surfaces.  
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achieve greater cell surface retention, we considered metabolic labeling strategies to 
deliver haptens at alternative positions within the stem peptide that. 
Recently, MurF, which is an intracellular enzyme responsible for the ligation of D-
Ala-D-Ala dipeptides onto the fourth and fifth positions of the growing peptidoglycan 
precursor molecule, was found to tolerate dipeptides displaying unnatural side chains.151, 
153 The use of D-amino acid-based dipeptides displaying either an alkyne or an azido group 
on the side chain led to the installment of unnatural D-amino acid at the fourth or fifth 
position on the stem peptide and was attributed to the MurF ligase activity. Dipeptide 
incorporation by MurF decouples the peptidoglycan remodeling process from competing 
with PBP transpeptidase activity, as is the case with single unnatural D-amino acids. 
Additionally, there is some evidence of the carboxypeptidase activity of PBP5 removing 
unnatural D-amino acids from the 5th position on the stem peptide.153 Conversely, 
incorporation of chemical modifications at the fourth position of the peptidoglycan 
oligopeptide are not hydrolyzed through the processes of transpeptidation or 
carboxypeptidation. By utilizing a dipeptide-based metabolic labeling strategy to 
incorporate DNP haptens into peptidoglycan, we hypothesized that it would be possible to 
achieve greater hapten retention on bacterial cell surfaces (Figure 5.1B).   
 
5.3 Results and Discussion 
5.3.1: Direct MurF Mediated Dipeptide Peptidoglycan Incorporation 
At first, we set out to explore the possibility that epitopes could be conjugated 
directly to the side chain of D-amino acid based dipeptides. Treatment of bacterial cells 
with D-amino acid based dipeptides with unnatural side chains handles on the N-terminus 
of the dipeptide unit were hypothesized to generate epitope installment at the 4th position 
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within the stem peptide. Therefore, by conjugating epitopes on the N-terminal amino acid 
of the dipeptide, greater protection from D,D-carboxypeptidase and -transpeptidase 
mediated hapten removal was expected. We previously found in our single amino acid 
strategy that D-Lys(DNP) was the most effective unnatural D-amino acid in the recruitment 
of anti-DNP antibodies. To evaluate labeling levels, we synthesized an analogous 
fluorescent amino acid D-Lys(NBD) (1). NBD served as an excellent surrogate for the 
similarly structured DNP hapten and it enabled quantification of relative metabolic labeling 
levels.  
Labeling levels were assessed with Bacillus subtilis (B. subtilis), which was chosen 
due to its extensive similarity to pathogenic bacteria.175 Consistent with our prior studies, 
Figure 5.2 MurF Mediated Peptidoglycan Incorporation of NBD-Conjugated 
Dipeptides. (A) Chemical structures of D-Lys(NBD) and NBD-conjugated 
dipeptides containing the fluorophore moiety on the sidechain of the N-terminal 
amino acid within the dipeptide. (B) B. subtilis cells were incubated overnight in the 
presence of 1mM NBD conjugates and analyzed using flow cytometry. Data are 
represented as the mean + SD (n =3).  
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treatment of B. subtilis cells with 1 led a 20-fold increase in fluorescence relative to 
untreated cells (Figure 5.2A and B). To assess the possibility that D,D-carboxypeptidase 
may reduce valency of the unnatural cell surface handle, 1 was incubated with a genetically 
modified strain of B. subtilis devoid of dacA (D,D-carboxypeptidase). Cellular fluorescence 
in B. subtilis DdacA variants increased ~7.5-fold relative to wild type cells, thus indicating 
epitopes installed on the terminal position via unnatural single amino acids are susceptible 
to removal by endogenous enzymes.  
In an effort to minimize enzymatic removal of unnatural modifications, we sought 
a strategy that installed epitopes onto the 4th position within the stem peptide via the MurF 
dipeptide pathway. Dipeptide 2 was synthesized to mimic the lysine side chain in the single 
amino acid metabolic labeling strategy (Figure 5.2A). Treatment of B. subtilis cells with 
dipeptide 2 led to an insignificant fluorescence increase over untreated cells. From these 
results, it became apparent that side chain size may have contributed to drastically reduced 
labeling levels. We proceeded to synthesize a similar dipeptide using D-2,3-
diaminopropionic acid (3) with the aim of minimizing the overall size of the amino acid 
side chain. However, both flow cytometry analysis and fluorescent microscopy imaging of 
B. subtilis bacteria treated with dipeptides 2 and 3 revealed minimal increases in labeling. 
(Figure 5.2B). In conjunction with our previous findings in Chapter 4, it is apparent from 
these results that varying levels of tolerance for unnatural cell wall analogs exists 
depending on the entry point into the peptidoglycan biosynthesis pathway. We recently 
demonstrated that side chain structural features control incorporation efficiency of single 
D-amino acids.142 With these early results in hand, we set out to re-design a dipeptide based 
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labeling strategy that exploited the reduced removal of modifications at the 4th position of 
the stem peptide to improve hapten incorporation efficiency. 
 
5.3.2 Two-Step Dipeptide Bacterial Cell Surface Labeling 
The lack of NBD-displaying dipeptide incorporation prompted us to develop a two-
step labeling method. In this strategy, a small chemically reactive side chain can be 
integrated into the dipeptide to reduce steric hindrance. Upon chemical modulation of the 
bacterial cell surface, cells are treated with a complementary reaction handle modified with 
the DNP hapten (Figure 5.3). For a model reaction scheme, we used sulfhydryl and 
maleimide handles as complementary reactive partners. Thiol-maleimide chemistry 
provided a moderately selective and facile method to monitor modification of bacterial cell 
surfaces. We envisioned two distinct benefits of decoupling hapten conjugation from 
MurF-mediated metabolic labeling. First, incorporation of the dipeptide is expected to 
increase due to increased mimicry of the endogenous D-Ala-D-Ala substrate. Secondly, in 
a two-step strategy, it is possible to utilize DNP-linker molecules of lengths that are not 
Figure 5.3 Two-Step Dipeptide Antibody Recruitment Scheme. Utilizing a 
dipeptide that contains a reactive chemical handle, bacterial peptidoglycan surfaces 
can be remodeled. Bacterial cells incubated in the presence of a hapten-containing 
linker can then react with the chemical handle to yield a hapten-modified bacterial 
cell surface that can recruit antibodies to the cell surface.  
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enzymatically tolerated to provide improved cell surface hapten protrusion. Haptens 
imbedded within the peptidoglycan become unavailable for interaction and binding with 
antibodies. By utilizing tethers modified with hapten, it becomes possible to rescue 
epitopes that may be sterically occluded within the mesh-network of the peptidoglycan 
(Figure 5.4).  
Figure 5.4 Rescue of Peptidoglycan Buried Epitopes. A “one-step” labeling strategy 
limits protrusion of haptens from the peptidoglycan and therefore generates lower 
levels of bacterial cell antibody opsonization. Conversely, a “two-step” dipeptide 
strategy in which the hapten is conjugated to a linker molecule allows for greater 
protrusion of the antibody recruitment molecule from the peptidoglycan. This enhances 
bacterial cell opsonization and increases immune response.  
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 To test whether this two-step dipeptide strategy would provide greater cell surface 
modification, B. subtilis wild type cells were incubated in the presence of thiol containing 
dipeptides and subsequently reacted with a maleimide modified NBD fluorophore to 
Figure 5.5 Two-Step Labeling of Bacterial Peptidoglycan. (A) Installation of thiol-
containing dipeptides followed by reaction with maleimide fluorophores endows 
bacterial cell surface labeling through a two-step process. (B). B. subtilis cells were 
incubated overnight with 1mM of 4,5,6, 7, or 8. Cells were briefly treated with DTT 
to reverse any oxidation that may have occurred prior to treatment with 50µM FL0. 
Cells were analyzed for fluorescence using flow cytometry. Data are represented as 
the mean + SD (n =3). (C) Chemical structures of sulfhydryl-containing dipeptides 
use for two-step labeling of bacterial surfaces.  
119 
	  
quantify labeling levels (Figure 5.5A and 5.6). We synthesized two cysteine containing 
dipeptides, D-Cys-D-Ala (4) and D-Ala-D-Cys (5), to provide a thiol reactive handle at the 
fourth position or fifth position of the stem peptide, respectively (Figure 5.5B). As we had 
predicted, cells treated with dipeptide 4 displayed higher levels of fluorescence relative to 
the dipeptide 5 and single amino acid D-Cys (6). These results illustrate that a properly 
designed dipeptide can lead to higher levels of surface remodeling compared to the single 
amino acid strategy (Figure 5.11). Control dipeptides demonstrated stereochemistry to be 
critical in surface remodeling as treatment of cells with either the diastereomer (7) or the 
enantiomer (8) of dipeptide 4 lead to insignificant increases in fluorescence compared to 
untreated cells, thus lending support to the MurF-based metabolic pathway (Figure 5.5C). 
Figure 5.6 Phase and Fluorescence Microscopy of Dipeptide 
Labeled B. subtilis. B. subtilis cells (wild type) were incubated 
overnight with 1 mM of either D-Cys-D-Ala or D-Ala-D-Cys. 
Cells were subsequently treated with 50 µM of FL0 for 30 
minutes and visualized using fluorescence microscopy. Scale 
bars = 5 µm.  
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5.3.3 Peptidoglycan Pore Size Determination 
Having established that dipeptide 4 provided superior cell surface labeling relative 
to single D-amino acids, we sought to optimize the tether length connecting the stem 
peptide modification to the displayed epitopes. Crosslinking within the peptidoglycan layer 
creates pores that range from 5 nm - 25 nm in diameter, potentially reducing the recruitment 
of antibodies beyond surface-exposed haptens due to impeded permeation.178 We 
hypothesized that elongated tethers may facilitate antibody recruitment from stem peptides 
beyond the immediate surface. We constructed a panel of fluorophore-linker (FL) 
conjugates containing both a thiol-reactive maleimide handle and an NBD handle with the 
goal of determining permeability of tethers within the peptidoglycan. These molecular 
tethers were built with a central polar/flexible linker composed of repeating Gly-Gly-Ser 
amino acid units (GGS)n, where n = 0-4 (Figure 5.7A). To evaluate the effect of tether 
length, B. subtilis cells were incubated overnight in the presence of dipeptide 4, 
subsequently labeled with each variant (FL0-FL4), and analyzed for cellular fluorescence 
via flow cytometry. It is evident that FL0 and FL1 labeled bacterial cell surfaces to similar 
levels, an indication that smaller tethers can readily penetrate the peptidoglycan pores. 
Elongation of the tethers, revealed diminished labeling efficiency in a length-dependent 
manner, with the longest tether FL4 resulting in approximately half of the fluorescence 
levels of FL0 (Figure 5.7C). While these results serve as an integral part for the design of 
hapten molecular tethers, we also realize that they represent a facile assay for 
peptidoglycan permeability. We anticipate that based on the mechanism of incorporation, 
D-Cys epitopes are evenly dispersed throughout the entire peptidoglycan. Therefore, 
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labeling levels can be interpreted as a readout on the permeability of biomolecules from 
the extracellular space into the peptidoglycan network.  
 
5.3.4 Two-Step Antibody Recruitment  
Finally, we set out to demonstrate this strategy could be used to induce a 
recruitment of endogenous anti-DNP antibodies to the bacterial cell surface (Figure 5.8A). 
The series FL0-FL4 served to inform us about biomolecule permeation through the cell 
surface. However, labeling levels were measured based on total cellular fluorescence and 
may not necessarily reflect epitope availability for antibody binding. To optimize labeling 
levels concomitantly with availability to antibody binding, we built a second series of 
GGS-based tethered molecules. For this DNP-linker (DL) series, a DNP antigen was 
installed on the N-terminus in place of NBD (Figure 5.8B). B. subtilis cells incubated with 
Figure 5.7 Peptidoglycan Porosity Measurement. (A) Chemical structure of 
fluorescent linkers used to assess peptidoglycan porosity. (B) Nomenclature, 
structure, and predicted length of fluorescent linkers used to investigate peptidoglycan 
porosity. (C) B. subtilis cells were incubated overnight with 1mM dipeptide 4, 
subjected to DTT to reverse oxidation, and incubated with 50µM of FL0-4. Data are 
represented as the mean + SD (n=3).  
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dipeptide 4, were subsequently treated with the various DNP linker conjugates and  
incubated in the presence of FITC labeled anti-DNP IgG antibodies. Interestingly, flow 
cytometry analysis showed a sharp contrast in opsonization levels compared with the FL 
series (Figure 5.8C). Cells treated with DL1 led to the highest levels of anti-DNP antibody 
recruitment. Based on the extensive structural similarities between the FL and DL series, 
it is reasonable to expect that bacterial cell surfaces were remodeled with DL0 to a similar 
Figure 5.8 Two-Step Dipeptide Antibody Recruitment. (A) Scheme of Two-Step 
dipeptide mediated antibody recruitment. (B) Chemical structure of DNP-linkers 
used to assess antibody recruitment to bacterial cell surfaces. (C) B. subtilis cells 
were incubated overnight with 1mM dipeptide 4, subjected to DTT to reverse 
oxidation, and incubated with 50µM of DNP-linker. Following DNP-peptidoglycan 
installment, labeled bacterial cells were incubated with Alex Fluor 488 anti-DNP 
IgG antibody to assess bacterial cell opsonization. Data are represented as the mean 
+ SD (n=3).  
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level as DL1. Yet, DL0 treated cells led to over 2-fold decrease in recruitment levels than 
DL1. Furthermore, cells treated with DL3 generated greater labeling than DL0. Likewise, 
the much longer DL5 led to similar antibody recruitment levels as the shorter DL0. These 
results illustrate that to optimize bacterial cell opsonization using our strategy, it is 
necessary to balance tether permeation with hapten binding on the cell surface. Most 
importantly, we showed that by decoupling the MurF-mediated metabolic labeling from 
hapten conjugation it may be possible to increase the availability of haptens on the cell 
surface for antibody binding by adjusting the tether length.  
 
5.4 Conclusion 
In conclusion, we have demonstrated that dipeptide-based metabolic labeling 
strategy leads to higher levels of remodeling compared to single D-amino acids.215 MurF 
promiscuity was exploited to enable intracellular hijacking of the peptidoglycan 
biosynthetic pathway. By designing and synthesizing a dipeptide to install modifications 
onto the 4th position of the stem peptide, it became possible to improve retention of 
unnatural surface-bound epitopes. Through the evaluation of various fluorescently tagged 
maleimide heterobifunctional tethers, pore-size constraints for remodeling bacterial 
peptidoglycan were established. Based on tether length restrictions, we successfully 
installed haptens onto dipeptide modified bacterial cell surfaces and induced high levels of 
bacterial cell opsonization. These high levels of antibody recruitment are thought to be the 
result of improved epitope display for extracellular antibody interactions. We anticipate 
that based on the strategy disclosed here, it should be possible to use unnatural dipeptides 
displaying bioorthogonal handles to label bacterial cell surfaces for imaging and 
therapeutic applications. More importantly, we propose that the combination of elevated 
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metabolic labeling levels and the use of tethers to endow bacterial cells with readily 
accessible epitopes could provide the basis for improved immunomodulation strategies to 
combat bacterial infections.  
 
5.5 Future Work 
 The use of dipeptides facilitated the modulation of bacterial surfaces with larger 
molecules and enabled higher levels of antibody recruitment compared to single D-amino 
acids. Because the promiscuity exhibited by MurF does not allow for DNP haptens to be 
directly incorporated into the peptidoglycan, the use of two-step labeling was necessary. 
Although this dipeptide method procured greater bacterial cell surface antibody 
opsonization, the two-step labeling chemistry described above is not applicable in a 
biological setting. As the surface proteins of mammalian cells possess cysteine residues, 
the use of the thiol-maleimide conjugation does not represent a selective method of 
remodeling bacterial surfaces. The nondiscriminatory nature of cysteine-maleimide 
conjugations would lead to an immune response that could possibly inflict damage to host 
cells. To overcome this selectivity issue, the use of a bioorthogonal two-step labeling is 
necessary.  
 Future work will be conducted to generate dipeptide probes that enable selective 
remodeling of bacterial surfaces through use of bioorthogonal chemistry. Though several 
bioorthogonal reactions exist, limitations imposed by the need for rapid reactions in the 
without the use of an exogenous catalyst curtails the possible candidates. Although SPAAC 
reactions do not necessitate the use of copper, the kinetics of this reaction are relatively 
slow and are not applicable in a biological setting. Recently the use of tetrazine-TCO 
ligations has been performed bacterial cell surfaces. These reactions have demonstrated 
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rapid rates of reaction without the use of an exogenous catalyst. Future dipeptides will be 
synthesized to incorporate a tetrazine reactive handle. If MurF promiscuity enables the 
introduction of this reactive handle into the peptidoglycan, subsequent linker molecules 
containing TCO and DNP will be synthesized to enable rapid antigen labeling of bacterial 
surfaces. This tetrazine-TCO dipeptide strategy will then be evaluated for its ability to 
recruit antibodies to the cell surface and could possibly serve as a next generation immune 
stimulation therapy for pathogenic bacterial infections.  
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Chapter 6: 
D-amino carboxamide Antibody Recruitment Therapy 
6.1 Abstract 
 Our studies demonstrate that PBPs exhibit broad side chain promiscuity when 
integrating exogenous D-amino acids into bacterial peptidoglycan. Because the enzymes in 
the peptidoglycan biosynthetic pathway have been shown to be largely indiscriminate of 
the substrates that are metabolized, we hypothesized that PBPs might also tolerate changes 
within the D-amino acid backbone. In this chapter, we utilized D-amino carboxamide 
substrates modified with DNP side chains to generate a variation of DART that led to an 
enhanced immune response. The carboxamide modification was selected because it was 
hypothesized to better mimic the activity of the natural PBP substrate. Through this study, 
we demonstrated that C-terminus amidation of DNP modified D-amino acids leads to 
higher levels of cell surface antibody recruitment than observed with the original D-amino 
acids used in DART. This enhanced bacterial cell opsonization was observed at 
concentrations five times lower than with DNP-D-amino acids. We were also able to 
demonstrate opsonization to the surface of several pathogenic bacteria. Furthermore, DNP-
D-amino carboxamides facilitated bacterial cell surface opsonization from pooled human 
serum, thus highlighting the biological relevance of this immune stimulation strategy.  
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6.2 Introduction 
PBP facilitated displacement of the C-terminus D-alanine of peptidoglycan 
oligopeptides generates an acyl-enzyme intermediate. Nucleophilic attack by meso-
diaminopimelic acid (m-DAP) or L-Lys found within neighboring stem peptides displaces 
the PBP and tethers adjacent oligopeptides together and is critical for bacterial cell survival. 
In vitro studies of PBP facilitated exogenous D-amino acid swapping propose that these 
compounds mimic the nucleophile from an adjacent oligopeptide and subsequently is 
integrated into the peptidoglycan. Therefore, the swapping of the terminal D-alanine on the 
peptidoglycan with unnatural D-amino acids from the media occurs in competition with the 
crosslinking from a neighboring amino group. Although the native C-terminus on the 
oligopeptide is a carboxylic acid, in several organisms such as B. subtilis and S. aureus, 
the incoming nucleophilic amino group does not possess a carboxylic acid group.94 For 
example, the m-DAP group on vegetative B. subtilis naturally occurs almost exclusively as 
the neutral amidated form.216 Conversely, pathogens such as S. aureus and E. faecalis 
possess L-Lys at the third position of the peptidoglycan oligopeptide which serves as the 
nucleophile during PBP-mediated crosslinking of adjacent stem peptides.217, 218 We 
hypothesized that the neutralization of the C-terminal carboxylic acid into the carboxamide 
would be a better mimic of the incoming nucleophile on the neighboring peptide, and, 
therefore, result in more effective competition for the PBP acyl-intermediate. 
The recruitment of antibodies to the surface of bacteria is expected to induce a 
response by the host immune cells. We presumed that an impassive immune response while 
using DART could result from inadequate valency of DNP epitopes properly exposed to 
the extracellular media could serve. Therefore, structural modifications of the D-amino acid 
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that result in higher incorporation levels should also yield improved recruitment profiles. 
To enhance incorporation, we set out to introduce changes to the D-amino acid core that 
could improve exogenous D-amino acid swapping levels and potentially lead to better 
retention. It should be noted that at same time of this research, our lab and the Kahne lab 
both published findings that natural and unnatural D-amino acids possessing a carboxamide 
terminus are readily incorporated into the peptidoglycan of diverse bacterial strains.150, 151 
In our studies, several D-amino acids possessing diverse C-termini and a NBD fluorophore 
conjugated side chain, were used to evaluate C-terminus PBP D-amino acid promiscuity. 
From this study, we identified D-amino carboxamides as the chemical structure most 
readily integrated into the peptidoglycan.151 Herein, we describe a structural modification 
to the C-terminus of the D-amino acid that greatly enhances antibody recruitment. In 
addition, we show for the first time that the use of D-amino acids leads to the opsonization 
of bacterial cells directly in the presence of human serum. These results establish that our 
second generation DART agents displayed improved activities and represent lead agents 
for further in vivo evaluation. 
 
6.3 Results and Discussion 
6.3.1 Synthesis of DK-Amide 
In testing the ability of a D-amino carboxamide with a DNP displaying epitope to 
recruit antibodies to the bacterial surface, two D-Lys(DNP)-OH (DK-Acid) and D-
Lys(DNP)-NH2 (DK-Amide) were synthesized. These syntheses were performed on solid-
phase supports (Scheme 6.1). For the synthesis of DK-Acid, the orthogonally protected 
Boc-D-Lys(Fmoc)-OH was loaded onto 2-Chlorotrityl chloride resin (CTC). The synthesis 
of DK-Amide was initiated by loading the same amino acid onto Sieber resin. The 
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subsequent steps were identical for both compounds. Following the loading of the amino 
acid, the Fmoc protecting group was removed in the presence of piperazine. The unmasking 
of the ε-amino group on resin allowed for the derivatization with dinitrofluorobenzene 
(DNFB) in the presence of N,N-diisopropylethylamine (DIEA) base. Concomitant 
deprotection and cleavage was accomplished with the treatment of trifluoroacetic acid 
(TFA) and scavengers to yield the final products (Figure 6.1).  
 
6.3.2 Bacterial Cell Opsonization utilizing DK-Amide 
First, we set out to evaluate the ability of DK-Acid and DK-Amide to trigger the 
recruitment of anti-DNP antibodies to the surface of the Gram-positive bacterium, B. 
subtilis. Cells were incubated 
overnight in the presence of the D-
amino acid derivatives. After 
washing, cells were then incubated in 
the presence of FITC-labeled anti-
DNP IgG antibodies and cell-
associated fluorescence was 
measured by flow cytometry. 
Scheme 6.1 Synthetic scheme for DK-Acid and DK-Amide.  
Figure 6.1 Chemical structure of DK-Acid 
and DK-Amide. 
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Remarkably, incubation with the amidated C-terminus variant DK-Amide led to a vastly 
improved recruitment profile in B. subtilis. This improvement was evident by the much 
higher fluorescence levels compared to DK-Acid at all concentrations evaluated (Figure 
6.2). Previously, we had found that concentrations greater than 1 mM of DK-Acid were 
necessary to induce the recruitment levels observed for cells treated with 100 µM of DK-
Amide. However, by 250 µM of the D-amino acid derivatives there is an even larger 
Figure 6.2 DK-Acid and DK-Amide Labeled B. subtilis Antibody Recruitment. B. 
subtilis (wildtype) were incubated overnight in LB supplemented with the stated 
concentration of either DK-Acid or DK-Amide followed by incubation with Alexa 
Fluor 488-conjugated anti-DNP antibodies and analyzed using flow cytometry. Data 
are represented as mean + SD (n = 3). Inset, cells labeled with 250 µM of the specific 
agent followed by antibody opsonization were visualized using fluorescence 
microscopy. Scale bar represents 3 µm. 
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contrast in the antibody recruitment capacity between the two agents. DK-Amide induces 
recruitment 100-fold better than DK-Acid at 250 µM.  
Next, we set out to 
determine whether it would be 
possible to induce antibody 
recruitment to the bacterial 
surface using a pulse-labeling 
step. The pulse-labeling is 
designed to mimic the 
introduction of a single dosage of 
the D-amino acid variant at a high 
concentration. We envision that 
one possible route of 
administration of a DART agent 
may be via a single dosage at a 
high concentration. Millimolar concentrations of highly soluble molecules, such as amino 
acid derivatives, have shown to be achievable in rodent and primate models.219 When B. 
subtilis cells were incubated for 1 hour in the presence of 1 mM of DK-Amide, it was 
observed that anti-DNP antibodies were successfully recruited to the cell surface (Figure 
6.3). Reduction of the concentration to 100 µM led to no antibody recruitment with either 
D-amino acid derivative, thus indicating that it may be difficult to reduce both the time of 
incorporation step and the concentration of the agent without compromising the 
recruitment of antibodies to the surface. As expected, DK-Acid led to almost no 
Figure 6.3 DK-Acid and DK-Amide Pulse-
Labeled B. subtilis Antibody Recruitment. B. 
subtilis (wildtype) were incubated for 1 hour in LB 
supplemented with the stated concentration of either 
DK-Acid or DK-Amide followed by incubation 
with Alexa Fluor 488-conjugated anti-DNP 
antibodies and analyzed using flow cytometry. Data 
are represented as mean + SD (n = 3). 
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recruitment even at the 
elevated concentration of 1 
mM. These results clearly 
demonstrated that DK-
Amide is superior to DK-
Acid in the induction of 
endogenous antibody 
recruitment to the surface 
of bacterial cells.  
We also evaluated 
the recruitment of 
antibodies to the surface of 
the human opportunistic 
pathogen S. epidermidis. 
As with B. subtilis, we 
observed that DK-Amide 
leads to a stronger 
induction in antibody 
recruitment to the surface 
of S. epidermidis 
compared to DK-Acid 
(Figure 6.4A). Although 
the contrast between the 
Figure 6.4 DK-Acid and DK-Amide Facilitated 
Antibody Recruitment to Pathogenic Bacteria. (A) S. 
epidermidis and (B) E. faecalis cells were incubated 
overnight in LB supplemented with 250 µM of either DK-
Acid or DK-Amide followed by incubation with Alexa 
Fluor 488-conjugated anti-DNP antibodies and analyzed 
using flow cytometry. Data are represented as mean + SD 
(n = 3). 
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two molecules is not as prominent in S. epidermidis, the amidation of the C-terminus in 
DK-Amide still leads to a doubling in antibody recruitment at 100 µM. Next, we evaluated 
our strategy with the human pathogen E. faecalis. This opportunistic microbe has evolved 
resistance to the glycopeptide antibiotic vancomycin and is the causative agent of some of 
the most difficult to treat infections in humans. Consequently, new antimicrobial agents 
are desperately needed against this type of bacteria. Following an overnight labeling 
incubation with both DNP derivatized D-amino acids, it was found that both agents 
successfully recruited anti-DNP antibodies to the bacterial surface, with DK-Amide 
demonstrating much more effective antibody recruitment than the carboxylic acid 
counterpart (Figure 6.4B). Together, we demonstrated that our strategy is compatible with 
several human pathogens and amidation of the C-terminus potentiated antibody 
recruitment.  
 
6.3.3 Pooled Human Serum Bacterial Cell Opsonization 
Finally, we set out to show that our proposed DART strategy is effective in 
conditions that simulate a human host. Up to this point, we have shown that the remodeling 
of bacterial surfaces with DNP-modified D-amino acids can trigger the recruitment of 
purified FITC-labeled anti-DNP IgG antibodies. While these results establish the 
feasibility of the overall strategy, the recruitment of IgG antibodies in a human host would 
have to be derived directly from the serum. The recruitment of serum-associated IgG 
antibodies could potentially fail due to interference with serum proteins, lack of specificity, 
and overall lack of anti-DNP abundance. Therefore, it was critical to evaluate this DART 
strategy in the biologically relevant conditions. The lack of a fluorescent handle on IgG 
antibodies from the pooled human serum necessitated the introduction of a secondary  
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Figure 6.5 Pooled Human Serum Antibody Recruitment. (A) Cartoon representation 
of the antibody recruitment using pooled human serum. (B) B. subtilis (wildtype) were 
incubated overnight in LB supplemented with 250 µM of either DK-Acid or DK-
Amide. Cells were subsequently incubated with either 10% pooled human serum or 
PBS, followed by the incubation with FITC-labeled anti-human IgG antibodies and 
analyzed using flow cytometry. Data are represented as mean + SD (n = 3). 
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antibody. In this assay, IgG antibodies from pooled human serum that had opsonized the 
bacteria cell surface were detected using a FITC-labeled anti-human IgG antibody via flow 
cytometry (6.5A). We observed that in the absence of pooled human serum, there was no 
cell-associated fluorescence signal from B. subtilis cells treated with either DK-Amide or 
DK-Acid (Figure 6.5B). These results indicated that there is minimal non-specific binding 
of the FITC-labeled anti-human antibody on the surface of D-amino acid remodeled cells. 
Upon the introduction of 10% pooled human serum to cells treated with DK-Amide and 
DK-Acid, there was a clear increase in cell-associated fluorescence. Significantly, DK-
Amide treated cells were labeled over three fold better with IgG antibodies than DK-Acid 
treated cells. These findings are consistent with the improved capacity of DK-Amide to 
induce recruitment of antibodies to bacterial surfaces in our previous assays. Most 
importantly, we show for the first time that DART is compatible with conditions that mimic 
the human host environment.  
The marked improvement in recruitment upon amidation of the C-terminus is likely 
being driven by a few factors. First, studies performed in our lab have demonstrated the 
amidated C-terminus to be a better mimic for the preferred incoming nucleophile to the 
PBP acyl-intermediate.151 Enhanced mimicry of the endogenous substrate is expected to 
lead to more efficient competition by the unnatural D-amino acid. Second, the swapping of 
the terminal D-alanine on the peptidoglycan oligopeptide by DK-Amide leads to 
neutralization of the peptide C-terminus. We propose that subsequent processing by PBPs 
(transpeptidase and/or carboxypeptidase activity) can be disrupted by the amidation of the 
C-terminus of the oligopeptide. Processing by PBP transpeptidases and carboxypeptidases 
is expected to result in the removal of the fifth position amino acid, therefore, reducing the 
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overall level of DNP epitopes displayed on the bacterial surface. Finally, a much subtler 
factor that may be playing a role in facilitating antibody recruitment to the surface of DK-
Amide treated bacteria versus DK-Acid treated bacteria. We had previously observed that 
the treatment of bacteria with D-Ala-NH2 led to enhanced association with macromolecules 
from the extracellular space, presumably due to the interference with crosslinking by 
PBP.151 Likewise, the treatment with DK-Amide likely leads to greater permeability of the 
IgG molecule to surface anchored DNP epitopes. 
 
6.4 Conclusion 
Emerging non-traditional strategies aimed at combating bacterial infections are 
expected to play a role in complementing traditional therapeutic interventions. The use of 
small immune system stimulating molecules to promote the clearance of diseased cells has 
recently shown clear and exciting promise in the field of cancer therapy. We have 
previously showed that D-amino acids derivatized with DNP handles can induce the 
recruitment of anti-DNP antibodies to the surface of bacterial cells as well. In this report, 
we divulge our findings that a simple, but critical, modification to the C-terminus can 
greatly enhance the display of DNP epitopes, and, therefore, more efficiently trigger the 
recruitment of antibodies to the surface.220 DK-Amide, the carboxamide counterpart to 
DK-Acid, led to 100-fold better recruitment in wildtype B. subtilis. Importantly, elevated 
recruitment of anti-DNP antibodies to bacterial surfaces was observed directly from pooled 
human serum for the first time. Together, we demonstrate a second generation DART 
molecule that could potentially have antibiotic activity using a previously unexplored mode 
of action. We anticipate that these agents will be excellent lead compounds to apply 
synthetic immunology in in vivo models in the future. 
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6.5 Future Work 
 Having developed several variations of our original DART method, we believe that 
amidation of the C-terminus of D-amino acids with DNP conjugated side chains represents 
the most promising strategy for combating pathogenic bacteria in live organisms. Our 
studies using fluorescent probes demonstrate that D-amino acids containing an amidated 
carboxylic acid are more readily integrated into the peptidoglycan than the natural 
carboxylic acid terminus. Currently, we are working towards determining if D-amino acids 
are capable of labeling bacterial cell surfaces in vivo. In pursuing live organism labeling, 
we have recently started a collaboration with Dr. Mohammed Seleem at Purdue University.  
Initial confocal microscopy experiments were performed by the Seleem lab to 
ensure the ability of D-amino acids to selectively label S. aureus in the presence of J774A.1 
murine macrophage cells. In this experiment, S. aureus were incubated with J774A.1 
macrophages for 30 minutes to allow for natural phagocytosis of the bacteria. Following 
engulfment of the pathogen, extracellular bacteria were removed through lysostaphin 
treatment. The cells were then incubated overnight in the presence of either 10 µM D-
Lys(FITC)-NH2 or L-Lys(FITC)-NH2 and analyzed via confocal microscopy. Imaging of 
these experiments revealed D-Lys(FITC)-NH2 to be highly selective in labeling S. aureus 
cell surfaces over macrophages. As expected, imaging of the L-Lys(FITC)-NH2 
demonstrated labeling of neither bacteria or mammalian cells. The labeling of bacterial 
cells at these low concentrations demonstrates that labeling of bacterial cells in vivo may 
be possible. Furthermore, the selective nature of this labeling highlights the ability of this 
potential immune stimulation strategy to eliminate damage to host cells.  
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Currently, we plan to collaborate with the Seleem lab to determine if D-Lys(FITC)-
NH2 is capable of labeling S. aureus cells in pathogen challenged mice models. For these 
experiments, mice will be infected subcutaneously with S. aureus. After pathogen 
challenging of the mice develop localized infections, topical administration of D-
Lys(FITC)-NH2 will be performed for eight hours. Cells will subsequently be harvested 
and analyzed for fluorescence via flow cytometry. The data generated from this experiment 
will determine, for the first time, if D-amino acid swapping occurs in live organism bacteria. 
If swapping occurs, subsequent experiments will be designed for the implementation of in 
vivo DART.  
Figure 6.6 Intracellular S. aureus D-amino carboxamide Labeling. Confocal 
microscopy of S. aureus phagocytosed by J774A.1 macrophage cells. Macrophages 
were infected with S. aureus and subsequently treated with lysostaphin to eliminate 
any extracellular bacteria. Macrophage cells were subsequently incubated with 10 
µM of either D-Lys(FITC)-NH2 or L-Lys(FITC)-NH2 for 20 hours. Cells were then 
washed and imaged with confocal microscopy. Scale bars = 2.30 µm.  
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Chapter 7: 
Materials and Methods 
7.1 Materials 
Amino acids were purchased from Chem-Impex. Antibody reagents were 
purchased from Life Technologies. Protein A was purchased from Sigma-Aldrich. All other 
organic chemical reagents were purchased from Fisher Scientific or Sigma Aldrich and 
used without further purification. 
 
7.2 Bacterial Strains 
 Bacterial strains used throughout this thesis are listed below.  
Bacterial Strains  
Bacterial Strain Classification Chapter  
B. subtilis ΔdacA Gram Positive 3, 4, 5, 6 
B. subtilis NCIB 3610 Gram Positive 4, 5, 6 
S. aureus ATCC 25923 Gram Positive 3, 4 
S. epidermidis NRS 101 Gram Positive 3, 4, 6 
E. faecalis ATCC 29212 Gram Positive 3, 4, 6 
E. coli MG1665 Gram Negative 4 
B. subtilis ΔpbpA Gram Positive 4, 6 
B. subtilis ΔpbpC Gram Positive 4, 6 
B. subtilis ΔpbpD Gram Positive 4, 6 
B. subtilis ΔpbpF Gram Positive 4, 6 
B. subtilis ΔpbpG Gram Positive 4. 6 
B. subtilis ΔpbpH Gram Positive 4, 6 
B. subtilis ΔpbpI Gram Positive 4, 6 
B. subtilis ΔPonA Gram Positive 4, 6 
 
7.3 Solution Phase Synthesis of NBD-amino acid Synthesis. 
Sodium bicarbonate (853 mg, 10.5 mmol), Boc-L-Lys-OH (500 mg, 2.1 mmol), NBD-F 
(183mg, 1.8 mmol) and 15 mL of H2O/CH3CN (1:1) were added to a flask. The solution 
was stirred at 75 °C (oil bath) for 1 hour. The solvents were removed in vacuo, and the 
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remaining crude material was used without further purification. The crude Boc-protected 
amino acid was dissolved in 30 mL of CH2Cl2/TFA (1:1) at 0 °C (ice bath) for 1 hour. The 
solvent was removed in vacuo and the product was trituated with cold diethyl ether. The 
solid was recovered following centrifugation. The compound was then purified using RP-
HPLC with a Phenomenex C8 prep column and an eluent consisting of solvent A (H2O / 
0.1% TFA) and solvent B (MeOH / 0.1% TFA) using a 60 minute gradient transitioning 
from 5% B to 100% B at a flow rate of 10 ml min-1. The purity of the compound was 
verified by analytical RP-HPLC using a Phenomenex C4 column with an eluent consisting 
of solvent A (H2O /0.01% TFA) and solvent B (CH3CN / 0.01% TFA) with a 30 minute 
gradient transitioning from 5% B to 100% B at a flow rate of 3 ml min-1 and monitored at 
220nm and molecular weight was confirmed using ESI-MS. This procedure was repeated 
for D-Lys(NBD) as well.  
 
7.4 Solid Phase Peptide Synthesis of NBD and DNP-D-amino acids 
A 25 ml synthetic flask was charged with 400 mg (0.20 mmol) of 2-Chlorotrityl 
Resin (CTC). The resin was initially washed with CH2Cl2 (3 x 5 ml) and DMF (3 x 5 ml). 
Initial loading was performed by the addition of Boc-protected amino acids (5 equiv, 1.0 
mmol) in CH2Cl2 (5 ml) to the reaction flask with and DIEA (10 equiv, 2.0 mmol), and the 
flask was agitated for 2 hours at room temperature. The resin was consequently washed 
with DMF, CH2Cl2, MeOH, CH2Cl2, and DMF (3 x 5 ml each). When necessary, the Fmoc 
protecting group was removed with a solution of 6 M piperazine/100 mM HOBt in DMF 
(7 ml). The flask was agitated for 25 minutes and the deprotection solution was drained. 
The resin was washed with DMF, CH2Cl2, and MeOH (2 x 5 ml each). These steps were 
repeated until all amino acids were coupled to the resin. For the DNP modification step, 
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the resin was treated with dinitrofluorobenzene (DNFB) (5 equiv, 1.0 mmol) and DIEA 
(10 equiv, 2.0 mmol) in DMF (5 ml) in the dark and the flask was agitated for 1 hour at 
room temperature. The resin was drained and subsequently washed with DMF, CH2Cl2, 
MeOH (3 x 5 ml each). For the deprotection/cleavage of amino acids, a trifluoroacetic acid 
(TFA) cocktail solution (50% TFA, 50% CH2Cl2, 10 ml) was added to the resin, and the 
mixture was agitated for 1 hour at room temperature. The resulting solution was 
concentrated in vacuo to remove the TFA. The residue was triturated in cold diethyl ether, 
the precipitate was collected by centrifugation and dissolved in H2O. Compounds were 
then purified using RP-HPLC with a Phenomenex C8 prep column and an eluent consisting 
of solvent A (H2O / 0.1% TFA) and solvent B (MeOH / 0.1% TFA) using a 60 minute 
gradient transitioning from 5% B to 100% B at a flow rate of 10 ml min-1. The purity of 
the peptides was verified by analytical reverse phase HPLC using a Phenomenex C18 
column with an eluent consisting of solvent A (CH3CN/0.1% TFA) and solvent B 
(H2O/0.1% TFA) with a 30 minute gradient consisting of 5 to 100 % B, and a flow rate of 
1 ml min-1 and monitored at 220 nm. Purified amino acids were subsequently characterized 
using ESI-MS and MALDI-TOF MS.  
 
7.5 Solid Phase Peptide Synthesis of Sulfhydryl-D-amino acids 
A 25ml synthetic flask was charged with 200 mg (0.275 mmol) of CTC. The resin 
was initially washed with dry CH2Cl2 (3 x 5 ml) and dry DMF (3 x 5ml). Initial loading 
was performed by the addition of Fmoc-protected amino acids (1 equiv, 0.275 mmol) in 
dry CH2Cl2 (5 ml) to the reaction flask with DIEA (4 equiv, 1.1 mmol) and the flask was 
agitated for 2 hours at room temperature. The resin was consequently washed with DMF, 
CH2Cl2, MeOH, CH2Cl2 and DMF (3 x 5 ml each). The Fmoc-protecting group was 
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removed with a solution of 6 M piperazine/100 mM HOBt in DMF (10 ml). The flask was 
agitated for 25 minutes and the deprotection solution was drained. The resin was washed 
with DMF, CH2Cl2, MeOH, CH2Cl2, and DMF (2 x 5 ml each). The addition of the second 
amino acid was performed by adding Fmoc-protected amino acids (4 equiv, 1.1 mmol), 
HBTU (4 equiv, 1.1 mmol), DIEA (8 equiv, 2.2 mmol) in DMF and agitating for two hours. 
Dipeptides were subsequently Fmoc-deprotected, washed as stated before and then cleaved 
using a TFA cocktail solution (82.5% TFA, 2.5% 1,2 ethanedithiol (EDT), 5% thioanisole, 
5% H2O, 5% phenol). The resulting solutions were concentrated in vacuo to remove the 
TFA. The residue was triturated in cold diethyl ether and the precipitate was collected by 
centrifugation. Peptides were purified using RP-HPLC using a Phenomenex C8 prep 
column with an eluent consisting of solvent A (H2O / 0.1% TFA) and solvent B (MeOH / 
0.1% TFA) using a 60 minute gradient transitioning from 5% B to 100% B at a flow rate 
of 10 ml min-1. The purity of the peptides was verified by analytical RP-HPLC using a 
Phenomenex C4 column with an eluent consisting of solvent A (H2O /0.01% TFA) and 
solvent B (CH3CN / 0.01% TFA) with a 30 minute gradient transitioning from 5% B to 
100% B at a flow rate of 3 ml min-1 and monitored at 220nm and molecular weight was 
confirmed using ESI-MS. 
 
7.6 Solid Phase Peptide Synthesis of Dipeptides 
A 25ml synthetic flask was charged with 200 mg (0.275 mmol) of CTC resin. The 
resin was initially washed with dry CH2Cl2 (3 x 5 ml) and dry DMF (3 x 5ml). Initial 
loading was performed by the addition of Fmoc-protected amino acids (1 equiv, 0.275 
mmol) in dry CH2Cl2 (5 ml) to the reaction flask with DIEA (4 equiv, 1.1 mmol) and the 
flask was agitated for 2 hours at room temperature. The resin was consequently washed 
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with DMF, CH2Cl2, MeOH, CH2Cl2 and DMF (3 x 5 ml each). The Fmoc-protecting group 
was removed with a solution of 6 M piperazine/100 mM HOBt in DMF (10 ml). The flask 
was agitated for 25 minute and the deprotection solution was drained. The resin was washed 
with DMF, CH2Cl2, MeOH, CH2Cl2, and DMF (2 x 5 ml each). The addition of the second 
amino acid was performed by adding Fmoc-protected amino acids (4 equiv, 1.1 mmol), 
HBTU (4 equiv, 1.1 mmol), DIEA (8 equiv, 2.2 mmol) in DMF and agitating for two hours. 
Dipeptides were subsequently Fmoc-deprotected, washed as stated before and then cleaved 
using a TFA cocktail solution (82.5% TFA, 2.5% 1,2 ethanedithiol (EDT), 5% thioanisole, 
5% H2O, 5% phenol). The resulting solutions were concentrated in vacuo to remove the 
TFA. The residue was triturated in cold diethyl ether and the precipitate was collected by 
centrifugation. Peptides were purified using RP-HPLC using a Phenomenex C8 prep 
column with an eluent consisting of solvent A (H2O / 0.1% TFA) and solvent B (MeOH / 
0.1% TFA) using a 60 minute gradient transitioning from 5% B to 100% B at a flow rate 
of 10 ml min-1. The purity of the peptides was verified by analytical RP-HPLC using a 
Phenomenex C4 column with an eluent consisting of solvent A (H2O /0.01% TFA) and 
solvent B (CH3CN / 0.01% TFA) with a 30 minute gradient transitioning from 5% B to 
100% B at a flow rate of 3 ml min-1 and monitored at 220nm and molecular weight was 
confirmed using ESI-MS. 
 
7.7 Solid Phase Peptide Synthesis of FL and AL Linkers 
A 25ml synthetic flask was charged with 250 mg (0.12 mmol) of Rink Amide 
Resin. The resin was initially washed with DMF (3 x 5 ml) and deprotected with 6 M 
piperazine/100 mM HOBT. The flask was agitated for 25 minutes and the deprotection 
solution was drained. The resin was washed with DMF, CH2Cl2, MeOH, CH2Cl2, and DMF 
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(2 x 5 ml each). Initial loading was performed by the addition of Nα-Fmoc-Nε-methyltrityl-
L-Lysine (3 equiv, 0.36 mmol), HBTU (3 equiv, 0.36 mmol), and DIEA (6 equiv, 0.72 
mmol) in DMF to the reaction flask and was agitated for 2 hours at room temperature. 
Addition of Fmoc-protected amino acids was carried out using the afore mentioned 
protocol to produce linker molecules constituted of Gly-Gly-Ser amino acid repeating units 
of differing length. Once the desired linker length was achieved, the Fmoc-protecting group 
of the terminal glycine was then removed with 6M piperazine/100 mM HOBt solution by 
agitating the flask for 25 minutes. The protecting solution was then drained and the resin 
was washed with DMF, CH2Cl2, MeOH, CH2Cl2, and DMF (2 x 5 ml each). Subsequently, 
NBD-Chloride or DNFB, (5 equiv, 0.60 mmol) with DIEA (7.5 equiv 0.90 mmol) in DMF 
was added to the resin and agitated for 1 hour protected from light to conjugate the either 
the NBD fluorophore or DNP antigen. Following addition of the fluorophore or hapten, the 
solution was drained and washed as stated before. The Nε-methyltrityl protecting group of 
the lysine was then deprotected by adding a 10mls of a TFA cocktail solution (1% TFA, 
2% TIPS in CH2Cl2) to the resin and agitating for 10 minutes protected from light. The 
solution was drained and this procedure was repeated four additional times. The solution 
was then drained and washed as previously stated. Upon MTT deprotection, 3-
maleimidopropionic acid (3 equiv, 0.36 mmol), HBTU (0.36 equiv, 0.36 mmol), and DIEA 
(6 equiv, 0.72 mmol) in DMF was added to the resin. The peptides were cleaved by adding 
a TFA cocktail solution (95%, TFA, 2.5% TIPS, and 2.5 % H2O) to the resin and the 
mixture was agitated for 1 hour at room temperature protected from light. The resulting 
solution was concentrated in vacuo to remove the TFA. The residue was triturated in cold 
diethyl ether and the precipitate was collected by centrifugation. Peptides were purified 
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using RP-HPLC using a Phenomenex C8 prep column with an eluent consisting of solvent 
A (H2O / 0.1% TFA) and solvent B (MeOH / 0.1% TFA) using a 60 minute gradient 
transitioning from 5% B to 100% B at a flow rate of 10 ml min-1. The purity of the peptides 
was verified by analytical RP-HPLC using a Phenomenex C4 column with an eluent 
consisting of solvent A (H2O /0.01% TFA) and solvent B (CH3CN / 0.01% TFA) with a 
30 minute gradient transitioning from 5% B to 100% B at a flow rate of 3 ml min-1 and 
monitored at 220nm and molecular weight was confirmed using MALDI-TOF MS. 
 
7.8 Synthesis of DK-Amide 
A 25 mL synthetic flask was charged with 500 mg (0.25 mmol) of Sieber amide 
resin. The resin was initially washed with CH2Cl2 (3 x 5 mL) and DMF (3 x 5 mL). The 
Fmoc protecting group was removed with a solution of 6M piperazine/ 100 mM HOBt in 
DMF (10 mL). The flask was agitated for 25 minutes at room temperature and the 
deprotection solution was drained. The resin was washed with DMF, CH2Cl2, and MeOH 
(3 x 5 mL each). Initial loading was performed by the addition of Nα -Boc-Nε -Fmoc-D-
Lysine (4 eq., 1.0 mmol) and HBTU (4 eq., 1.0 mmol) in DMF to the reaction flask with 
DIEA (8 eq., 2.0 mmol) and the flask was agitated for 2 hours. The resin was drained and 
subsequently washed with DMF, CH2Cl2, and MeOH (3 x 5 mL each). The Fmoc protecting 
group was then removed as previously described. For the DNP modification, the resin was 
treated with 2,4-dinitrofluorobenzene (10 eq. 2.5 mmol) and DIEA (15 eq., 3.75 mmol) in 
DMF, and the flask was agitated in the dark for 1 hour at room temperature. The resin was 
drained and subsequently washed with DMF, CH2Cl2, and MeOH (3 x 5 mL each). For the 
deprotection/cleavage of the Boc-amino acids, a TFA cocktail solution (95% TFA, 2.5% 
H2O, 2.5%TIPS) was added to the resin, and the mixture was agitated for 1 hour at room 
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temperature. The resulting solution was concentrated in vacuo to remove the TFA. The 
residue was triturated in cold diethyl ether and the precipitate was collected by 
centrifugation and dissolved in H2O. The purity of the peptides was verified by analytical 
reverse phase HPLC using a Phenomenex C4 column with an eluent consisting of solvent 
A (CH3CN/0.01% TFA) and solvent B (H2O/0.01% TFA) with a 35 minute gradient 
consisting of 0 – 100% B, and a flow rate of 3 mL min-1 and at 220 nm) 
 
7.9 D-Amino Acid Fluorescent Labeling.  
B. subtilis was grown at 37 °C to an OD600 0.6 in LB broth, at which point the 
medium was replaced with LB broth supplemented with either D- or L-Lys(NBD). The 
bacteria were then incubated at 37 °C overnight or for the desired time, harvested, washed 
three times with phosphate buffered saline (PBS), fixated with 2% formaldehyde solution 
and analyzed via flow cytometry on a BDFacs Canto II flow cytometer (BD Biosciences, 
San Jose, CA) equipped with a 488 nm argon laser and a 530 bandpass filter (FL1). A 
minimum of 10,000 events were counted for each data point. The data were analyzed using 
the FACSDiva version 6.1.1 software. Cells were also imaged with Nikon Eclipse TE2000-
U microscope at 100x magnification. For inhibition of D-Lys(NBD) incorporation, the 
medium was additionally supplemented with varying concentrations of D-Ala when 
incubating bacteria in the presence D-Lys(NBD). 
 
7.10 D-Amino Acid Antibody Binding Assay.  
B. subtilis bacteria were grown at 37 °C to OD600 0.6 in LB broth, at which point 
the medium was replaced with LB broth containing 250 µM of the appropriate D-amino 
acid. The bacteria were incubated for 4 hours at 37 °C before being harvested and washed 
147 
	  
three times with PBS. Approximately 2 × 106 colony forming units (cfus) were then 
incubated in 100 µL of PBS containing 10% (v/v) FBS and 1 µL of Alexa Fluor 488 
conjugated rabbit anti-dinitrophenyl IgG-fraction KLH (2 mg mL−1, Life Technologies, 
catalog no. A11097). All experiments were protected from light and incubated at 37 °C for 
1 hour. Samples were then immediately analyzed by flow cytometry or imaged using 
fluorescence microscopy. Fluorescence data are expressed as mean arbitrary fluorescence 
units and were gated to include all healthy bacteria. For exponential phase labeling: 
Bacteria were grown at 37 °C to an OD600 0.6 before harvesting and replacing the medium 
with D-amino acid supplemented LB. For stationary phase labeling: Bacteria were grown 
at 37 °C to an OD600 1.5 before harvesting and replacing the medium with D-amino acid 
supplemented LB. For bacteria labeled with DNP displaying amino acids, the background 
fluorescence (unlabeled bacteria incubated with anti-DNP) was subtracted from the final 
values. 
 
7.11 S. aureus D-Amino Acid Antibody Binding Assay.  
S. aureus bacteria were grown overnight at 37 °C in LB broth either in the presence 
or absence of 0.4 µg mL-1 tunicamycin. The medium was then replaced with LB broth 
containing 1 mM D-Lys(DNP) and the bacteria were incubated at 37 °C for 4 hours before 
being harvested and washed three times with phosphate buffer saline (PBS). Approximately 
2 × 106 cfus were then incubated in 100 µL of PBS containing 10% (v/v) FBS and 1 µL of 
Alexa Fluor 488 conjugated rabbit anti-DNP IgG-fraction KLH (2 mg mL−1, Life 
Technologies, catalog no. A11097). To decrease background fluorescence from native S. 
aureus protein A binding the IgG antibody, these solutions were supplemented with soluble 
S. aureus protein A to a final concentration of 1.6 mg mL−1. All experiments were protected 
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from light and incubated at 37 °C for 1 hour. Samples were immediately analyzed using 
flow cytometry. 
 
7.12 Phagocytosis of Opsonized B. Subtilis.  
B. subtilis were inoculated (1:100) in LB broth supplemented with 1 mM D-
Lys(DNP) and grown overnight at 37 °C with shaking. Cells were washed, harvested, the 
cells were resuspended in PBS containing 10 µM calcein-AM, and incubated at 37 °C for 
30 minutes. The bacteria were then washed three times with PBS and incubated with 20 µg 
mL-1 of rabbit anti-DNP IgG-fraction KLH (2 mg mL−1, Life Technologies, catalog no. 
A6430) and 10% (v/v) heat inactivated FBS in PBS to opsonize the bacteria. J774A.1 cells 
were cultured at 37 °C (in the presence of 5% CO2) in DMEM medium supplemented with 
50 µg mL-1 streptomycin, 50 IU mL-1 penicillin, 2 mM L-glutamine, and 10% heat 
inactivated FBS. On the day of the experiments, J774A.1 cells were washed twice with 
balanced salt solution (BSS) by centrifuging for 5 minutes at 250g at 4 °C. The washed 
J774A.1 cells were then mixed with opsonized B. subtilis in a ratio of 1:5 and incubated in 
BSS containing 5% FBS. The cell mixtures were then rotated at 37 °C for 20 minutes to 
induce phagocytosis, washed three times with cold BSS, and fixed for 30 minutes in PBS 
with 4% paraformaldehyde. Following fixation, the cells were resuspended in 0.5 mL PBS 
and analyzed by flow cytometry. The fluorescence data are expressed as mean arbitrary 
fluorescence units and were gated to include all J774A.1 cells. 
 
7.13 Peptidoglycan Isolation. 
50 mL of B. subtilis bacteria were grown at 37 °C to OD600 0.6 in LB broth. The 
medium was replaced with LB broth supplemented with 500 µM of either D-Dab(DNP), D-
149 
	  
Lys(DNP), or D-Lys-PEG1(DNP). The cells were incubated at 37 °C for 4 hours in this 
medium before being harvested and washed with PBS (3 x 50 mL each). The cells were 
then resuspended in PBS and boiled for 7 minutes and then centrifuged at 14,000g for 8 
minutes at 4 °C. Cells were then placed in 25 mL of 5% (w/v) sodium dodecyl sulfate (SDS) 
and boiled for 25 minutes followed by centrifugation at 14,000g for 8 minutes at 4 °C. 
Following centrifugation, cells were boiled again in 25 mL of 4% (w/v) SDS for 15 minutes 
followed by centrifugation using same parameters as before. Cells were then washed 5 
times with 60 °C deionized water to remove all SDS. After washing, cells were incubated 
in 6 mL of 50 mM Tris HCl and 2 mg mL−1 Proteinase K for 1 hour at 60 °C, and then 
washed 3 times with deionized water. The cell wall pellet was then resuspended and 
digested with 250 µg mL-1 lysozyme in 25 mM sodium phosphate buffer pH 5.6 for 15 
hours at 37 °C. The digestion was then ceased by boiling for 3 minutes. Incorporation was 
analyzed using a Shimadzu UV-2101PC, PerkinElmer Series 200 HPLC, and Bruker 
Microflex MALDI-TOF MS. 
 
7.14 MTT Cell Viability Assay.  
Cells were cultured at 37 °C with 5% CO2. HeLa cells were cultured in DMEM 
medium supplemented with 10% fetal bovine serum (Cambrex Bio Science Walkersville, 
Inc.), 2 mM L-glutamine (Cellgro, Mediatech), and 50 units mL-1 penicillin and 50 µg      
mL-1 streptomycin (Cellgro, Mediatech). HeLa cells were seeded at a density of 3,000 cells 
per well in a 96 well plate and incubated overnight at 37 °C with 5% CO2 in DMEM 
medium. After 24 hours, the medium was replaced with DMEM medium supplemented 
with varying concentrations of D-Lys(DNP) and incubated for 72 hours. After incubation, 
the medium was removed and cells were treated with 100 µL of 0.5 mg mL−1 3-(4,5-
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dimethylthiazol-2yl)-2,5 diphenyltetrazolium bromide (MTT) in the dark for 2 hours. The 
MTT solution was then removed and the formazan crystals were resolubilized in 200 µL 
DMSO. The absorbance was determined at 580 nm to determine cell viability using an 
Infinite 200 PRO microplate reader (Tecan). 
 
7.15 Bacteria Growth Curve.  
Overnight cultures of B. subtilis were diluted 1:100 in LB growth medium in the 
absence or presence of the appropriate concentration of D-Lys(DNP) at 37 °C. Bacteria 
were grown in culture flasks and OD600 was recorded every 30 minutes to determine 
bacterial viability in the presence of D-Lys(DNP). 
 
7.16 Sodium Dithionite Quenching of Fluorescently Labeled Bacteria.  
B. subtilis cells were grown overnight at 37 °C with shaking in LB medium that 
was supplemented with either 100 µM D-Lys(NBD) or 100 µM L-Lys(NBD). The 
following morning the cells were washed three times with PBS. The bacteria were then 
subjected to incubation with 5 mM sodium dithionite for 5 minutes. The bacteria were then 
washed again three more times with PBS, fixated with a 4 % formaldehyde solution and 
then analyzed via flow cytometry. 
 
7.17 NBD-D-amino acid Series Labeling of Bacteria  
Bacteria cells were grown overnight at 37 ⁰ C in LB Broth. The following day, the medium 
was replaced with LB supplemented with fluorescently labeled D-amino acids. The bacteria 
were grown in the presence of the fluorescent D-amino acid for either four hours or 
overnight depending on the experiment. Following incubation, the bacteria were harvested, 
washed three times with PBS, and then fixated with a 4 % formaldehyde solution. All 
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experiments were run in triplicate from independent bacterial cell cultures and analyzed 
using flow cytometry as previously stated. 
 
7.18 Sulfhydryl Fluorescent Labeling of Bacterial Surface 
Compounds SH-1, SH-4, and SH-6 were bought from ChemImpex and used 
without any further purification. B. subtilis ΔdacA were incubated for 4 hours at 37 °C with 
shaking in LB medium that was supplemented with 500µM of each sulfhydryl compound, 
respectively. The cells were harvested and washed three times in a 5mM DTT solution to 
reverse any oxidation that may have occurred overnight. The cells were then washed an 
additional five times with PBS. The cells were then incubated in PBS containing 50µM of 
the NBD-L-Lys-(Maleimide) conjugate at 37 °C for 30 minutes. The cells were then 
washed an additional three more times with PBS and fixated with a 4 % formaldehyde 
solution. Following fixation, the cells were analyzed via flow cytometry. To confirm that 
labeling was occurring due to the presence of the incorporated sulfhydryl group, cells were 
incubated with 50µM N-ethyl maleimide for 30 minutes. following the overnight 
incubation with the sulfhydryl compounds as previously described. The cells were then 
wash three times and then incubated with NBD-L-Lys-(Maleimide), washed, and analyzed 
as previously described. To confirm that cell labeling was occurring on the cell surface, the 
labeled cells were subjected to treatment with sodium dithionite to quench fluorescence 
from the NBD fluorophore as previously described.  
 
7.19 D-Lys(FITC) Pulse Labeling of B. subtilis Mutant Strains. 
B. subtilis mutants were grown in LB medium at 37 °C overnight with shaking. The 
following morning, the OD600 of all the mutants was diluted to OD600 = 0.1. The bacteria 
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were then grown in LB medium until reaching either early log (OD600 = 0.3), mid Log 
(OD600 = 0.6), or stationary phase (OD600 > 1.0). At the respective phase, D-Lys(FITC) 
was spiked into the solution to achieve a final concentration of 1mM in LB medium. The 
cells were then incubated for fifteen minutes in the presence of the D-amino acid 
fluorophore. Following incubation, the cells were washed three times with PBS, fixated 
with a 4 % formaldehyde solution and then analyzed via flow cytometry or imaged with a 
Nikon Eclipse TE2000-U microscope at 100x magnification.  
 
7.20 Direct Dipeptide Cell Surface Modification.  
B. subtilis NCIB 3610 and B. subtilis ΔdacA were grown in LB medium at 37 °C 
with shaking. Cells were incubated overnight at 37 °C with shaking in LB medium that 
was supplemented with 1 mM of compounds 1, 2, or 3 (Chapter 5) and protected from 
light. The following morning, the cells were washed with PBS three times. A 4% 
formaldehyde fixation solution was prepared in PBS and used to fixate the cells prior to 
preforming flow cytometry analysis and fluorescence microscopy. The fluorescence data 
are expressed as mean arbitrary fluorescence units and were gated to include all healthy 
bacteria. Fluorescence microscopy was conducted as previously discussed. 
 
7.21 Two-Step Dipeptide Cell Surface Modification.  
B. subtilis NCIB 3610 and B. subtilis ΔdacA were grown in LB medium at 37 °C 
with shaking. These cells were then incubated overnight at 37 °C with shaking in LB 
medium that was supplemented with 1 mM of compounds 4-8. The following morning the 
cells were washed three times with 5 mM DTT to reverse any thiol oxidation that may have 
occurred. The cells were then subsequently washed five times with PBS to remove any 
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residual DTT. Following PBS washing, the cells were then incubated with 50 µM of FL0 
for 30 minutes at 37 °C and protected from light. The cells were then fixated in a 4% 
formaldehyde solution prior to preforming flow cytometry analysis and fluorescence 
microscopy as previously stated.  
 
7.22 Peptidoglycan Pore Size Exclusion Determination.  
B. subtilis NCIB 3610 were grown in LB medium at 37 °C with shaking. These 
cells were then incubated overnight at 37 °C with shaking in LB medium that was 
supplemented with 1 mM of D-Cys-D-Ala. The following morning the cells were washed 
three times with 5 mM DTT to reverse any thiol oxidation that may have occurred. The 
cells were then subsequently washed five times with PBS to remove any residual DTT. 
Following washing, the cells were then incubated with 50 µM of FL0-4 for 30 minutes at 
37 °C and protected from light. The cells were washed three more times with PBS and were 
then fixated in a 4% formaldehyde solution prior to preforming flow cytometry analysis as 
previously stated. Linker lengths were calculated using PyMol. 
 
7.23 Two-Step Anti-DNP IgG Antibody Bacterial Cell Opsonization. 
B. subtilis ΔdacA were grown in LB medium at 37 °C with shaking. These cells 
were then incubated overnight at 37 °C with shaking in LB medium that was supplemented 
with 1 mM D-Cys-D-Ala. The following morning the cells were washed three times with 5 
mM DTT to reverse any thiol oxidation that may have occurred. The cells were then 
subsequently washed five times with PBS to remove any residual DTT. Following 
washing, the cells were then incubated with 50 µM of DL0-5 for 30 minutes at 37 °C and 
protected from light. The cells were then incubated for 1 hour at 37 °C in a 100 µL of a 
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PBS solution containing 10% fetal bovine serum (FBS) and 0.02 mg ml-1 Alex Fluor 488 
conjugated rabbit anti-DNP IgG-fraction KLH (Life-Technologies, catalog no. A11097). 
The cells were analyzed for bacterial cell opsonization using flow cytometry as previously 
stated. 
 
7.24 Bacterial Opsonization with Pooled Human Serum 
B. subtilis NCIB 3610 was grown at 37 °C in LB broth supplemented with 250 µM 
DK-Acid or DK-Amide overnight protected from light. The next morning, the bacteria 
were harvested and washed three times with PBS solution. Pooled human serum was 
diluted to 50% in PBS solution and incubated with 5% sodium bentonite for 15 minutes at 
37 °C to inactivate human serum lysozyme. The mixture was then centrifuged to remove 
the bentonite, and the supernatant was recovered to yield lysozyme inactivated pooled 
human serum. The lysozyme inactivated pooled human serum was then diluted in PBS to 
yield a final concentration of 10% lysozyme inactivated pooled human serum. B. subtilis 
cells labeled with either DK-Acid or DK-Amide were then incubated in the presence of 
10% lysozyme inactivated pooled human serum for 1 hour at 37 °C. The opsonized cells 
were then washed with PBS three times, and then incubated with Anti-Human IgG-FITC 
diluted 1:1000 in PBS containing 10% FBS. The samples were incubated for 30 minutes 
at 4 °C and then washed three times with cool PBS. Following washing, the cells were 
immediately analyzed by flow cytometry.  
7.25 Phagocytosed S. aureus D-Lys(FITC)-NH2 Labeling 
J774A.1 murine macrophage cells were seeded in a cover slip containing 6-well 
tissue culture plates. After cells were adhered to the cover slips, cells were infected with S. 
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aureus (MRSA USA300) for 30 minutes at a1:200 multiplicity of infection (MOI). Then 
the cells were washed three times with DMEM medium containing 10 IU lysostaphin to 
kill the extracellular bacteria. DMEM medium supplemented with 10% FBS, 4 IU 
lysostaphin and either 10 µM D-Lys(FITC)-NH2 or L-Lys(FITC)-NH2 at a concentration 
of 10µM were added. After 20 hours of incubation, the cells were washed seven times with 
plain DMEM medium without amino acids and fixed with paraformaldehyde and imaged 
using confocal microscopy. 
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Appendices 
A.1 Molecular Weights and Purities of NBD and DNP-D-amino acids 
Compound Calculated               [M + H+] 
Found                              
[M + H+] Purity 
L-Lys(NBD) 310.1 310.3 >95% 
D-Lys(NBD) 310.1 310.3 >95% 
D-Dab(DNP) 285.1 285.2 >95% 
D-Orn(DNP) 299.1 299.3 >95% 
D-Lys(DNP) 313.1 313.3 >95% 
D-Dab-G(DNP) 342.1 342.4 >95% 
D-Dab-β(A(DNP) 356.1 356.7 >95% 
D-Lys-PEG1(DNP) 458.2 458.1 >95% 
D-Lys-PEG2(DNP) 603.3 603.6 >95% 
D-Lys-PEG3(DNP) 748.3 748.9 >95% 
 
 
A.2 NMR of NBD and DNP D-amino acid Compounds 
L-Lys(NBD) 
1H NMR (500 MHz, methanol-d4): δ 1.62 (br. m, 2H), 1.83 (m, 2H), 1.99 (br. m, 2H), 3.53 
(br. s,2H), 3.99 (t, 1H), 6.26 (d, J = 8.9, 1H), 8.40 (d, J = 8.7, 1H). 
13C NMR (500 MHz, methanol-d4): δ 170.82, 143.89, 137.22, 121.32, 115.68, 113.88, 
98.49,52.58, 43.09, 30.01, 27.19, 22.06. 
D-Lys(NBD) 
1H NMR (500 MHz, methanol-d4): δ 1.61 (br. m, 2H), 1.83 (m, 2H), 1.99 (br. m, 2H), 3.56 
(br. s,2H), 3.97 (t, 1H), 6.33 (d, J = 8.9, 1H), 8.49 (d, J = 8.9, 1H). 
13C NMR (500 MHz, methanol-d4): δ 170.31, 137.48, 131.32, 129.53, 115.42, 113.63, 
98.24,52.32, 43.09, 30.01, 27.19, 22.06. 
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D-Dab(DNP) 
1H NMR (500 MHz, D2O): δ 1.86 (m, 2H), 3.22 (t, 1H), 3.46 (t, 2H), 7.00 (d, J = 9.9, 1H), 
8.15(d, J = 10.0, 1H), 8.96 (s, 1H). 
13C NMR (500 MHz, D2O): δ 182.54, 148.79, 134.90, 130.42, 129.63, 124.53, 114.60, 
54.12, 40.01, 32.83. 
D-Orn(DNP) 
1H NMR (500 MHz, methanol-d4): δ 1.85 (m, 2H), 1.92 (m, 2H), 3.55 (t, 2H), 3.78 (t, 1H), 
7.18 (d, J = 9.6 Hz, 1H), 8.29 (d, J = 9.6 Hz, 1H), 9.02 (s, 1H). 
13C NMR (500 MHz, D2O): δ 172.59, 148.54, 135.14, 130.24, 129.18, 123.86, 114.49, 
52.99, 42.14, 27.24, 24.05. 
D-Lys(DNP) 
1H NMR (500 MHz, CDCl3): δ 1.45 (s, 9H), 1.60 (m, 2H), 1.83 (br. m, 4H), 3.45 (t, 2H), 
5.11 (d,1H), 6.93 (d, J = 9.8, 1H), 8.25 (d, J = 9.8, 1H), 9.12 (s, 1H). 
13C NMR (500 MHz, CDCl3): δ 176.98, 155.95, 148.39, 135.98, 130.38, 130.27, 124.14, 
113.88, 80.54, 53.09, 43.09, 32.32, 31.04, 27.96, 22.83. 
D-Dab-G(DNP) 
1H NMR (500 MHz, methanol-d4): δ 1.99 (m, 2H), 3.48 (m, 2H), 3.61 (t, 1H), 4.21 (s, 2H), 
6.98 (d, J = 11.5, 1H), 8.31 (d, J = 11.5, 1H), 9.06 (s, 1H). 
13C NMR (500 MHz, D2O): δ 171.92, 171.26, 148.37, 136.18, 130.68, 130.50, 124.27, 
114.52, 51.17, 45.76, 35.20, 29.51. 
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D-Dab-βA(DNP) 
1H NMR (500 MHz, D2O): δ 1.92 (m, 2H), 2.45 (t, 2H), 3.20 (m, 2H), 3.49 (t, 2H), 3.82 (t, 
2H), 7.88 (d, J = 10.7, 1H), 6.78 (d, J = 9.9, 1H), 8.51 (s, 1H). 
13C NMR (500 MHz, D2O): δ 171.21, 162.34, 148.15, 135.05, 130.41, 129.52, 123.97, 
114.66, 50.79, 39.48, 35.48, 34.38, 29.27. 
D-Lys-PEG1(DNP) 
1H NMR (500 MHz, D2O): δ 1.21 (m, 2H), 1.36 (m, 2H), 1.68 (m, 2H), 3.03 (t, 2H), 3.19 
(s, 1H), 3.54 (m, 6H), 3.71 (s, 2H), 3.84 (s, 2H), 6.96 (d, J = 8.8, 1H), 8.05 (d, J = 9.2, 1H), 
8.77 (s, 1H). 
13C NMR (500 MHz, methanol-d4): δ 171.34, 170.54, 148.49, 135.75, 130.18, 129.62, 
123.25, 114.81, 70.43, 69.92, 68.41, 65.53, 52.52, 42.91, 38.12, 30.21, 29.01, 21.82. 
D-Lys-PEG2(DNP) 
1H NMR (500 MHz, D2O): δ1.29 (m, 2H), 1.43 (m, 2H), 1.79 (m, 2H), 3.09 (t, 2H), 3.29 
(t, 2H),3.43 (br. s, 2H), 3.47 (t, 2H), 3.52 (s, 4H), 3.59 (s, 4H), 3.67 (s, 2H), 3.82 (t, 1H), 
3.85 (s, 2H),3.89 (s, 2H), 6.81 (d, J = 9.8, 1H), 7.85 (d, J = 9.6, 1H), 8.37 (s, 1H). 
13C NMR (500 MHz, methanol-d4): δ 171.30, 171.26, 148.45, 135.71, 130.01, 129.73, 
123.45, 114.91, 70.52, 69.89, 69.10, 68.39, 53.13, 42.66, 38.37, 38.11, 29.94, 28.74, 22.09. 
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D-Lys-PEG3(DNP) 
1H NMR (500 MHz, methanol-d4): δ1.38 (m, 2H), 1.49 (m, 2H), 1.84 (m, 2H), 3.34 (m, 
4H), 3.48 (m, 4H), 3.56 (m, 12H), 3.63 (m, 4H), 3.73 (m, 2H), 3.88 (m, 7H), 7.09 (d, J = 
9.7, 1H), 8.14 (d, J = 9.5, 1H), 8.83 (s, 1H). 
13C NMR (500 MHz, methanol-d4): δ 171.31, 170.84, 148.44, 135.68, 130.08, 129.77, 
123.31, 114.91, 70.57, 69.90, 69.16, 68.40, 52.71, 42.70, 38.39, 38.13, 29.90, 28.73, 21.94. 
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A.3 Molecular Weights and Purities of NBD and Sulfhydryl-D-amino acids 
Compound  Calculated               [M + H+] 
Found                              
[M + H+] Purity 
    
1 268.2 268.2 >95% 
2 282.2 282.1 >95% 
3 296.3 296.4 >95% 
4 310.3 310.2 >95% 
5 455.4 455.4 >95% 
6 600.6 600.3 >95% 
7 745.8 745.5 >95% 
8 325.3 325.2 >95% 
9 339.3 339.2 >95% 
10 353.3 353.4 >95% 
11 353.3 353.2 >95% 
12 353.3 353.4 >95% 
13 368.3 368.2 >95% 
14 358.3 358.2 >95% 
15 397.3 397.0 >95% 
16 294.2 294.2 >95% 
SH1 Purchased from ChemImpex 
SH2 250.3 250.4 >95% 
SH3 395.5 395.4 >95% 
SH4 Purchased from ChemImpex 
SH5 234.3 234.1 >95% 
SH6 Purchased from ChemImpex 
D-Lys(FITC) 536.6 536.3 >95% 
NBD-L-Lys(Maleimide) 461.4 461.3 >95% 
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A.4 B. subtilis PBP Mutant Labeling with NBD-D-Amino Acid Series 
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A.5 D-amino acids used in Competition Assay 
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A.5 D-amino acids used in Competition Assay (Continued) 
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A.5 D-amino acids used in Competition Assay (Continued) 
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A.6 Molecular Weights and Purities of Dipeptides and Linker Molecules  
Compound  Calculated               [M + H+] 
Found                              
[M + H+] Purity 
1 310.3 310.3 >95% 
2 339.3 339.4 >95% 
3 381.4 381.2 >95% 
4 193.3 193.3 >95% 
5 193.3 193.3 >95% 
6 Purchased from ChemImpex 
7 193.3 193.3 >95% 
8 193.3 193.3 >95% 
FL0 461.2 461.3 >95% 
FL1 683.6 683.5 >95% 
FL2 886.8 886.5 >95% 
FL3 1086.0 1086.4 >95% 
FL4 1287.2 1287.1 >95% 
DL0 463.4 463.2 >95% 
DL1 686.6 686.7 >95% 
DL2 887.8 887.7 >95% 
DL3 1089.0 1088.4 >95% 
DL4 1290.1 1290.3 >95% 
DL5 1491.3 1489.0 >95% 
 
A.7 NMR of Dipeptide Compounds  
Compound 2 
1H NMR (500 MHz, methanol-d4): δ 1.49 (d, 3H), 4.07 (t, 1H), 4.26 (q, 1H), 4.46 (t, 2H), 
6.53 (d, 1H), 8.53 (d. 
13C NMR (500 MHz, methanol-d4): δ 173.98, 166.54, 144.84, 143.78, 136.55, 124.21, 
99.97, 51.47, 4849, 43.53, 16.13. 
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Compound 3 
1H NMR (500 MHz, methanol-d4): δ 1.44 (d, 3H), 1.64 (m, 2H), 1.85 (m, 2H), 1.95 (m,2H), 
3.62 (br. t, 1H), 3.89 (t, 2H), 4.45 (q, 1H), 6.36 (d, 1H), 8.53 (d, 1H). 
13C NMR (500 MHz, methanol-d4): δ 174.20, 168.45, 161.01, 145.69, 144.42, 137.19, 
99.48, 52.96, 31.05, 27.86, 21.48, 15.95. 
Compound 4 
1H NMR (500 MHz, methanol-d4): δ 1.45 (d, 3H), 3.04 (m, 2H), 4.17 (t, 1H), 4.43 (q, 1H). 
13C NMR (500 MHz, methanol-d4): δ 174.62, 17.18, 55.45, 48.92, 25.31, 16.16. 
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A.8 Molecular Weight and NMR of DK-Amide 
1H NMR (500 MHz, methanol-d4): δ 1.58 (m, 2H), 1.82 (m, 2H), 1.94 (m, 2H), 3.54 (t, 
1H), 3.89 (t, 2H), 7.17 (d, 1H), 8.30 (d, 1H), 9.05 (s, 1H) 
13C NMR (500 MHz, methanol-d4): δ 170.81, 148.28, 135.62, 130.19, 129.71, 123.38, 
114.28, 52.74, 42.39, 30.83, 27.91, 21.81. 
 
  
DK-­‐Amide	  1H	  NMR	  
194 
	  
 
  
DK-­‐Amide	  13C	  NMR	  
195 
	  
References 
 
1. Aminov, R. I.  A brief history of the antibiotic era: lessons learned and challenges for the 
future. Front Microbiol 2010, 1, 134. 
2. Davies, J.  Where have All the Antibiotics Gone? Can J Infect Dis Med Microbiol 2006, 
17, (5), 287-90. 
3. Ventola, C. L.  The antibiotic resistance crisis: part 1: causes and threats. P T 2015, 40, (4), 
277-83. 
4. Walsh, C.  Molecular mechanisms that confer antibacterial drug resistance. Nature 2000, 
406, (6797), 775-81. 
5. Sauvage, E.; Kerff, F.; Terrak, M.; Ayala, J. A.; Charlier, P.  The penicillin-binding 
proteins: structure and role in peptidoglycan biosynthesis (vol 32, pg 234, 2008). Fems 
Microbiol Rev 2008, 32, (3), 556-556. 
6. Lock, R. L.; Harry, E. J.  Cell-division inhibitors: new insights for future antibiotics. Nat 
Rev Drug Discov 2008, 7, (4), 324-38. 
7. Finch, R. G.  Antibiotic resistance. J Antimicrob Chemother 1998, 42, (2), 125-8. 
8. Cox, G.; Wright, G. D.  Intrinsic antibiotic resistance: mechanisms, origins, challenges and 
solutions. Int J Med Microbiol 2013, 303, (6-7), 287-92. 
9. Hammes, W. P.; Neuhaus, F. C.  On the mechanism of action of vancomycin: inhibition of 
peptidoglycan synthesis in Gaffkya homari. Antimicrob Agents Chemother 1974, 6, (6), 
722-8. 
10. Tsuchido, T.; Takano, M.  Sensitization by heat treatment of Escherichia coli K-12 cells 
to hydrophobic antibacterial compounds. Antimicrob Agents Chemother 1988, 32, (11), 
1680-3. 
11. Blair, J. M.; Webber, M. A.; Baylay, A. J.; Ogbolu, D. O.; Piddock, L. J.  Molecular 
mechanisms of antibiotic resistance. Nat Rev Microbiol 2015, 13, (1), 42-51. 
12. Yasufuku, T.; Shigemura, K.; Shirakawa, T.; Matsumoto, M.; Nakano, Y.; Tanaka, K.; 
Arakawa, S.; Kinoshita, S.; Kawabata, M.; Fujisawa, M.  Correlation of overexpression of 
efflux pump genes with antibiotic resistance in Escherichia coli Strains clinically isolated 
from urinary tract infection patients. J Clin Microbiol 2011, 49, (1), 189-94. 
13. Askoura, M.; Mottawea, W.; Abujamel, T.; Taher, I.  Efflux pump inhibitors (EPIs) as new 
antimicrobial agents against Pseudomonas aeruginosa. Libyan J Med 2011, 6. 
14. Coban, A. Y.; Tanriverdi Cayci, Y.; Erturan, Z.; Durupinar, B.  Effects of efflux pump 
inhibitors phenyl-arginine-beta-naphthylamide and 1-(1-naphthylmethyl)-piperazine on 
the antimicrobial susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis 
patients. J Chemother 2009, 21, (5), 592-4. 
15. Majiduddin, F. K.; Materon, I. C.; Palzkill, T. G.  Molecular analysis of beta-lactamase 
structure and function. Int J Med Microbiol 2002, 292, (2), 127-37. 
16. Drawz, S. M.; Bonomo, R. A.  Three decades of beta-lactamase inhibitors. Clin Microbiol 
Rev 2010, 23, (1), 160-201. 
17. Bush, L. M.; Johnson, C. C.  Ureidopenicillins and beta-lactam/beta-lactamase inhibitor 
combinations. Infect Dis Clin North Am 2000, 14, (2), 409-33, ix. 
18. Walsh, T. R.  The emergence and implications of metallo-beta-lactamases in Gram-
negative bacteria. Clin Microbiol Infect 2005, 11 Suppl 6, 2-9. 
19. Livermore, D. M.  Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob 
Chemother 2003, 51 Suppl 2, ii9-16. 
20. Smith, T. L.; Pearson, M. L.; Wilcox, K. R.; Cruz, C.; Lancaster, M. V.; Robinson-Dunn, 
B.; Tenover, F. C.; Zervos, M. J.; Band, J. D.; White, E.; Jarvis, W. R.  Emergence of 
vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate 
Staphylococcus aureus Working Group. N Engl J Med 1999, 340, (7), 493-501. 
196 
	  
21. Rice, L. B.  Emergence of vancomycin-resistant Enterococci. Emerg Infect Dis 2001, 7, 
(2), 183-7. 
22. Xie, J.; Pierce, J. G.; James, R. C.; Okano, A.; Boger, D. L.  A redesigned vancomycin 
engineered for dual D-Ala-D-ala And D-Ala-D-Lac binding exhibits potent antimicrobial 
activity against vancomycin-resistant bacteria. J Am Chem Soc 2011, 133, (35), 13946-9. 
23. Leclercq, R.; Courvalin, P.  Resistance to glycopeptides in Enterococci. Clin Infect Dis 
1997, 24, (4), 545-54; quiz 555-6. 
24. Handwerger, S.; Pucci, M. J.; Volk, K. J.; Liu, J.; Lee, M. S.  Vancomycin-resistant 
Leuconostoc mesenteroides and Lactobacillus casei synthesize cytoplasmic peptidoglycan 
precursors that terminate in lactate. J Bacteriol 1994, 176, (1), 260-4. 
25. Okano, A.; Nakayama, A.; Schammel, A. W.; Boger, D. L.  Total synthesis of 
[Psi[C(NH)NH]Tpg(4)]vancomycin and its (4-chlorobiphenyl)methyl derivative: impact 
of peripheral modifications on vancomycin analogues redesigned for dual D-Ala-D-Ala and 
D-Ala-D-Lac binding. J Am Chem Soc 2014, 136, (39), 13522-5. 
26. Solomon, S. L.; Oliver, K. B.  Antibiotic resistance threats in the United States: stepping 
back from the brink. Am Fam Physician 2014, 89, (12), 938-41. 
27. Fisher, J. F.; Meroueh, S. O.; Mobashery, S.  Bacterial resistance to beta-lactam antibiotics: 
compelling opportunism, compelling opportunity. Chem Rev 2005, 105, (2), 395-424. 
28. Levy, S. B.; Marshall, B.  Antibacterial resistance worldwide: causes, challenges and 
responses. Nat Med 2004, 10, (12 Suppl), S122-9. 
29. Lewis, K.  Persister cells, dormancy and infectious disease. Nat Rev Microbiol 2007, 5, (1), 
48-56. 
30. Ambrose, P. G.; Hammel, J. P.; Bhavnani, S. M.; Rubino, C. M.; Ellis-Grosse, E. J.; 
Drusano, G. L.  Frequentist and Bayesian pharmacometric-based approaches to facilitate 
critically needed new antibiotic development: overcoming lies, damn lies, and statistics. 
Antimicrob Agents Chemother 2012, 56, (3), 1466-70. 
31. Cegelski, L.; Marshall, G. R.; Eldridge, G. R.; Hultgren, S. J.  The biology and future 
prospects of antivirulence therapies. Nat Rev Microbiol 2008, 6, (1), 17-27. 
32. Nathan, C.  Fresh approaches to anti-infective therapies. Sci Transl Med 2012, 4, (140), 
140sr2. 
33. Hancock, R. E.; Nijnik, A.; Philpott, D. J.  Modulating immunity as a therapy for bacterial 
infections. Nat Rev Microbiol 2012, 10, (4), 243-54. 
34. Akira, S.; Uematsu, S.; Takeuchi, O.  Pathogen recognition and innate immunity. Cell 
2006, 124, (4), 783-801. 
35. Beutler, B. A.  TLRs and innate immunity. Blood 2009, 113, (7), 1399-407. 
36. Adams, S.  Toll-like receptor agonists in cancer therapy. Immunotherapy 2009, 1, (6), 949-
64. 
37. Munoz, N.; Van Maele, L.; Marques, J. M.; Rial, A.; Sirard, J. C.; Chabalgoity, J. A.  
Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung 
infection. Infect Immun 2010, 78, (10), 4226-33. 
38. Yu, F. S.; Cornicelli, M. D.; Kovach, M. A.; Newstead, M. W.; Zeng, X.; Kumar, A.; Gao, 
N.; Yoon, S. G.; Gallo, R. L.; Standiford, T. J.  Flagellin stimulates protective lung mucosal 
immunity: role of cathelicidin-related antimicrobial peptide. J Immunol 2010, 185, (2), 
1142-9. 
39. Perry, F. E.; Elson, C. J.; Mitchell, T. J.; Andrew, P. W.; Catterall, J. R.  Characterisation 
of an oxidative response inhibitor produced by Streptococcus pneumoniae. Thorax 1994, 
49, (7), 676-83. 
40. Hayashi, F.; Smith, K. D.; Ozinsky, A.; Hawn, T. R.; Yi, E. C.; Goodlett, D. R.; Eng, J. K.; 
Akira, S.; Underhill, D. M.; Aderem, A.  The innate immune response to bacterial flagellin 
is mediated by Toll-like receptor 5. Nature 2001, 410, (6832), 1099-103. 
197 
	  
41. Kinnebrew, M. A.; Ubeda, C.; Zenewicz, L. A.; Smith, N.; Flavell, R. A.; Pamer, E. G.  
Bacterial flagellin stimulates Toll-like receptor 5-dependent defense against vancomycin-
resistant Enterococcus infection. J Infect Dis 2010, 201, (4), 534-43. 
42. Evans, S. E.; Scott, B. L.; Clement, C. G.; Larson, D. T.; Kontoyiannis, D.; Lewis, R. E.; 
Lasala, P. R.; Pawlik, J.; Peterson, J. W.; Chopra, A. K.; Klimpel, G.; Bowden, G.; Hook, 
M.; Xu, Y.; Tuvim, M. J.; Dickey, B. F.  Stimulated innate resistance of lung epithelium 
protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol 2010, 42, (1), 
40-50. 
43. Barochia, A.; Solomon, S.; Cui, X.; Natanson, C.; Eichacker, P. Q.  Eritoran tetrasodium 
(E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug 
Metab Toxicol 2011, 7, (4), 479-94. 
44. Tidswell, M.; Tillis, W.; Larosa, S. P.; Lynn, M.; Wittek, A. E.; Kao, R.; Wheeler, J.; 
Gogate, J.; Opal, S. M.  Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 
antagonist, in patients with severe sepsis. Crit Care Med 2010, 38, (1), 72-83. 
45. Ungaro, R.; Fukata, M.; Hsu, D.; Hernandez, Y.; Breglio, K.; Chen, A.; Xu, R.; Sotolongo, 
J.; Espana, C.; Zaias, J.; Elson, G.; Mayer, L.; Kosco-Vilbois, M.; Abreu, M. T.  A novel 
Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal 
healing in murine colitis. Am J Physiol Gastrointest Liver Physiol 2009, 296, (6), G1167-
79. 
46. Perencevich, M.; Burakoff, R.  Use of antibiotics in the treatment of inflammatory bowel 
disease. Inflamm Bowel Dis 2006, 12, (7), 651-664. 
47. Zasloff, M.  Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, 
characterization of two active forms, and partial cDNA sequence of a precursor. 
Proceedings of the National Academy of Sciences of the United States of America 1987, 
84, (15), 5449-53. 
48. Hancock, R. E.; Lehrer, R.  Cationic peptides: a new source of antibiotics. Trends 
Biotechnol 1998, 16, (2), 82-8. 
49. Hancock, R. E.; Sahl, H. G.  Antimicrobial and host-defense peptides as new anti-infective 
therapeutic strategies. Nat Biotechnol 2006, 24, (12), 1551-7. 
50. Scott, M. G.; Dullaghan, E.; Mookherjee, N.; Glavas, N.; Waldbrook, M.; Thompson, A.; 
Wang, A.; Lee, K.; Doria, S.; Hamill, P.; Yu, J. J.; Li, Y.; Donini, O.; Guarna, M. M.; 
Finlay, B. B.; North, J. R.; Hancock, R. E.  An anti-infective peptide that selectively 
modulates the innate immune response. Nat Biotechnol 2007, 25, (4), 465-72. 
51. Cherkasov, A.; Jankovic, B.  Application of 'inductive' QSAR descriptors for quantification 
of antibacterial activity of cationic polypeptides. Molecules 2004, 9, (12), 1034-52. 
52. Haney, E. F.; Hancock, R. E.  Peptide design for antimicrobial and immunomodulatory 
applications. Biopolymers 2013, 100, (6), 572-83. 
53. Nijnik, A.; Madera, L.; Ma, S.; Waldbrook, M.; Elliott, M. R.; Easton, D. M.; Mayer, M. 
L.; Mullaly, S. C.; Kindrachuk, J.; Jenssen, H.; Hancock, R. E.  Synthetic cationic peptide 
IDR-1002 provides protection against bacterial infections through chemokine induction 
and enhanced leukocyte recruitment. Journal of immunology 2010, 184, (5), 2539-50. 
54. Madera, L.; Hancock, R. E.  Synthetic immunomodulatory peptide IDR-1002 enhances 
monocyte migration and adhesion on fibronectin. J Innate Immun 2012, 4, (5-6), 553-68. 
55. Garlapati, S.; Eng, N. F.; Kiros, T. G.; Kindrachuk, J.; Mutwiri, G. K.; Hancock, R. E.; 
Halperin, S. A.; Potter, A. A.; Babiuk, L. A.; Gerdts, V.  Immunization with PCEP 
microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense 
regulator peptide induces protective immunity against pertussis. Vaccine 2011, 29, (38), 
6540-8. 
56. Turner-Brannen, E.; Choi, K. Y.; Lippert, D. N.; Cortens, J. P.; Hancock, R. E.; El-
Gabalawy, H.; Mookherjee, N.  Modulation of interleukin-1beta-induced inflammatory 
198 
	  
responses by a synthetic cationic innate defence regulator peptide, IDR-1002, in synovial 
fibroblasts. Arthritis Res Ther 2011, 13, (4), R129. 
57. Wieczorek, M.; Jenssen, H.; Kindrachuk, J.; Scott, W. R.; Elliott, M.; Hilpert, K.; Cheng, 
J. T.; Hancock, R. E.; Straus, S. K.  Structural studies of a peptide with immune modulating 
and direct antimicrobial activity. Chem Biol 2010, 17, (9), 970-80. 
58. Mansour, S. C.; de la Fuente-Nunez, C.; Hancock, R. E.  Peptide IDR-1018: modulating 
the immune system and targeting bacterial biofilms to treat antibiotic-resistant bacterial 
infections. J Pept Sci 2015, 21, (5), 323-9. 
59. Ceri, H.; Olson, M. E.; Stremick, C.; Read, R. R.; Morck, D.; Buret, A.  The Calgary 
Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of 
bacterial biofilms. J Clin Microbiol 1999, 37, (6), 1771-6. 
60. McEnaney, P. J.; Parker, C. G.; Zhang, A. X.; Spiegel, D. A.  Antibody-recruiting 
molecules: an emerging paradigm for engaging immune function in treating human 
disease. ACS Chem Biol 2012, 7, (7), 1139-51. 
61. Podack, E. R.  Molecular composition of the tubular structure of the membrane attack 
complex of complement. J Biol Chem 1984, 259, (13), 8641-7. 
62. Weiner, L. M.; Surana, R.; Wang, S.  Monoclonal antibodies: versatile platforms for cancer 
immunotherapy. Nat Rev Immunol 2010, 10, (5), 317-27. 
63. Smyth, M. J.; Cretney, E.; Kelly, J. M.; Westwood, J. A.; Street, S. E.; Yagita, H.; Takeda, 
K.; van Dommelen, S. L.; Degli-Esposti, M. A.; Hayakawa, Y.  Activation of NK cell 
cytotoxicity. Mol Immunol 2005, 42, (4), 501-10. 
64. Nimmerjahn, F.; Ravetch, J. V.  Fcgamma receptors as regulators of immune responses. 
Nat Rev Immunol 2008, 8, (1), 34-47. 
65. Harris, J. R.; Markl, J.  Keyhole limpet hemocyanin (KLH): a biomedical review. Micron 
1999, 30, (6), 597-623. 
66. Galili, U.; Rachmilewitz, E. A.; Peleg, A.; Flechner, I.  A unique natural human IgG 
antibody with anti-alpha-galactosyl specificity. J Exp Med 1984, 160, (5), 1519-31. 
67. Parker, W.; Bruno, D.; Holzknecht, Z. E.; Platt, J. L.  Characterization and affinity isolation 
of xenoreactive human natural antibodies. J Immunol 1994, 153, (8), 3791-803. 
68. Galili, U.; Clark, M. R.; Shohet, S. B.; Buehler, J.; Macher, B. A.  Evolutionary relationship 
between the natural anti-Gal antibody and the Gal alpha 1-3Gal epitope in primates. Proc 
Natl Acad Sci U S A 1987, 84, (5), 1369-73. 
69. Owen, R. M.; Carlson, C. B.; Xu, J.; Mowery, P.; Fasella, E.; Kiessling, L. L.  Bifunctional 
ligands that target cells displaying the alpha v beta3 integrin. Chembiochem 2007, 8, (1), 
68-82. 
70. Carlson, C. B.; Mowery, P.; Owen, R. M.; Dykhuizen, E. C.; Kiessling, L. L.  Selective 
tumor cell targeting using low-affinity, multivalent interactions. ACS Chem Biol 2007, 2, 
(2), 119-27. 
71. Naicker, K. P.; Li, H.; Heredia, A.; Song, H.; Wang, L. X.  Design and synthesis of alpha 
Gal-conjugated peptide T20 as novel antiviral agent for HIV-immunotargeting. Org 
Biomol Chem 2004, 2, (5), 660-4. 
72. Perdomo, M. F.; Levi, M.; Sallberg, M.; Vahlne, A.  Neutralization of HIV-1 by redirection 
of natural antibodies. Proc Natl Acad Sci U S A 2008, 105, (34), 12515-20. 
73. Oyelaran, O.; McShane, L. M.; Dodd, L.; Gildersleeve, J. C.  Profiling human serum 
antibodies with a carbohydrate antigen microarray. J Proteome Res 2009, 8, (9), 4301-10. 
74. Huflejt, M. E.; Vuskovic, M.; Vasiliu, D.; Xu, H.; Obukhova, P.; Shilova, N.; Tuzikov, A.; 
Galanina, O.; Arun, B.; Lu, K.; Bovin, N.  Anti-carbohydrate antibodies of normal sera: 
findings, surprises and challenges. Mol Immunol 2009, 46, (15), 3037-49. 
199 
	  
75. Jakobsche, C. E.; Parker, C. G.; Tao, R. N.; Kolesnikova, M. D.; Douglass, E. F., Jr.; 
Spiegel, D. A.  Exploring binding and effector functions of natural human antibodies using 
synthetic immunomodulators. ACS Chem Biol 2013, 8, (11), 2404-11. 
76. Sheridan, R. T.; Hudon, J.; Hank, J. A.; Sondel, P. M.; Kiessling, L. L.  Rhamnose 
glycoconjugates for the recruitment of endogenous anti-carbohydrate antibodies to tumor 
cells. Chembiochem 2014, 15, (10), 1393-8. 
77. Jin, Y.; Xin, Y.; Zhang, W.; Ma, Y.  Mycobacterium tuberculosis Rv1302 and 
Mycobacterium smegmatis MSMEG_4947 have WecA function and MSMEG_4947 is 
required for the growth of M. smegmatis. FEMS Microbiol Lett 2010, 310, (1), 54-61. 
78. Li, X.; Rao, X.; Cai, L.; Liu, X.; Wang, H.; Wu, W.; Zhu, C.; Chen, M.; Wang, P. G.; Yi, 
W.  Targeting Tumor Cells by Natural Anti-Carbohydrate Antibodies Using Rhamnose-
Functionalized Liposomes. ACS Chem Biol 2016, 11, (5), 1205-9. 
79. Six, H. R.; Uemura, K. I.; Kinsky, S. C.  Effect of immunoglobulin class and affinity on 
the initiation of complement-dependent damage to liposomal model membranes sensitized 
with dinitrophenylated phospholipids. Biochemistry 1973, 12, (20), 4003-11. 
80. Farah, F. S.  Natural antibodies specific to the 2,4-dinitrophenyl group. Immunology 1973, 
25, (2), 217-26. 
81. Ortega, E.; Kostovetzky, M.; Larralde, C.  Natural DNP-binding immunoglobulins and 
antibody multispecificity. Mol Immunol 1984, 21, (10), 883-8. 
82. Karjalainen, K.; Makela, O.  Concentrations of three hapten-binding immunoglobulins in 
pooled normal human serum. Eur J Immunol 1976, 6, (2), 88-93. 
83. Parker, C. G.; Domaoal, R. A.; Anderson, K. S.; Spiegel, D. A.  An antibody-recruiting 
small molecule that targets HIV gp120. J Am Chem Soc 2009, 131, (45), 16392-4. 
84. Lu, Y.; You, F.; Vlahov, I.; Westrick, E.; Fan, M.; Low, P. S.; Leamon, C. P.  Folate-
targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor 
activity and allergic potential. Mol Pharm 2007, 4, (5), 695-706. 
85. Murelli, R. P.; Zhang, A. X.; Michel, J.; Jorgensen, W. L.; Spiegel, D. A.  Chemical control 
over immune recognition: a class of antibody-recruiting small molecules that target 
prostate cancer. J Am Chem Soc 2009, 131, (47), 17090-2. 
86. Bertozzi, C. R.; Bednarski, M. D.  Antibody Targeting to Bacterial-Cells Using Receptor-
Specific Ligands. J Am Chem Soc 1992, 114, (6), 2242-2245. 
87. Bertozzi, C. R.; Bednarski, M. D.  A Receptor-Mediated Immune-Response Using 
Synthetic Glycoconjugates. J Am Chem Soc 1992, 114, (14), 5543-5546. 
88. Li, J.; Zacharek, S.; Chen, X.; Wang, J.; Zhang, W.; Janczuk, A.; Wang, P. G.  Bacteria 
targeted by human natural antibodies using alpha-Gal conjugated receptor-specific 
glycopolymers. Bioorg Med Chem 1999, 7, (8), 1549-58. 
89. Metallo, S. J.; Kane, R. S.; Holmlin, R. E.; Whitesides, G. M.  Using bifunctional polymers 
presenting vancomycin and fluorescein groups to direct anti-fluorescein antibodies to self-
assembled monolayers presenting D-alanine-D-alanine groups. J Am Chem Soc 2003, 125, 
(15), 4534-4540. 
90. Krishnamurthy, V. M.; Quinton, L. J.; Estroff, L. A.; Metallo, S. J.; Isaacs, J. M.; Mizgerd, 
J. P.; Whitesides, G. M.  Promotion of opsonization by antibodies and phagocytosis of 
Gram-positive bacteria by a bifunctional polyacrylamide. Biomaterials 2006, 27, (19), 
3663-74. 
91. Kaewsapsak, P.; Esonu, O.; Dube, D. H.  Recruiting the host's immune system to target 
Helicobacter pylori's surface glycans. Chembiochem 2013, 14, (6), 721-6. 
92. Silhavy, T. J.; Kahne, D.; Walker, S.  The bacterial cell envelope. Cold Spring Harb 
Perspect Biol 2010, 2, (5), a000414. 
93. Glauert, A. M.; Thornley, M. J.  The topography of the bacterial cell wall. Annu Rev 
Microbiol 1969, 23, 159-98. 
200 
	  
94. Vollmer, W.; Blanot, D.; de Pedro, M. A.  Peptidoglycan structure and architecture. FEMS 
Microbiol Rev 2008, 32, (2), 149-67. 
95. Freudl, R.; MacIntyre, S.; Degen, M.; Henning, U.  Cell surface exposure of the outer 
membrane protein OmpA of Escherichia coli K-12. J Mol Biol 1986, 188, (3), 491-4. 
96. Charbit, A.; Boulain, J. C.; Ryter, A.; Hofnung, M.  Probing the topology of a bacterial 
membrane protein by genetic insertion of a foreign epitope; expression at the cell surface. 
EMBO J 1986, 5, (11), 3029-37. 
97. Wu, C. H.; Mulchandani, A.; Chen, W.  Versatile microbial surface-display for 
environmental remediation and biofuels production. Trends Microbiol 2008, 16, (4), 181-
8. 
98. van Bloois, E.; Winter, R. T.; Kolmar, H.; Fraaije, M. W.  Decorating microbes: surface 
display of proteins on Escherichia coli. Trends Biotechnol 2011, 29, (2), 79-86. 
99. Daugherty, P. S.  Protein engineering with bacterial display. Curr Opin Struct Biol 2007, 
17, (4), 474-80. 
100. Prescher, J. A.; Bertozzi, C. R.  Chemistry in living systems. Nat Chem Biol 2005, 1, (1), 
13-21. 
101. Link, A. J.; Tirrell, D. A.  Cell surface labeling of Escherichia coli via copper(I)-catalyzed 
[3+2] cycloaddition. J Am Chem Soc 2003, 125, (37), 11164-5. 
102. Link, A. J.; Vink, M. K.; Tirrell, D. A.  Presentation and detection of azide functionality in 
bacterial cell surface proteins. J Am Chem Soc 2004, 126, (34), 10598-602. 
103. Link, A. J.; Vink, M. K.; Agard, N. J.; Prescher, J. A.; Bertozzi, C. R.; Tirrell, D. A.  
Discovery of aminoacyl-tRNA synthetase activity through cell-surface display of 
noncanonical amino acids. Proc Natl Acad Sci U S A 2006, 103, (27), 10180-5. 
104. Tanrikulu, I. C.; Schmitt, E.; Mechulam, Y.; Goddard, W. A., 3rd; Tirrell, D. A.  Discovery 
of Escherichia coli methionyl-tRNA synthetase mutants for efficient labeling of proteins 
with azidonorleucine in vivo. Proc Natl Acad Sci U S A 2009, 106, (36), 15285-90. 
105. Ngo, J. T.; Tirrell, D. A.  Noncanonical amino acids in the interrogation of cellular protein 
synthesis. Acc Chem Res 2011, 44, (9), 677-85. 
106. Wang, L.; Brock, A.; Herberich, B.; Schultz, P. G.  Expanding the genetic code of 
Escherichia coli. Science 2001, 292, (5516), 498-500. 
107. Kauer, J. C.; Erickson-Viitanen, S.; Wolfe, H. R., Jr.; DeGrado, W. F.  p-Benzoyl-L-
phenylalanine, a new photoreactive amino acid. Photolabeling of calmodulin with a 
synthetic calmodulin-binding peptide. J Biol Chem 1986, 261, (23), 10695-700. 
108. Mori, H.; Ito, K.  Different modes of SecY-SecA interactions revealed by site-directed in 
vivo photo-cross-linking. Proc Natl Acad Sci U S A 2006, 103, (44), 16159-64. 
109. Yu, D.; Wowor, A. J.; Cole, J. L.; Kendall, D. A.  Defining the Escherichia coli SecA 
dimer interface residues through in vivo site-specific photo-cross-linking. J Bacteriol 2013, 
195, (12), 2817-25. 
110. Drummelsmith, J.; Whitfield, C.  Gene products required for surface expression of the 
capsular form of the group 1 K antigen in Escherichia coli (O9a:K30). Mol Microbiol 1999, 
31, (5), 1321-32. 
111. Nesper, J.; Hill, C. M.; Paiment, A.; Harauz, G.; Beis, K.; Naismith, J. H.; Whitfield, C.  
Translocation of group 1 capsular polysaccharide in Escherichia coli serotype K30. 
Structural and functional analysis of the outer membrane lipoprotein Wza. J Biol Chem 
2003, 278, (50), 49763-72. 
112. Nickerson, N. N.; Mainprize, I. L.; Hampton, L.; Jones, M. L.; Naismith, J. H.; Whitfield, 
C.  Trapped translocation intermediates establish the route for export of capsular 
polysaccharides across Escherichia coli outer membranes. Proc Natl Acad Sci U S A 2014, 
111, (22), 8203-8. 
201 
	  
113. Rangan, K. J.; Yang, Y. Y.; Charron, G.; Hang, H. C.  Rapid visualization and large-scale 
profiling of bacterial lipoproteins with chemical reporters. J Am Chem Soc 2010, 132, (31), 
10628-9. 
114. Ivanov, S. S.; Charron, G.; Hang, H. C.; Roy, C. R.  Lipidation by the host prenyltransferase 
machinery facilitates membrane localization of Legionella pneumophila effector proteins. 
J Biol Chem 2010, 285, (45), 34686-98. 
115. Hicks, S. W.; Charron, G.; Hang, H. C.; Galan, J. E.  Subcellular targeting of Salmonella 
virulence proteins by host-mediated S-palmitoylation. Cell Host Microbe 2011, 10, (1), 9-
20. 
116. Liu, F.; Aubry, A. J.; Schoenhofen, I. C.; Logan, S. M.; Tanner, M. E.  The engineering of 
bacteria bearing azido-pseudaminic acid-modified flagella. Chembiochem 2009, 10, (8), 
1317-20. 
117. Koenigs, M. B.; Richardson, E. A.; Dube, D. H.  Metabolic profiling of Helicobacter pylori 
glycosylation. Mol Biosyst 2009, 5, (9), 909-12. 
118. Sadamoto, R.; Matsubayashi, T.; Shimizu, M.; Ueda, T.; Koshida, S.; Koda, T.; Nishimura, 
S.  Bacterial surface engineering utilizing glucosamine phosphate derivatives as cell wall 
precursor surrogates. Chemistry 2008, 14, (33), 10192-5. 
119. Kieser, K. J.; Rubin, E. J.  How sisters grow apart: mycobacterial growth and division. Nat 
Rev Microbiol 2014, 12, (8), 550-62. 
120. Guenin-Mace, L.; Simeone, R.; Demangel, C.  Lipids of pathogenic Mycobacteria: 
contributions to virulence and host immune suppression. Transbound Emerg Dis 2009, 56, 
(6-7), 255-68. 
121. Philips, J. A.; Ernst, J. D.  Tuberculosis pathogenesis and immunity. Annu Rev Pathol 2012, 
7, 353-84. 
122. Tufariello, J. M.; Chan, J.; Flynn, J. L.  Latent tuberculosis: mechanisms of host and 
bacillus that contribute to persistent infection. Lancet Infect Dis 2003, 3, (9), 578-90. 
123. Adams, D. O.  The granulomatous inflammatory response. A review. Am J Pathol 1976, 
84, (1), 164-92. 
124. Nobre, A.; Alarico, S.; Maranha, A.; Mendes, V.; Empadinhas, N.  The molecular biology 
of mycobacterial trehalose in the quest for advanced tuberculosis therapies. Microbiology 
2014, 160, (Pt 8), 1547-70. 
125. Brennan, P. J.; Crick, D. C.  The cell-wall core of Mycobacterium tuberculosis in the 
context of drug discovery. Curr Top Med Chem 2007, 7, (5), 475-88. 
126. Hoffmann, C.; Leis, A.; Niederweis, M.; Plitzko, J. M.; Engelhardt, H.  Disclosure of the 
mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the 
lipid bilayer structure. Proc Natl Acad Sci U S A 2008, 105, (10), 3963-7. 
127. Daffe, M.; Draper, P.  The envelope layers of mycobacteria with reference to their 
pathogenicity. Adv Microb Physiol 1998, 39, 131-203. 
128. Belisle, J. T.; Vissa, V. D.; Sievert, T.; Takayama, K.; Brennan, P. J.; Besra, G. S.  Role of 
the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 1997, 
276, (5317), 1420-2. 
129. Backus, K. M.; Boshoff, H. I.; Barry, C. S.; Boutureira, O.; Patel, M. K.; D'Hooge, F.; Lee, 
S. S.; Via, L. E.; Tahlan, K.; Barry, C. E., 3rd; Davis, B. G.  Uptake of unnatural trehalose 
analogs as a reporter for Mycobacterium tuberculosis. Nat Chem Biol 2011, 7, (4), 228-35. 
130. Swarts, B. M.; Holsclaw, C. M.; Jewett, J. C.; Alber, M.; Fox, D. M.; Siegrist, M. S.; Leary, 
J. A.; Kalscheuer, R.; Bertozzi, C. R.  Probing the mycobacterial trehalome with 
bioorthogonal chemistry. J Am Chem Soc 2012, 134, (39), 16123-6. 
131. Foley, H. N.; Stewart, J. A.; Kavunja, H. W.; Rundell, S. R.; Swarts, B. M.  Bioorthogonal 
Chemical Reporters for Selective In Situ Probing of Mycomembrane Components in 
Mycobacteria. Angew Chem Int Ed Engl 2016, 55, (6), 2053-7. 
202 
	  
132. Urbanek, B. L.; Wing, D. C.; Haislop, K. S.; Hamel, C. J.; Kalscheuer, R.; Woodruff, P. 
J.; Swarts, B. M.  Chemoenzymatic synthesis of trehalose analogues: rapid access to 
chemical probes for investigating mycobacteria. Chembiochem 2014, 15, (14), 2066-70. 
133. Dumont, A.; Malleron, A.; Awwad, M.; Dukan, S.; Vauzeilles, B.  Click-mediated labeling 
of bacterial membranes through metabolic modification of the lipopolysaccharide inner 
core. Angew Chem Int Ed Engl 2012, 51, (13), 3143-6. 
134. Mas Pons, J.; Dumont, A.; Sautejeau, G.; Fugier, E.; Baron, A.; Dukan, S.; Vauzeilles, B.  
Identification of living Legionella pneumophila using species-specific metabolic 
lipopolysaccharide labeling. Angew Chem Int Ed Engl 2014, 53, (5), 1275-8. 
135. Yi, W.; Liu, X.; Li, Y.; Li, J.; Xia, C.; Zhou, G.; Zhang, W.; Zhao, W.; Chen, X.; Wang, 
P. G.  Remodeling bacterial polysaccharides by metabolic pathway engineering. Proc Natl 
Acad Sci U S A 2009, 106, (11), 4207-12. 
136. Besanceney-Webler, C.; Jiang, H.; Wang, W.; Baughn, A. D.; Wu, P.  Metabolic labeling 
of fucosylated glycoproteins in Bacteroidales species. Bioorg Med Chem Lett 2011, 21, 
(17), 4989-92. 
137. Typas, A.; Banzhaf, M.; Gross, C. A.; Vollmer, W.  From the regulation of peptidoglycan 
synthesis to bacterial growth and morphology. Nature Reviews Microbiology 2012, 10, (2), 
123-136. 
138. de Pedro, M. A.; Quintela, J. C.; Holtje, J. V.; Schwarz, H.  Murein segregation in 
Escherichia coli. J Bacteriol 1997, 179, (9), 2823-34. 
139. Cava, F.; Lam, H.; de Pedro, M. A.; Waldor, M. K.  Emerging knowledge of regulatory 
roles of D-amino acids in bacteria. Cell Mol Life Sci 2011, 68, (5), 817-31. 
140. Lupoli, T. J.; Tsukamoto, H.; Doud, E. H.; Wang, T. S.; Walker, S.; Kahne, D.  
Transpeptidase-mediated incorporation of D-amino acids into bacterial peptidoglycan. J 
Am Chem Soc 2011, 133, (28), 10748-51. 
141. Kuru, E.; Hughes, H. V.; Brown, P. J.; Hall, E.; Tekkam, S.; Cava, F.; de Pedro, M. A.; 
Brun, Y. V.; VanNieuwenhze, M. S.  In Situ probing of newly synthesized peptidoglycan 
in live bacteria with fluorescent D-amino acids. Angew Chem Int Ed Engl 2012, 51, (50), 
12519-23. 
142. Fura, J. M.; Kearns, D.; Pires, M. M.  D-Amino Acid Probes for Penicillin Binding Protein-
based Bacterial Surface Labeling. J Biol Chem 2015, 290, (51), 30540-50. 
143. Siegrist, M. S.; Whiteside, S.; Jewett, J. C.; Aditham, A.; Cava, F.; Bertozzi, C. R.  (D)-
Amino acid chemical reporters reveal peptidoglycan dynamics of an intracellular pathogen. 
ACS Chem Biol 2013, 8, (3), 500-5. 
144. Siegrist, M. S.; Aditham, A. K.; Espaillat, A.; Cameron, T. A.; Whiteside, S. A.; Cava, F.; 
Portnoy, D. A.; Bertozzi, C. R.  Host actin polymerization tunes the cell division cycle of 
an intracellular pathogen. Cell Rep 2015, 11, (4), 499-507. 
145. Ngo, J. T.; Adams, S. R.; Deerinck, T. J.; Boassa, D.; Rodriguez-Rivera, F.; Palida, S. F.; 
Bertozzi, C. R.; Ellisman, M. H.; Tsien, R. Y.  Click-EM for imaging metabolically tagged 
nonprotein biomolecules. Nat Chem Biol 2016, 12, (6), 459-65. 
146. Qiao, Y.; Lebar, M. D.; Schirner, K.; Schaefer, K.; Tsukamoto, H.; Kahne, D.; Walker, S.  
Detection of lipid-linked peptidoglycan precursors by exploiting an unexpected 
transpeptidase reaction. J Am Chem Soc 2014, 136, (42), 14678-81. 
147. Pidgeon, S. E.; Pires, M. M.  Metabolic remodeling of bacterial surfaces via tetrazine 
ligations. Chem Commun (Camb) 2015, 51, (51), 10330-3. 
148. MacKenzie, D. A.; Sherratt, A. R.; Chigrinova, M.; Kell, A. J.; Pezacki, J. P.  
Bioorthogonal labelling of living bacteria using unnatural amino acids containing nitrones 
and a nitrone derivative of vancomycin. Chem Commun (Camb) 2015, 51, (62), 12501-4. 
149. Grass, G.; Rensing, C.; Solioz, M.  Metallic copper as an antimicrobial surface. Appl 
Environ Microbiol 2011, 77, (5), 1541-7. 
203 
	  
150. Lebar, M. D.; May, J. M.; Meeske, A. J.; Leiman, S. A.; Lupoli, T. J.; Tsukamoto, H.; 
Losick, R.; Rudner, D. Z.; Walker, S.; Kahne, D.  Reconstitution of peptidoglycan cross-
linking leads to improved fluorescent probes of cell wall synthesis. J Am Chem Soc 2014, 
136, (31), 10874-7. 
151. Pidgeon, S. E.; Fura, J. M.; Leon, W.; Birabaharan, M.; Vezenov, D.; Pires, M. M.  
Metabolic Profiling of Bacteria by Unnatural C-terminated D-Amino Acids. Angew Chem 
Int Ed Engl 2015, 54, (21), 6158-62. 
152. Vinatier, V.; Blakey, C. B.; Braddick, D.; Johnson, B. R.; Evans, S. D.; Bugg, T. D.  In 
vitro biosynthesis of bacterial peptidoglycan using D-Cys-containing precursors: 
fluorescent detection of transglycosylation and transpeptidation. Chem Commun (Camb) 
2009, (27), 4037-9. 
153. Liechti, G. W.; Kuru, E.; Hall, E.; Kalinda, A.; Brun, Y. V.; VanNieuwenhze, M.; Maurelli, 
A. T.  A new metabolic cell-wall labelling method reveals peptidoglycan in Chlamydia 
trachomatis. Nature 2014, 506, (7489), 507-10. 
154. Sarkar, S.; Libby, E. A.; Pidgeon, S. E.; Dworkin, J.; Pires, M. M.  In Vivo Probe of Lipid 
II-Interacting Proteins. Angew Chem Int Ed Engl 2016, 55, (29), 8401-4. 
155. Olrichs, N. K.; Aarsman, M. E.; Verheul, J.; Arnusch, C. J.; Martin, N. I.; Herve, M.; 
Vollmer, W.; de Kruijff, B.; Breukink, E.; den Blaauwen, T.  A novel in vivo cell-wall 
labeling approach sheds new light on peptidoglycan synthesis in Escherichia coli. 
Chembiochem 2011, 12, (7), 1124-33. 
156. Sadamoto, R.; Niikura, K.; Sears, P. S.; Liu, H.; Wong, C. H.; Suksomcheep, A.; Tomita, 
F.; Monde, K.; Nishimura, S.  Cell-wall engineering of living bacteria. J Am Chem Soc 
2002, 124, (31), 9018-9. 
157. Sadamoto, R.; Niikura, K.; Monde, K.; Nishimura, S.  Cell wall engineering of living 
bacteria through biosynthesis. Methods Enzymol 2003, 362, 273-86. 
158. Sadamoto, R.; Niikura, K.; Ueda, T.; Monde, K.; Fukuhara, N.; Nishimura, S.  Control of 
bacteria adhesion by cell-wall engineering. J Am Chem Soc 2004, 126, (12), 3755-61. 
159. Nelson, J. W.; Chamessian, A. G.; McEnaney, P. J.; Murelli, R. P.; Kazmierczak, B. I.; 
Spiegel, D. A.  A biosynthetic strategy for re-engineering the Staphylococcus aureus cell 
wall with non-native small molecules. ACS Chem Biol 2010, 5, (12), 1147-55. 
160. Foster, T. J.; Hook, M.  Surface protein adhesins of Staphylococcus aureus. Trends 
Microbiol 1998, 6, (12), 484-8. 
161. Marraffini, L. A.; Dedent, A. C.; Schneewind, O.  Sortases and the art of anchoring proteins 
to the envelopes of gram-positive bacteria. Microbiol Mol Biol Rev 2006, 70, (1), 192-221. 
162. Mazmanian, S. K.; Liu, G.; Ton-That, H.; Schneewind, O.  Staphylococcus aureus sortase, 
an enzyme that anchors surface proteins to the cell wall. Science 1999, 285, (5428), 760-3. 
163. Kruger, R. G.; Otvos, B.; Frankel, B. A.; Bentley, M.; Dostal, P.; McCafferty, D. G.  
Analysis of the substrate specificity of the Staphylococcus aureus sortase transpeptidase 
SrtA. Biochemistry 2004, 43, (6), 1541-51. 
164. Hansenova Manaskova, S.; Nazmi, K.; van 't Hof, W.; van Belkum, A.; Martin, N. I.; 
Bikker, F. J.; van Wamel, W. J.; Veerman, E. C.  Staphylococcus aureus Sortase A-
Mediated Incorporation of Peptides: Effect of Peptide Modification on Incorporation. PLoS 
One 2016, 11, (1), e0147401. 
165. Gautam, S.; Kim, T.; Lester, E.; Deep, D.; Spiegel, D. A.  Wall teichoic acids prevent 
antibody binding to epitopes within the cell wall of Staphylococcus aureus. ACS Chem Biol 
2016, 11, (1), 25-30. 
166. Gautam, S.; Kim, T.; Shoda, T.; Sen, S.; Deep, D.; Luthra, R.; Ferreira, M. T.; Pinho, M. 
G.; Spiegel, D. A.  An Activity-Based Probe for Studying Crosslinking in Live Bacteria. 
Angew Chem Int Ed Engl 2015, 54, (36), 10492-6. 
204 
	  
167. Gautam, S.; Kim, T.; Spiegel, D. A.  Chemical probes reveal an extraseptal mode of cross-
linking in Staphylococcus aureus. J Am Chem Soc 2015, 137, (23), 7441-7. 
168. Oka, T.; Hashizume, K.; Fujita, H.  Inhibition of peptidoglycan transpeptidase by beta-
lactam antibiotics: structure-activity relationships. J Antibiot (Tokyo) 1980, 33, (11), 1357-
62. 
169. van Heijenoort, J.  Recent advances in the formation of the bacterial peptidoglycan 
monomer unit. Nat Prod Rep 2001, 18, (5), 503-19. 
170. Kohanski, M. A.; Dwyer, D. J.; Collins, J. J.  How antibiotics kill bacteria: from targets to 
networks. Nat Rev Microbiol 2010, 8, (6), 423-35. 
171. Gautam, S.; Gniadek, T. J.; Kim, T.; Spiegel, D. A.  Exterior design: strategies for 
redecorating the bacterial surface with small molecules. Trends Biotechnol 2013, 31, (4), 
258-67. 
172. Lam, H.; Oh, D. C.; Cava, F.; Takacs, C. N.; Clardy, J.; de Pedro, M. A.; Waldor, M. K.  
D-amino acids govern stationary phase cell wall remodeling in bacteria. Science 2009, 325, 
(5947), 1552-5. 
173. Pilhofer, M.; Aistleitner, K.; Biboy, J.; Gray, J.; Kuru, E.; Hall, E.; Brun, Y. V.; 
VanNieuwenhze, M. S.; Vollmer, W.; Horn, M.; Jensen, G. J.  Discovery of chlamydial 
peptidoglycan reveals bacteria with murein sacculi but without FtsZ. Nat Commun 2013, 
4, 2856. 
174. Rader, C.; Sinha, S. C.; Popkov, M.; Lerner, R. A.; Barbas, C. F., 3rd.  Chemically 
programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on 
a covalent antibody catalyst. Proc Natl Acad Sci U S A 2003, 100, (9), 5396-400. 
175. Sonenshein, A. L.; Hoch, J. A.; Losick, R., Bacillus subtilis and other gram-positive 
bacteria : biochemistry, physiology, and molecular genetics. American Society for 
Microbiology: Washington, D.C., 1993; p xiii, 987 p. 
176. Popham, D. L.; Gilmore, M. E.; Setlow, P.  Roles of low-molecular-weight penicillin-
binding proteins in Bacillus subtilis spore peptidoglycan synthesis and spore properties. J 
Bacteriol 1999, 181, (1), 126-32. 
177. Buchanan, C. E.; Gustafson, A.  Mutagenesis and mapping of the gene for a sporulation-
specific penicillin-binding protein in Bacillus subtilis. J Bacteriol 1992, 174, (16), 5430-5. 
178. Meroueh, S. O.; Bencze, K. Z.; Hesek, D.; Lee, M.; Fisher, J. F.; Stemmler, T. L.; 
Mobashery, S.  Three-dimensional structure of the bacterial cell wall peptidoglycan. Proc 
Natl Acad Sci U S A 2006, 103, (12), 4404-9. 
179. Hurdle, J. G.; O'Neill, A. J.; Chopra, I.; Lee, R. E.  Targeting bacterial membrane function: 
an underexploited mechanism for treating persistent infections. Nat Rev Microbiol 2011, 
9, (1), 62-75. 
180. Levin, B. R.; Rozen, D. E.  Non-inherited antibiotic resistance. Nat Rev Microbiol 2006, 
4, (7), 556-62. 
181. Lewis, K.  Persister cells. Annu Rev Microbiol 2010, 64, 357-72. 
182. Atrih, A.; Bacher, G.; Allmaier, G.; Williamson, M. P.; Foster, S. J.  Analysis of 
peptidoglycan structure from vegetative cells of Bacillus subtilis 168 and role of PBP 5 in 
peptidoglycan maturation. J Bacteriol 1999, 181, (13), 3956-66. 
183. Brown, S.; Santa Maria, J. P., Jr.; Walker, S.  Wall teichoic acids of gram-positive bacteria. 
Annu Rev Microbiol 2013, 67, 313-36. 
184. Swoboda, J. G.; Campbell, J.; Meredith, T. C.; Walker, S.  Wall teichoic acid function, 
biosynthesis, and inhibition. Chembiochem 2010, 11, (1), 35-45. 
185. Campbell, J.; Singh, A. K.; Santa Maria, J. P., Jr.; Kim, Y.; Brown, S.; Swoboda, J. G.; 
Mylonakis, E.; Wilkinson, B. J.; Walker, S.  Synthetic lethal compound combinations 
reveal a fundamental connection between wall teichoic acid and peptidoglycan 
biosyntheses in Staphylococcus aureus. ACS Chem Biol 2011, 6, (1), 106-16. 
205 
	  
186. Burton, D. R.  Antibody: the flexible adaptor molecule. Trends Biochem Sci 1990, 15, (2), 
64-9. 
187. Joiner, K.; Brown, E.; Hammer, C.; Warren, K.; Frank, M.  Studies on the mechanism of 
bacterial resistance to complement-mediated killing. III. C5b-9 deposits stably on rough 
and type 7 S. pneumoniae without causing bacterial killing. J Immunol 1983, 130, (2), 845-
9. 
188. Joiner, K. A.  Complement evasion by bacteria and parasites. Annu Rev Microbiol 1988, 
42, 201-30. 
189. Tarkkanen, J.; Saksela, E.  Potentiation of human natural killer cell cytotoxicity by 
Salmonella bacteria is an interferon- and interleukin-2-independent process that utilizes 
CD2 and CD18 structures in the effector phase. Infect Immun 1991, 59, (8), 2767-73. 
190. Aderem, A.; Underhill, D. M.  Mechanisms of phagocytosis in macrophages. Annu Rev 
Immunol 1999, 17, 593-623. 
191. Segura, M.; Gottschalk, M.  Streptococcus suis interactions with the murine macrophage 
cell line J774: adhesion and cytotoxicity. Infect Immun 2002, 70, (8), 4312-22. 
192. Takeda, K.; Akira, S.  Toll-like receptors in innate immunity. Int Immunol 2005, 17, (1), 
1-14. 
193. Loskill, P.; Pereira, P. M.; Jung, P.; Bischoff, M.; Herrmann, M.; Pinho, M. G.; Jacobs, K.  
Reduction of the peptidoglycan crosslinking causes a decrease in stiffness of the 
Staphylococcus aureus cell envelope. Biophys J 2014, 107, (5), 1082-9. 
194. Arthur, M.; Courvalin, P.  Genetics and mechanisms of glycopeptide resistance in 
enterococci. Antimicrob Agents Chemother 1993, 37, (8), 1563-71. 
195. Allen, N. E.; LeTourneau, D. L.; Hobbs, J. N., Jr.  Molecular interactions of a semisynthetic 
glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues. 
Antimicrob Agents Chemother 1997, 41, (1), 66-71. 
196. Fritz, J. H.; Ferrero, R. L.; Philpott, D. J.; Girardin, S. E.  Nod-like proteins in immunity, 
inflammation and disease. Nat Immunol 2006, 7, (12), 1250-7. 
197. Reed, P.; Atilano, M. L.; Alves, R.; Hoiczyk, E.; Sher, X.; Reichmann, N. T.; Pereira, P. 
M.; Roemer, T.; Filipe, S. R.; Pereira-Leal, J. B.; Ligoxygakis, P.; Pinho, M. G.  
Staphylococcus aureus Survives with a Minimal Peptidoglycan Synthesis Machine but 
Sacrifices Virulence and Antibiotic Resistance. PLoS Pathog 2015, 11, (5), e1004891. 
198. McPherson, D. C.; Popham, D. L.  Peptidoglycan synthesis in the absence of class A 
penicillin-binding proteins in Bacillus subtilis. J Bacteriol 2003, 185, (4), 1423-31. 
199. Daniel, R. A.; Williams, A. M.; Errington, J.  A complex four-gene operon containing 
essential cell division gene pbpB in Bacillus subtilis. J Bacteriol 1996, 178, (8), 2343-50. 
200. Kocaoglu, O.; Calvo, R. A.; Sham, L. T.; Cozy, L. M.; Lanning, B. R.; Francis, S.; Winkler, 
M. E.; Kearns, D. B.; Carlson, E. E.  Selective penicillin-binding protein imaging probes 
reveal substructure in bacterial cell division. ACS Chem Biol 2012, 7, (10), 1746-53. 
201. Tiyanont, K.; Doan, T.; Lazarus, M. B.; Fang, X.; Rudner, D. Z.; Walker, S.  Imaging 
peptidoglycan biosynthesis in Bacillus subtilis with fluorescent antibiotics. Proc Natl Acad 
Sci U S A 2006, 103, (29), 11033-8. 
202. Jacquier, N.; Frandi, A.; Pillonel, T.; Viollier, P. H.; Greub, G.  Cell wall precursors are 
required to organize the chlamydial division septum. Nat Commun 2014, 5, 3578. 
203. Cava, F.; de Pedro, M. A.; Lam, H.; Davis, B. M.; Waldor, M. K.  Distinct pathways for 
modification of the bacterial cell wall by non-canonical D-amino acids. EMBO J 2011, 30, 
(16), 3442-53. 
204. Shieh, P.; Siegrist, M. S.; Cullen, A. J.; Bertozzi, C. R.  Imaging bacterial peptidoglycan 
with near-infrared fluorogenic azide probes. Proc Natl Acad Sci U S A 2014, 111, (15), 
5456-61. 
206 
	  
205. Fleurie, A.; Lesterlin, C.; Manuse, S.; Zhao, C.; Cluzel, C.; Lavergne, J. P.; Franz-Wachtel, 
M.; Macek, B.; Combet, C.; Kuru, E.; VanNieuwenhze, M. S.; Brun, Y. V.; Sherratt, D.; 
Grangeasse, C.  MapZ marks the division sites and positions FtsZ rings in Streptococcus 
pneumoniae. Nature 2014, 516, (7530), 259-62. 
206. Monteiro, J. M.; Fernandes, P. B.; Vaz, F.; Pereira, A. R.; Tavares, A. C.; Ferreira, M. T.; 
Pereira, P. M.; Veiga, H.; Kuru, E.; VanNieuwenhze, M. S.; Brun, Y. V.; Filipe, S. R.; 
Pinho, M. G.  Cell shape dynamics during the staphylococcal cell cycle. Nat Commun 2015, 
6, 8055. 
207. Fura, J. M.; Sabulski, M. J.; Pires, M. M.  D-amino acid mediated recruitment of 
endogenous antibodies to bacterial surfaces. ACS Chem Biol 2014, 9, (7), 1480-9. 
208. McIntyre, J. C.; Sleight, R. G.  Fluorescence assay for phospholipid membrane asymmetry. 
Biochemistry 1991, 30, (51), 11819-27. 
209. Mukhopadhyay, K.; Whitmire, W.; Xiong, Y. Q.; Molden, J.; Jones, T.; Peschel, A.; 
Staubitz, P.; Adler-Moore, J.; McNamara, P. J.; Proctor, R. A.; Yeaman, M. R.; Bayer, A. 
S.  In vitro susceptibility of Staphylococcus aureus to thrombin-induced platelet 
microbicidal protein-1 (tPMP-1) is influenced by cell membrane phospholipid composition 
and asymmetry. Microbiology 2007, 153, (Pt 4), 1187-97. 
210. Kuru, E.; Tekkam, S.; Hall, E.; Brun, Y. V.; Van Nieuwenhze, M. S.  Synthesis of 
fluorescent D-amino acids and their use for probing peptidoglycan synthesis and bacterial 
growth in situ. Nat Protoc 2015, 10, (1), 33-52. 
211. Schouten, J. A.; Bagga, S.; Lloyd, A. J.; de Pascale, G.; Dowson, C. G.; Roper, D. I.; Bugg, 
T. D.  Fluorescent reagents for in vitro studies of lipid-linked steps of bacterial 
peptidoglycan biosynthesis: derivatives of UDPMurNAc-pentapeptide containing d-
cysteine at position 4 or 5. Mol Biosyst 2006, 2, (10), 484-91. 
212. Utsui, Y.; Yokota, T.  Role of an altered penicillin-binding protein in methicillin- and 
cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985, 28, (3), 
397-403. 
213. Alvarez, L.; Espaillat, A.; Hermoso, J. A.; de Pedro, M. A.; Cava, F.  Peptidoglycan 
remodeling by the coordinated action of multispecific enzymes. Microb Drug Resist 2014, 
20, (3), 190-8. 
214. Reynolds, P. E.; Courvalin, P.  Vancomycin resistance in enterococci due to synthesis of 
precursors terminating in D-alanyl-D-serine. Antimicrob Agents Chemother 2005, 49, (1), 
21-5. 
215. Fura, J. M.; Pidgeon, S. E.; Birabaharan, M.; Pires, M. M.  Dipeptide-Based Metabolic 
Labeling of Bacterial Cells for Endogenous Antibody Recruitment. ACS Infect Dis 2016, 
2, (4), 302-309. 
216. Warth, A. D.; Strominger, J. L.  Structure of the peptidoglycan from vegetative cell walls 
of Bacillus subtilis. Biochemistry 1971, 10, (24), 4349-58. 
217. Meadow, P. M.; Anderson, J. S.; Strominger, J. L.  Enzymatic polymerization of UDP-
acetylmuramyl.L-ala.D-glu.L-lys.D-ala.D-ala and UDP-acetylglucosamine by a particulate 
enzyme from Staphylococcus aureus and its inhibition by antibiotics. Biochem Biophys 
Res Commun 1964, 14, 382-7. 
218. Hancock, L. E.; Murray, B. E.; Sillanpaa, J.  Enterococcal Cell Wall Components and 
Structures. 2014. 
219. Jiang, S.; Rasmussen, R. A.; Nolan, K. M.; Frankel, F. R.; Lieberman, J.; McClure, H. M.; 
Williams, K. M.; Babu, U. S.; Raybourne, R. B.; Strobert, E.; Ruprecht, R. M.  Live 
attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus 
monkeys. Vaccine 2007, 25, (42), 7470-9. 
207 
	  
220. Fura, J. M.; Pires, M. M.  D-amino carboxamide-based recruitment of dinitrophenol 
antibodies to bacterial surfaces via peptidoglycan remodeling. Biopolymers 2015, 104, (4), 
351-9. 
 
  
  
208 
	  
Jonathan M. Fura 
	  
Education 
Lehigh University, College of Arts and Sciences   Bethlehem, PA 18015 
•   Doctor of Philosophy in Chemistry          Anticipated September 29, 2016 
 
DeSales University            Center Valley, PA 18034 
•   Bachelor of Science, Chemistry and Biochemistry         May 2011 
•   Honors: summa cum laude 
•   Minor: Mathematics 
Research Experience 
Lehigh University, College of Arts and Sciences    Bethlehem, 
PA 18015 
Graduate Student with Dr. Marcos M. Pires       2011-
Present 
Combating Pathogenic Bacterial Infections with Immune Stimulant D-Amino Acids. 
•   Developed bacterial cell surface modification technique to promote an 
immunomodulation response for combating pathogenic bacterial infections. 
•   Synthesized, purified, and characterized small molecules/peptides to determine the 
extent that bacterial peptidoglycan was modified through utilizing enzymatic 
assays.  
•   Cloned, expressed, and purified proteins utilized in assay to detect post-
translational protein modifications. 
 
DeSales University             Center Valley, PA  18034 
Undergraduate Research with Dr. Rodger Berg            2010-2011 
•   Established a methodology for the detection of pharmaceuticals in urban water 
sources utilizing HPLC and GC-MS. 
 
DeSales University             Center Valley, PA  18034 
Undergraduate Research with Dr. Francis Mayville           2009-2010 
•   Utilized dissolution techniques and UV-Vis spectroscopy to investigate the effects 
that different drying methods produced in the release mechanism of naproxen from 
cellulose and microcrystalline cellulose beads. 
 
Professional Experience 
Lehigh University                  Bethlehem, PA 
Teaching Assistant, Chemistry                      2011-2014 
•   Assisted in developing chemistry skills for undergraduate students enrolled in 
General Chemistry Concepts, Models and Experiments I and II. 
•   Prepared laboratory lectures. 
 
209 
	  
Benchmark Analytics              Center Valley, PA 1803 
Laboratory Technician             2010-2011 
•   Tested for pesticides, herbicides, and gas volatiles in water and soil samples using 
organic methods of extraction and GC-MS. 
 
DeSales University              Center Valley, PA 18034 
Student Instructional Leader            2009-2011 
•   Assisted students in developing chemistry skills for General Chemistry course 
•   Prepared two, one-hour lectures, weekly 
 
Publications 
Fura, J. M.; Sarkar, S.; Pidgeon, S. E.; Pires, M. M.  Combatting Bacterial Pathogens with 
Immunomodulation and Infection Tolerance Strategies. Curr Top Med Chem 2016 
 
Fura, J. M.; Pidgeon, S. E.; Birabaharan, M.; Pires, M. M., Dipeptide-based Metabolic 
Labeling of Bacterial Cells for Endogenous Antibody Recruitment. ACS Infect Dis 2016, 
2 (4), 302-09.  
 
Fura, J. M.; Kearns, D.; Pires, M. M., D-Amino Acid Probes for Penicillin Binding Protein-
based Bacterial Surface Labeling. J Biol Chem 2015, 290 (51), 30540-50. 
 
Pidgeon, S. E.; Fura, J. M.; Leon, W.; Birabaharan, M.; Vezenov, D.; Pires, M. M., 
Metabolic Profiling of Bacteria by Unnatural C-terminated D-Amino Acids. Angew Chem 
Int Ed Engl 2015, 54 (21), 6158-62. 
 
Fura, J. M.; Pires, M. M., D-Amino Carboxamide-Based Recruitment of Dinitrophenol 
Antibodies to Bacterial Surfaces via Peptidoglycan Remodeling. Biopolymers 2015. 104 
(4), 351-59. 
 
Fura, J. M.; Sabulski, M. J.; Pires, M. M., D-Amino Acid Mediated Recruitment of 
Endogenous Antibodies to Bacterial Surfaces. ACS Chem Biol 2014, 9 (7), 1480-9. 
 
Sabulski, M. J.; Fura, J. M.; Pires, M. M., Fluorescence Based Monitoring of PAD4 
Activity via a Pro-fluorescence Substrate Analog. J Vis Exp 2014, (93). 
 
Awards and Honors 
•   Lehigh University Biosystems Dynamics Summer Institute Fellowship (2016) 
•   Lehigh University Chemistry Departmental Fellowship (2014-2015) 
•   Lehigh University Dean’s Summer Fellowship (2013) 
•   American Chemical Society – Lehigh Valley Section Chemistry Award (2011)  
•   DeSales University Academic Excellence in Chemistry Award (2011) 
•   DeSales University Academic Excellence in Chemistry Research Award (2011) 
•   DeSales University Excellence in Chemistry Demonstrations Award (2011) 
•   DeSales University Academic Excellence Award (2008-2011)  
•   DeSales University Dean’s List (2006-2011)  
•   CIC Tuition Exchange Scholarship (2009-2011)  
210 
	  
•   DeSales University Biology Scholarship (2007-2009)  
•   Eagle Scout (2006) 
 
 
